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Abstract 
Furlong, Bróna A. Inactivity and Exercise in Peripheral Arterial Disease: Effect on 
Vascular Health and Functional Capacity 
Background: Peripheral arterial disease (PAD) is a form of cardiovascular disease 
characterized by atherosclerotic occlusion of blood flow to peripheral tissue. 
Intermittent claudication, a symptom of PAD, can severely impair functional capacity 
and daily physical activity.  Exercise is an established treatment for PAD and 
improvement in endothelial function is proposed as a mechanism through which 
exercise improves PAD symptoms. 
Study 1: This study determined total daily sedentary time and the duration of 
sedentary bouts in 22 men and women, 69.0 ± 8.4 yr, with PAD and examined the 
relation between these behaviours and disease severity, functional capacity, CV risk 
factors, endothelial function, and quality of life (QOL).  Participants spent 68% of the 
waking day sedentary and 36% of this time was accumulated in sedentary bouts >60 
min.  Excessive sedentary time was related to PAD severity and QOL.  Prolonged 
sedentary bouts were related to PAD severity and CV risk factors.   
Study 2: This study compared the effect of acute intermittent walking to the onset of 
claudication (OC) and to maximal claudication (MC) on endothelial function and 
inflammatory markers in 10 men and women, 70.4 ± 7.9 yr, with PAD.  Acute 
intermittent exercise to both OC and MC had no effect on endothelial function or 
inflammatory markers.   
Study 3: The effect of a 12-week community-based exercise programme on 
endothelial function, disease severity, functional capacity, daily activity and 
sedentary behaviour, and QOL was evaluated in 11 men and women, 67.6 ± 9.2 yr, 
with PAD.  There was a significant improvement in endothelial function, functional 
capacity, daily activity and sedentary behaviour, and QOL. 
Conclusion: Reducing and breaking up sedentary time may have positive health 
implications in PAD.  Intermittent exercise to MC may be a more effective and time 
efficient exercise prescription than submaximal exercise.  Community-based exercise 
is an effective treatment option for PAD. 
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Chapter I 
INTRODUCTION 
Peripheral arterial disease (PAD) is a form of cardiovascular disease (CVD) 
characterized by the obstruction of blood flow and consequently the delivery of 
oxygen and other nutrients to peripheral tissue.  The arteries of the lower 
extremities are most commonly affected 1.  The prevalence of PAD increases sharply 
with age and it is a common disease among the elderly population, with a 
prevalence of >20% in those aged ≥75 yr 2.  It is associated with substantial morbidity 
and a 2-3 fold increased risk of all-cause and cardiovascular (CV) mortality 3,4.  
Intermittent claudication, exercise-induced muscle pain that is relieved with rest, is 
the most common symptom of PAD and can severely impair functional capacity, 
therefore impeding daily physical activity and placing individuals with PAD at the 
extreme low end of the physical activity spectrum.   
Emerging evidence indicates that excessive sedentary behaviour may have 
deleterious cardiometabolic health effects, independent of physical activity 5,6.  In 
addition, the pattern in which sedentary time is accumulated is clinically significant.  
Breaking up sedentary time can have a beneficial effect on metabolic biomarkers, 
independent of total sedentary time 7.  To date, no published study has directly and 
objectively measured total daily sedentary time and the duration of sedentary bouts 
in individuals with PAD and determined the relation between these behaviours and 
CV risk, disease severity, and functional capacity.   
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Exercise rehabilitation is an effective treatment for PAD and is associated 
with substantial improvements in symptom severity, functional capacity and quality 
of life (QOL) 8,9.  Although the effectiveness of exercise rehabilitation is well 
established, the mechanisms through which these improvements occur are not fully 
understood.  Proposed mechanisms include the formation of collateral circulation 
and improvements in hemorheological properties, muscle metabolism, walking 
economy, muscular strength and endothelial function 10.   
Previous research has found significant improvements in endothelial function 
with exercise rehabilitation in individuals with PAD 11–13.  However, acute exercise is 
associated with a transient impairment in endothelial function in individuals with 
PAD 12,14–17.  This is in contrast to no change or increases in endothelial function 
following acute exercise in healthy individuals 18 and individuals with coronary artery 
disease (CAD) 19.  The impairment in endothelial function in individuals with PAD is 
dependent upon the degree of ischemia produced in the diseased limb during 
exercise and occurs following exercise to maximal claudication but not exercise to 
the onset of claudication 14.  The acute exercise protocols in previous studies have 
consisted of a single short continuous bout of exercise, whereas exercise 
rehabilitation programs designed for individuals with PAD and research studies 
investigating the effects of chronic exercise in individuals with PAD often employ 
intermittent exercise protocols to allow participants to accumulate minutes of 
exercise.  
 3
Previous research investigating the effect of chronic exercise on endothelial 
function in individuals with PAD has involved submaximal intermittent exercise 
programmes.  To date, no published study has determined the effect of exercise 
rehabilitation involving intermittent exercise to maximal claudication on endothelial 
function in individuals with PAD.  In addition, the previous studies have employed 
hospital- or laboratory-based exercise rehabilitation programmes.  The growing 
epidemic of CVD and its escalating economic burden requires the employment of 
viable secondary prevention strategies.  Home- and community-based exercise 
programmes provide an alternative to hospital-based programmes, but it is first 
necessary to determine the efficacy of these alternatives if there use is to become 
more widespread in the treatment of PAD.   
Purpose 
The purpose of the following series of studies is to determine i) sedentary 
behaviour and its effects, and ii) the effects of acute and chronic exercise on 
endothelial function in men and women with PAD.    
Objectives 
1. To determine total daily sedentary time and the duration of sedentary bouts 
in men and women with PAD and the relation between these behaviours and 
CV risk factors, disease severity, functional capacity, endothelial function, and 
QOL 
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2. To compare the effects of an acute bout of intermittent walking to the onset 
of claudication and maximal claudication on endothelial-dependent and 
endothelial-independent dilation in men and women with PAD 
3. To determine the effect of a 12-week community-based exercise 
rehabilitation programme on endothelial function, disease severity, 
functional capacity, daily physical activity, and QOL in men and women with 
PAD 
Hypotheses 
1. Total daily sedentary time and the duration of sedentary bouts will be 
associated with CV risk factors, disease severity, functional capacity, and QOL 
in men and women with PAD  
2. Acute intermittent exercise to maximal claudication, but not to the onset of 
claudication, will impair endothelial-dependent dilation in men and women 
with PAD 
3. Twelve weeks of community based-exercise rehabilitation will be associated 
with significant improvements in endothelial function, functional capacity, 
daily physical activity, and QOL in men and women with PAD 
 5
Chapter II 
REVIEW OF LITERATURE 
Cardiovascular Disease 
Cardiovascular disease is a class of disorders affecting the heart and 
circulatory system and includes coronary artery disease, cerebrovascular disease, 
peripheral arterial disease, rheumatic heart disease, congenital heart disease, heart 
failure, deep vein thrombosis and pulmonary embolism.  Cardiovascular disease is 
the leading cause of mortality worldwide, accounting for approximately 30% of 
global death annually 20.  In Ireland, approximately 10,000 people die each year from 
CVD, representing 35% of all deaths.  Cardiovascular disease is also a leading cause 
of morbidity, 1,391 per 100,000 disability-adjusted life years lost per annum in 
Ireland are a consequence of CVD 21.  The economic burden of CVD is substantial, 
costing the EU economy €192 billion in 2006 21.  Cardiovascular disease is a growing 
epidemic and the annual mortality rate is expected to rise by 6.3 million by 2030 as a 
consequence of population growth and aging 20.   
Peripheral Arterial Disease 
Peripheral arterial disease is a term that incorporates a collection of 
disorders characterized by altered structure and function of non-coronary arteries 22.  
Arteries commonly affected include the aorta and its visceral branches, such as the 
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renal and mesenteric arteries, the carotid and arteries of the upper and lower 
extremities 23 (figure 2.1).  The site of disease is important in determining symptoms.  
 
Figure 2.1: The arteries commonly affected by peripheral arterial disease 
PAD is characterized by the stenotic occlusion or aneurysmal dilation of the 
artery, which results in compromised blood flow.  Several pathophysiological 
processes may contribute to the development of PAD including atherosclerosis, 
degenerative diseases, dysplastic disorders, vasculitis, and thrombosis and 
thromboembolism 22.  Atherosclerosis is the most common cause of PAD and the 
focus of the following series of studies is atherosclerotic PAD of the lower 
extremities. 
Common iliac artery 
Internal iliac artery 
External iliac artery 
Femoral artery 
Popliteal artery 
Superior mesenteric artery 
Inferior mesenteric artery 
Anterior tibal artery 
Posterior tibial artery 
Peroneal artery 
Renal artery Abdominal aorta 
Subclavian artery Carotid artery 
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PAD is a progressive arterial occlusive disease and hence a spectrum of 
symptoms is observed ranging from asymptomatic PAD to symptomatic PAD or 
intermittent claudication to critical limb ischemia (figure 2.2). 
 
 
 
Figure 2.2: The peripheral arterial disease spectrum 
Intermittent Claudication 
Intermittent claudication (IC) is defined as exercise-induced muscle ischemia 
that is accompanied with pain, discomfort, cramping or fatigue in specific muscle 
groups, and is relieved by rest.  It is the most common symptom of PAD and occurs 
following shorter periods of exercise as the disease progresses 24.  Exercise increases 
the local muscle demand for oxygen to support metabolism.  Stenosis and impaired 
compensatory mechanisms, such as impaired endothelial dilation, restrict blood flow 
to the peripheral tissue leading to an oxygen supply-demand mismatch, producing 
ischemia in the affected region.  The severity of exercise-induced muscle ischemia in 
individuals with IC is commonly classified using either the Fontaine or Rutherford 
scale 25,26 (table 2.1).  
  
Asymptomatic 
PAD 
Intermittent 
Claudication 
Critical Limb 
Ischemia 
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Table 2.1: The Fontaine and Rutherford classification scales 25,26 
Fontaine Rutherford 
Stage Clinical  Grade Category Clinical 
I Asymptomatic  0 0 Asymptomatic 
IIa Mild claudication  0 1 Mild claudication 
IIb Moderate to severe 
claudication 
 I 2 Moderate claudication 
III Ischemic rest pain  I 3 Severe claudication 
IV Ulceration or gangrene  II 4 Ischemic rest pain 
   III 5 Minor tissue loss 
   III 6 Major tissue loss 
The site of the claudication pain often corresponds to the site of the stenotic 
artery.  Occlusion of the iliac artery tends to produce hip, buttock, and thigh pain, 
whereas femoral and popliteal artery occlusion typically causes calf pain.  Tibial 
artery stenosis can produce calf pain or, in some cases, foot pain and numbness.  
The superficial femoral and popliteal arteries are the most commonly affected by 
atherosclerosis, and hence IC is most frequently experienced in the calf muscles 1.  
Classic claudication is defined by the World Health Organization (WHO) as leg 
pain that occurs in one or both calves while walking that does not begin at rest, does 
not disappear with walking, is provoked by hurrying or walking uphill, makes the 
individual stop or decrease walking speed, but disappears after stopping for ≤10 min 
27.  Many individuals do not meet all the criteria of classic claudication and are 
classified as having atypical claudication.  Atypical leg pain may arise because of the 
strict limitations of the WHO definition 28 and/or the presence of comorbidities that 
alter the symptoms, such as arthritis, neuropathy and spinal stenosis, or prevent 
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sufficient activity to produce limb symptoms, such as heart failure, severe pulmonary 
disease and musculoskeletal disease 29.  
Critical Limb Ischemia  
Critical limb ischemia (CLI) is defined as ischemic limb pain at rest or 
impending limb loss due to severely impaired blood flow to the affected limb.  It is 
distinct from acute limb ischemia by the presence of symptoms for >2 weeks and if 
untreated the natural history would lead to major limb amputation within 6 months 
22.  In CLI, resting perfusion is inadequate to meet the metabolic demand of distal 
tissues or to sustain viability of distal vessels.  It is characterized by chronic ischemic 
related pain at rest, ulcers, or gangrene attributable to atherosclerotic occlusion of 
the arteries 30 and is associated with a reduction in ankle brachial index (ABI), the 
ratio of systolic blood pressure (SBP) at the ankle and the brachial artery, to ≤0.4, an 
ankle SBP <50 mmHg, or a toe pressure <40 mmHg 26,31.  The atherosclerosis that 
gives rise to CLI is often diffuse, multisegmental and multilevel and its systemic 
nature means the contralateral limb may also be affected by ischemic symptoms. 
Acute Limb Ischemia  
Acute limb ischemia (ALI) is a sudden reduction in limb perfusion that 
threatens tissue viability 30.  Presentation is generally within 2 weeks of the acute 
event.  An acute ischemic event may be the first presentation of PAD in previously 
asymptomatic individuals or it may progress claudication symptoms.  Progression 
along the PAD spectrum may be the result of multiple acute ischemic events.  The 
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severity of an acute event depends on the location and extent of the arterial 
occlusion and the extent to which collateral blood vessels have perfused the area 22.   
The two most common causes of ALI are embolic and in situ thrombotic 
occlusion.  Thrombosis due to atherosclerotic plaque rupture or thrombosis of a 
lower limb bypass graft account for 85% of ALI cases 32.  Embolic occlusion 
originating from the heart or an arterial aneurysm account for the remaining 15%.  
Approximately 90% of the emobli causing ALI are of cardiac origin, generally as a 
result of atrial fibrillation or an acute myocardial infraction (MI).  
Epidemiology of Peripheral Arterial Disease 
Prevalence  
The prevalence of PAD varies across epidemiological studies depending on 
the diagnostic method used and the study population.  The use of questionnaires 
determines the prevalence of claudication symptoms and therefore measures only 
one aspect of the PAD spectrum and underestimates the prevalence of PAD.  In the 
Framingham Offspring Study of 3313 men and women aged ≥40 yr, IC, defined by 
questionnaire, was found in 1.9% of men and 0.8% of women 33.  Using the objective 
measure of ABI <0.90, PAD was evident in 3.6% of the population.  Similarly, in the 
Edinburgh Artery Study of 1592 men and women aged 55 to 74 yr, an ABI <0.90 was 
found in 9% and questionnaire-determined IC was found in 4.5% of the population 
34.   
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The use of ABI <0.90 to diagnose PAD has been given an American Heart 
Association (AHA) Class I recommendation 35 and table 2.2 summarizes the 
prevalence of PAD in epidemiological studies employing this criteria.  The prevalence 
ranges from 3.6% to 19%.   
Table 2.2: The prevalence of peripheral arterial disease, defined as ABI <0.90, in 
epidemiological studies 
Author  n Age  
(yr) 
Cohort Prevalence 
of PAD (%) 
Murabito et al., 
2002 33 
3313 ≥40 Framingham Offspring 
Study 
3.6 
McDermott et al., 
2005 36 
6570 45-84  Multi-Ethnic Study of 
Atherosclerosis 
3.7 
Selvin & Erlinger 
2004 37 
2174 ≥40 NHANES 4.3 
Kröger et al., 2006 
38 
4735 45-75 Heinz Nixdorf Recall Study 6.4 M, 5.1 F 
Stoffers et al., 
1996 39 
3171 40-75  Limburg PAOD Study 6.9 
Fowkes et al., 1991 
34 
1592 55-74 Edinburgh Artery Study 9 
Criqui et al., 1985 2 624 38-82 Californian community 11.7 
Newman et al., 
1993 40 
5084 ≥65 Cardiovascular Health Study 12.4 
Sigvant et al., 2007 
41 
5080 60-90 Swedish population 18 
Meijer et al., 1998 
42 
7715 ≥55 The Rotterdam Study 19 
F, female; M, male; n, number of study participants; NHANES, National Health and 
Nutrition Examination Survey; PAD, peripheral arterial disease; PAOD, peripheral 
arterial occlusive disease 
The prevalence of PAD increases sharply with age.  In a population of 624 
men and women aged 38 to 82 yr, the prevalence of PAD, defined by 4 non-invasive 
measures of limb perfusion, increased from <3% at <60 yr to >20% at ≥75 yr 2 (figure 
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2.3).  In the National Health and Nutrition Examination Survey (NHANES) the 
prevalence of PAD was 4.3% in 2174 US adults aged ≥40 yr and 14.5% in the men and 
women aged ≥70 yr 37.  In the Framingham Offspring Study, the risk of developing 
PAD increased 2.6-fold for each decade of life 33.  
 
Figure 2.3: Prevalence of peripheral arterial disease by age and gender 2 
The prevalence of PAD, defined by segmental blood pressure, flow velocity by Doppler 
ultrasound, post-occlusive reactive hyperemia, and pulse reappearance half-time, 
increased with age in 624 men and women with PAD from <3% at <60 yr to >20% at ≥75 
yr.  At most ages PAD was slightly more common in men than women. 
Risk Factors 
In addition to age, cigarette smoking and diabetes mellitus (DM) are the most 
powerful risk factors for PAD (figure 2.4).  Other modifiable risk factors include 
dyslipidemia, hypertension, hyperhomocysteinemia, and elevated C-reactive protein 
(CRP) levels.  
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Figure 2.4: Modifiable risk factors for peripheral arterial disease 22 
The range of relative risk (RR) for the modifiable risk factors of PAD estimated from 
epidemiological studies.  The RR for smoking is ~2-4-fold compared with former 
smokers and non-smokers.  The presence of DM has a RR of ~2-4-fold compared with 
the absence of DM.  The presence of hypertension has a RR of ~1.5-2.5-fold compared 
with the absence of hypertension.  The RR of ~1-2-fold for hypercholesterolemia is 
based on a 10% risk for each 10 mg.L
-1
 increase in total cholesterol.  The highest 
quartiles of homocysteinemia and CRP have a ~2-3 fold and ~2-fold RR for PAD, 
respectively, compared with the lowest quartile.  
Cigarette smoking is a 2-3 fold more powerful risk factor for PAD than for 
CAD 43.  Most epidemiological studies have found a 2-5 fold increase risk of 
developing PAD among smokers compared with former smokers and non-smokers 
33,37,40.  Smokers develop PAD 10 years earlier than non-smokers 44.  The association 
is dose-dependent.  The risk of PAD increases with increasing years smoked and 
packs per year smoked.  Price et al., (1999) found that the prevalence of PAD 
increased from 2.6% in never smokers to 4.5% in moderate smokers (0-25 packyears) 
to 9.8% in heavy smokers (>25 packyears) 43.  At least 80% of individuals with PAD 
are current or former smokers 4,42.  Smoking is also associated with the progression 
of PAD and with an enhanced risk of developing CLI 45.  
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Diabetes mellitus increases the risk of PAD by 2-4 fold and is present in 10-
27% of PAD patients 36,37,40,42.  The duration and severity of DM affects the 
associated risk for PAD.  For every 1% increase in glycosylated hemoglobin (HbA1C) 
there is an associated increased relative risk (RR) of developing PAD of 1.28 and 1.77 
fold in diabetic and non-diabetic individuals, respectively 46.  The presence of DM 
may accelerate the atherosclerotic development and increase the risk of progressing 
to CLI 47.  The risk of lower limb amputation is approximately 5 times greater in 
diabetic PAD patients compared with non-diabetic PAD patients 48. 
Dyslipidemia is a risk factor for PAD.  In the Framingham Study, a fasting 
cholesterol level >7 mmol.L-1 was associated with a doubling of IC incidence 49.  In 
the Cardiovascular Health Study, each 10 ml.dL-1 increase in total cholesterol 
increased the risk of developing PAD by approximately 10% 40.  Some studies have 
failed to find an association between PAD and hypercholesterolemia 50,51, but there 
is evidence that treatment of dyslipidemia decreases the progression of 
atherosclerosis in PAD and the incidence of IC 52.  The ratio of total cholesterol to 
high-density lipoprotein cholesterol (HDL-C) is a strong risk factor for CAD and the 
ratio has been found to be higher in PAD patients than controls 51.  In a prospective 
study, Ridker et al., (2001) found this ratio to be the strongest lipid predictor of risk 
for developing PAD 53.   
Hypertension is the most prevalent CVD risk factor worldwide 54.  The 
Framingham Study reported a strong association between hypertension and the risk 
of developing IC and there was a gender difference in this association 55.  The odds 
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ratio was 2.5 and 4.0 for males and females, respectively.  Other epidemiological 
studies have reported age and gender adjusted risk ratios of 1.4-2.6 33,37,40,56, while 
some have failed to find an association between PAD and hypertension 4,57.   
Hyperhomocysteinemia, defined as plasma homocysteine >15 μmol.L-1, has 
been identified as an independent risk factor for PAD 58.  Graham et al., (1997) 
described a 1.35 and 1.42 fold increased risk of PAD for males and females, 
respectively, with each 5 μmol.L-1 increase in fasting homocysteine level 59.  Higher 
levels of CRP, a marker of systemic inflammation, have been found in PAD patients 
than healthy controls 53,60.  In a prospective study, Ridker et al., (1998) reported that 
individuals in the highest quartile of baseline CRP levels were twice as likely to 
develop PAD than the lowest quartile (RR, 2.1) 61.  Vainas et al., (2005) found a 
significant inverse relation between CRP levels and ABI in 387 men and women with 
PAD, suggesting that CRP levels may be related to the severity of PAD 62.  Other CVD 
risk factors such as obesity and alcohol consumption have shown inconsistent 
associations with PAD. 
Natural History of Peripheral Arterial Disease 
The clinical course of PAD is relatively benign.  Within 5 years, 7-15% of 
asymptomatic PAD patients will develop IC 3, 25% of claudicants will experience a 
deterioration in symptoms 30, <5% will develop CLI 63, <10% will require 
revascularization 1 and only 1-3.3% of claudicants will require amputation 64.  
Therefore, approximately 70% of PAD patients will experience symptom stabilization 
or improvement 65.  This may be due in part to physiological adaptations resulting 
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from chronic exposure to ischemia such as the development of collateral vessels or 
metabolic adaptations, or to an alteration in gait in favour of non-ischemic muscle 
groups to minimize claudication pain 30.  In 25% of claudicants, deterioration occurs 
most frequently during the first year, before physiological adaptations have time to 
occur, with 7-9% deterioration compared with 2-3% per year thereafter 66.  In 
addition, the systemic nature of atherosclerosis means stenosis typically develop at 
>1 site, limiting local progression 67.  The risk of deterioration in individuals with PAD 
is influenced by risk factors such as smoking, DM, and dyslipidemia 30.  The 
progression of PAD may be gradual or rapid, if ALI occurs suddenly decreasing limb 
perfusion.   
Although PAD represents a spectrum of symptoms, progression along the 
spectrum is the exception rather than the rule.  In a systematic review of 13 
population studies, Hooi et al., (1999) reported that only a small percentage of 
asymptomatic patients developed IC and similarly only a small percentage of 
patients with IC advanced to CLI 68.  In 100 patients with CLI, Matzke and Lepantalo 
(2001) found that CLI was the first indication of PAD in 37% of patients 69.  In some 
cases, IC may not precede CLI due to extreme sedentary behaviour, which does not 
allow IC to manifest.  
The best predictor of deterioration in individuals with PAD is lower limb 
hemodynamics.  Ankle SBP <70 mmHg, toe SBP <40 mmHg, and ABI <0.50 have been 
found to be independent predictors of the progression of atherosclerotic disease, 
defined as the development of rest pain or gangrene 66.  Low ABI is also significantly 
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associated with functional decline.  In a study by McDermott et al., (2004), a baseline 
ABI <0.50 was associated with a 13 fold increased risk of being unable to walk 
continuously for 6 min 2 yr later compared with an ABI of 1.10-1.50 70.  
Despite the relatively stable prognosis of the diseased limb, atherosclerosis is 
systemic in nature and individuals with PAD have significant concomitant CAD and 
cerebrovascular disease (CBVD).  In fact, in the prognosis of individuals with PAD, CV 
events and mortality are a greater concern than lower limb ischemia.  
Concomitant Coronary and Cerebrovascular Disease 
Coronary artery and/or cerebrovascular disease is present in 40% to 60% of 
individuals with PAD 30,71.  Cardiovascular causes are by far the leading cause of 
mortality in individuals with PAD, with approximately 50% of deaths attributed to 
CAD, 15% to CBVD, and 10% to other vascular events, such as a ruptured aortic 
aneurysm.  Individuals with PAD have a 2-3 fold increased risk of fatal or non-fatal 
MI, stroke, and all-cause mortality 3,4,40,72,73.  The annual major CV event rate in 
individuals with PAD is approximately 5-7% 30.  The 5-, 10-, and 15-yr morbidity and 
all-cause mortality rates in individuals with PAD are approximately 30%, 50% and 
70%, respectively.   
ABI is a robust and independent predictor of fatal and non-fatal CV events 
and all cause mortality 40,74.  Research has found a significant association between 
ABI and the degree of coronary involvement (number of vessels with >75% stenosis) 
75 and coronary artery calcium scores 36.  A U-shaped association between ABI and 
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mortality has been reported 76 (figure 2.5).  In a historical cohort study, Sikkink et al., 
(1997) reported a RR of mortality of 3.1 per 0.50 decrease in resting ABI and 2.4 per 
0.50 decrease in post-exercise ABI 77.  The cumulative survival after 5 years was 63% 
for resting ABI <0.50, 71% for ABI 0.50-0.69 and 91% for ABI of 0.70-0.89.  ABI >1.40 
predicts mortality to a similar strength as ABI <0.90.  An ABI >1.40 is indicative of 
non-compressible vessels, common in individuals with DM.   
 
Figure 2.5: Ankle brachial index and mortality 76 
The association between low and high ABI and all-cause and cardiovascular mortality in 
4393 men and women, mean age 57.5 yr, was U-shaped.  Mortality risk increased at ABI 
<1.0 and progressively increased with decreasing ABI.  ABI >1.40 predicts mortality with 
similar strength as ABI <0.90. 
Diagnosis of Peripheral Arterial Disease 
Establishment of an accurate diagnosis can facilitate the formation of a 
therapeutic plan and diminish the morbidity and mortality associated with PAD.  The 
diagnosis of PAD begins with an accurate history and physical examination.   Vascular 
tests are required to confirm the diagnosis.  Intra-arterial angiography is considered 
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the gold standard test for the diagnosis of PAD 78.  However, this technique is 
invasive, expensive, and time-consuming.  There are a number of non-invasive 
hemodynamic measurements that have been validated against angiography and can 
be used to detect the presence, location, and severity of PAD and identify patients 
for further investigations. 
Ankle Brachial Index 
Ankle brachial index is the ratio of SBP at the ankle and the brachial artery.  It 
is the standard test used for the diagnosis of PAD in field epidemiological studies, 
vascular laboratories and office practice 22.  It is determined by measuring SBP in 
both brachial arteries and the dorsalis pedis and posterior tibial arteries of both 
ankles (figure 2.6).  A number of techniques may be used to determine the ankle 
SBP, including Doppler ultrasound, oscillometric methods, and plethysmography.  
The Doppler method has received an AHA Class I recommendation for the use in 
determining ankle SBP 35.   
The most commonly used method to calculate ABI is to divide the highest of 
the posterior tibialis and dorsalis pedis arteries pressures by the higher of the two 
brachial pressures.  However, it has been suggested that this method may 
underestimate the prevalence and/or severity of PAD and using the lowest ankle 
artery pressure or the average of the 2 pressures may be more suitable 79.  Using the 
highest pressure has less sensitivity but greater specificity than using the lowest 
pressure 80 and the AHA has given a Class I recommendation to using the highest 
ankle pressure 35.   
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Figure 2.6: Ankle brachial index measurement sites 81 
DP, dorsalis pedis artery; PT, posterior tibial artery 
Table 2.3 outlines the American College of Cardiology (ACC)/AHA guidelines 
for the interpretation of ABI 22.  Pulse wave reflection in healthy individuals results in 
an ankle SBP 10-15 mm Hg higher than brachial SBP and therefore, a healthy ABI is 
generally >1.00.  An abnormally high ABI, >1.40, is a false positive result.  
Calcification of arterial walls, prevalent in individuals with DM and renal 
insufficiency, inhibits the abolishment of SBP by cuff inflation resulting in an 
artificially high ABI.  An alternative diagnostic test such as toe brachial index (TBI) is 
required to detect PAD in these situations.  
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Table 2.3: Interpretation of ankle brachial index results 22 
ABI Classification 
>1.40 Noncompressible arteries 
0.90-1.29 Healthy 
0.81-0.89 Mild disease 
0.51-0.80 Moderate disease 
0.30.-0.50 Severe disease 
<0.30 Critical disease 
The diagnostic performance of ABI varies depending on the cut-off threshold, 
the technique used to measure flow in the ankle arteries, and the population 
studied.  In a review of the accuracy of an ABI ≤0.90 to detect a ≥50% stenosis, 
specificity and accuracy were high at 83.3-99.0% and 72.1-89.2%, respectively, 
however sensitivity varied from 15% to 79% 82.  The sensitivity was lowest in the 
elderly and in those with DM.  The optimal ABI threshold for detecting PAD has not 
been clearly defined.  The lower limit of the 95% CI ranges from 0.85 to 0.97 in older 
studies 83,84, whereas more recent studies using the ROC curve proposed an optimal 
threshold of 0.92 to 0.97 78,85.  The AHA gave a Class I recommendation for the use of 
an ABI threshold ≤0.90 for the diagnosis of PAD.  However, when ABI is >0.90 but 
there is clinical suspicion of PAD based on symptoms and clinical findings, post-
exercise ABI or other non-invasive tests should be used.  Intraobsever variability in 
the measurement of ABI ranges from 4.7% to 13.0%, with an average of 10% 35.  
Interobserver variability ranges from 5.4% to 24%, with an average of 13%.   
In addition to diagnosing PAD, ABI can be used to quantitatively assess the 
severity of PAD, determine the temporal progression of PAD and the response to 
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treatment, and provide prognostic information to predict limb survival and patient 
survival.  There is also evidence that ABI may enhance the predictive accuracy of the 
Framingham risk score 86.  Overall, ABI is a valid biological parameter, non-invasive, 
cost-effective, and easy to perform and has been given an AHA Class I 
recommendation as the tool that should be used to establish lower-extremity PAD 
diagnosis in patients suspected of PAD 35.   
Toe Brachial Index 
In individuals with DM and renal insufficiency, calcification of arterial walls 
renders lower limb arteries incompressible and an accurate ABI difficult to obtain.  
An abnormally high ABI (>1.40) or elevated ankle pressure (>250 mmHg) may 
indicate incompressible arteries 30.  The prevalence of PAD in individuals with DM is 
approximately 20-fold higher than in age- and gender-matched controls 87 and in a 
situation where incompressible arteries are suspected, the measurement of toe SBP 
is recommended to obtain an accurate assessment of distal limb perfusion 22.  
Calcification does not tend to extend to digital arteries and the calculation of TBI can 
be used to diagnose PAD.   
Toe SBP is measured by placing a small occlusive cuff on the proximal portion 
of the first or second toe and detecting the pressure using a plethysmographic 
device.  Toe SBP is generally 30 mmHg less than ankle pressure and a TBI <0.70 is 
considered diagnostic of lower extremity PAD 88. The sensitivity and specificity of TBI 
for the detection of vessel stenosis are 90-100% and 65-100%, respectively 88.  
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Exercise Testing 
A normal ABI may be obtained despite clinical suspicion of PAD based on 
symptoms and clinical findings.  This may occur in individuals with mild arterial 
narrowing or isolated iliac stenosis, whereby the stenosis is not hemodynamically 
significant at rest.  In this situation the measurement of post-exercise ABI is 
recommended 22.  Lower extremity exercise produces peripheral vasodilation and a 
decrease in ankle SBP.  In healthy individuals, a mild decrease in ABI is evident 
immediately post exercise, which rapidly returns to baseline within 1-2 min.  In 
individuals with PAD, the post-exercise decrease in ABI is of a greater magnitude and 
persists for a longer duration.  A decrease of 30 mm Hg in ankle SBP or a 15-20% 
decrease in ABI post-exercise are proposed as diagnostic of PAD 30,89.  
Post-exercise ABI provides information on the dynamic functional significance 
of a stenosis and can also be used to differentiate arterial claudication from non-
arterial or pseudoclaudication in those with exertional leg symptoms.  
Segmental Pressure Examination 
Segmental pressure examination can be used to diagnose PAD and determine 
the anatomic location of the lower extremity stenosis.  Specially designed 
plethysmographic cuffs, with bladders that encircle the entire limb, are placed 
sequentially along the limb at various locations, most commonly the upper thigh, 
lower thigh, upper calf, and lower calf 22.  A Doppler probe is used to determine the 
SBP in the major arteries under the cuff and the identification of a significant 
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pressure gradient can determine the location of an arterial stenosis.  In general, a 
gradient of >20 mmHg between adjacent segments is considered a physiologically 
important focal stenosis 90.  
Pulse Volume Recording  
The location of the stenotic occlusion can also be determined by pulse 
volume recording.  Similar to segmental pressure examination, blood pressure cuffs 
are placed sequentially along the limb, generally at the thigh, calf and ankle 30.  The 
cuffs are connected to a plethysmograph, an instrument that detects and graphs 
alterations in limb volume.  Arterial blood flow to the lower limbs is pulsatile and 
results in changes in limb volume with each cardiac cycle.  Detection of these cyclical 
volume changes by the plethysmograph are translated into pulsatile pressure and an 
arterial pressure waveform profile is produced 90.  The magnitude and amplitude of 
the waveform shape are used to measure vessel patency and correlate with blood 
flow.  Changes in waveform shape or amplitude signify the presence of a flow-
limiting stenosis 22.  
Continuous-Wave Doppler Ultrasound 
Continuous-wave Doppler ultrasound is used to obtain arterial flow velocity 
waveforms and to measure SBP at sequential segments of the lower limb and can 
provide an estimate of disease location, severity, progression, and response to 
treatment 22,30.  PAD not only changes lower extremity pressure but also the pattern 
of blood flow velocity distal to the stenosis.  Flow-limiting lesions can result in an 
 25
increase in peak systolic velocity at the site of narrowing, a decrease in peak systolic 
velocity distal to the site of narrowing, turbulence distal to the lesion, and loss of the 
reverse flow component 1.  The pulsatility index is a commonly used quantitative 
measure of limb perfusion and is defined as peak systolic velocity minus minimum 
diastolic velocity divided by mean blood flow velocity.  A decrease in pulsatility index 
between adjacent proximal and distal limb segments indicates the presence of an 
occlusive lesion between the 2 segments.  The magnitude of the decrease is 
generally proportional to the severity of disease 22.  
Duplex Ultrasound 
Duplex ultrasound is an imaging technique that is useful to diagnose the 
anatomic location and degree of blood vessel stenosis and can be used to identify 
lesions suitable for revascularization and monitor patients following 
revascularization 22.  Quantitative data on the degree of stenosis is provided by the 
analysis of blood flow velocities by Doppler ultrasound.   
Pathophysiology of Peripheral Arterial Disease 
Atherosclerosis 
Inflammation, the movement of cellular elements from the blood to tissues 
in response to an injury on the vascular wall or of surrounding tissues, is the basis of 
all pathogenetic aspects of atherosclerosis 91.  Many of the molecular aspects of 
vascular inflammation present in atherosclerosis have as their basis a condition of 
endothelial dysfunction (endothelial “activation”) and subsequent early selective 
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expression by the endothelium of an adhesive phenotype towards monocytes from 
peripheral blood.  Specifically, the expression of immunoglobulin vascular cell 
adhesion molecule-1 (VCAM-1) and subsequent interaction with the intergrin very 
late activation antigen-4 (VLA4) results in monocyte recruitment.  In addition to the 
adhesion and migration of monocytes (inception), inflammation is also involved in 
the growth (accumulation of cells and matrix) and clinical emergence (fissuring) of 
atheroma.  Endothelial dysfunction occurs when established CVD risk factors conjure 
with altered physical forces to increase adhesion of circulating monocytes that 
subsequently infiltrate the arterial intima resulting in a proatherogenic phenotype 92.   
Ischemia-Reperfusion Injury 
Ischemia-reperfusion injury (I-RI), tissue damage caused by the restoration of 
blood-flow following an ischemic episode, may contribute to disease progression in 
PAD.  Exercise to claudication followed by rest may be considered a low-grade I-RI 93 
(figure 2.7).  Ischemia results in a decrease in cellular oxidative phosphorylation and 
consequently a failure to resynthesize adenosine triphosphate (ATP) levels.  
Adenosine triphosphate is degraded to hypoxanthine by the purine metabolic 
pathway.  Under normoxic conditions endothelial cell xanthine dehydrogenase (XD) 
subsequently converts hypoxanthine to xanthine.  Under hypoxic conditions, cellular 
ionic gradients are disrupted leading to a calcium-induced protease attack on XD, 
forming xanthine oxidase (XO).  Xanthine oxidase requires oxygen as a co-factor and 
consequently, ischemia results in the accumulation of hypoxanthine.  Reperfusion 
with oxygenated blood allows XO to convert hypoxanthine to xanthine with the 
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production of large quantities of oxygen free radicals, superoxide and hydrogen 
peroxide.   
 
Figure 2.7: Generation of reactive oxygen species during ischemia-reprefusion injury 
in claudication 93 
ATP, adenosine triphosphate; XD, xanthine dehydrogenase; XO, xanthine oxidase 
Ischemia is induced in the skeletal muscle of the lower limb in individuals with PAD 
during exercise to maximal claudication pain.  Ischemia results in a decrease in cellular 
oxidative phosphorylation and consequently failure to resynthesize ATP.  ATP is 
degraded to hypoxanthine by the purine pathway.  Under normoxic conditions 
endothelial cell XD converts hypoxanthine to xanthine.  Under hypoxic conditions, 
cellular ionic gradients are disrupted leading to a calcium-induced protease attack on 
XD, forming XO.  XO requires oxygen as a co-factor and reperfusion with oxygenated 
blood allows XO to convert hypoxanthine to xanthine with the production of 
superoxide. 
Reperfusion is followed by an acute inflammatory response triggered by 
tissue damage incurred during ischemia.  Restoration of blood flow promotes the 
recruitment of leukocytes including neutrophils into the post-ischemic tissue.  
Activated neutrophils contain the membrane-bound enzyme, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase that oxidizes cytoplasmic NADPH to NADP+ 
and reduces molecular oxygen to superoxide, which can dismutate to form hydrogen 
peroxide 94.   
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Plasma markers of oxidative stress 14 and oxidative damage 95 are 
significantly increased in PAD patients compared with healthy controls following 
acute exercise.  Exercise to maximal claudication appears necessary to produce I-RI, 
as plasma levels of thiobarbituric acid reactive substances (markers of oxidative 
stress) were unchanged following exercise to the onset of claudication 14.  In 
addition, there is evidence of impaired antioxidant defences in individuals with PAD.  
Compared with healthy controls, there is a significant reduction in the activity of 
manganese superoxide dismutase (MnSOD) 96 and glutathione peroxidase (GPX) and 
in plasma levels of selenium 97, an essential cofactor of GPX, in the skeletal muscle of 
individuals with PAD.  Exposure to I-RI, in combination with reduced antioxidant 
defences, may result in damage to endothelial cells contributing to the progression 
of atherosclerosis in individuals with PAD.  Ischemia-reperfusion injury may also 
result in damage to PAD skeletal muscle.  
Skeletal Muscle Myopathy 
Although hemodynamic restriction to peripheral tissue caused by 
atherosclerotic stenosis is the primary pathophysiology of PAD, chronic restriction of 
blood flow may lead to secondary complications distal to the stenosis.  This is 
indicated by a number of findings in individuals with PAD, including 1) a weak or 
absent relation between limb hemodynamics and functional capacity 98, 2) the 
absence of changes in functional capacity despite improvement in limb 
hemodynamics with extremity revascularization 99, 3) the absence of changes in limb 
hemodynamics despite improvements in functional capacity with exercise training 
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100 or no relation between changes in limb hemodynamics and improvements in 
functional capacity with exercise training 101, 4) impairment in oxygen-independent 
attributes such as anaerobic power 102, and 5) no relation between limb 
hemodynamics and impaired exercise oxygen uptake (VQO2) kinetics 
103.  These 
findings imply the presence of a skeletal muscle myopathy in PAD, which is likely to 
contribute to functional impairment in individuals with PAD.  
Alterations in Skeletal Muscle Metabolism 
One of the earliest indications of a metabolic abnormality in PAD was the 
unexpected finding of increased mitochondrial content, as assessed by 
mitochondrial enzyme activity 104–107.  The increased mitochondrial content was 
significantly related with the severity of PAD, determined by ABI (r=-0.54) 105, 
suggesting that it may represent a compensatory mechanism for impaired oxygen 
delivery.  In contrast, more recent research has reported a significant decrease in 
mitochondrial enzyme activity 96,108.  Whether the mitochondrial content is increased 
or not, mitochondrial function appears to be compromised and PAD is associated 
with impaired mitochondrial respiration.  Using gastrocnemius muscle, Pipinos et al., 
(2003) measured respiratory rate in vitro under normoxic conditions (to remove the 
influence from potential blood flow limitations) in 9 men and women with PAD and 9  
healthy controls 109.  Mitochondrial respiratory rate after maximal stimulation of the 
electron transport chain (ETC) with Kreb cycle substrates malate and glutamate in 
the presence of adenosine diphosphate (ADP) (VADP) was significantly lower in PAD 
muscle than control, whereas respiratory rate after maximal inhibition of ETC with 
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atractyloside, which inhibits ATP-ADP translocase, depriving mitochondria of ADP 
(VAT) was similar between groups.  The ratio of VADP to VAT, an indicator of 
mitochondrial function, was significantly lower in PAD muscle than control.    
Elevated levels of ROS resulting from I-RI in combination with impaired 
antioxidant defences can lead to significant oxidative damage to the ETC in skeletal 
muscle distal to the stenosis.  Complexes I and III of the ETC are particularly 
susceptible to oxidative damage and the enzyme activity of complexes I, III and IV 
have been found to be significantly diminished in PAD gastrocnemius muscle 
compared with healthy controls 96.  The decline in enzyme activity in complexes I and 
III was significantly related with an impairment in oxidative phosphorylation.  In 
addition, complexes I and III are the main sites of mitochondrial ROS production 
required at low levels for cellular signal transduction 110.  Damage to these sites can 
dramatically increase ROS production, which in turn can act in an autocrine fashion, 
damaging the ETC further and also resulting in significant oxidative damage to 
cellular proteins and lipids 96.   
Mitochondrial DNA (mtDNA) may be susceptible to oxidative damage in men 
and women with PAD.  Complex II, the only ETC complex entirely encoded by nuclear 
DNA, is the only ETC complex unaffected in PAD skeletal muscle 96.  All other 
complexes are partly encoded by mtDNA, suggesting that close proximity to the ETC 
exposes mtDNA to the elevated levels of ROS.  Mitochondrial DNA mutations have 
been found in PAD skeletal muscle 111.  The mutations may result in the transcription 
of defective ETC complexes and consequently further increases in ROS and impaired 
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oxidative phosphorylation 112, thus initiating and perpetuating a destructive cycle of 
oxidative damage and mitochondrial dysfunction (figure 2.8).  
 
Figure 2.8: The cycle of mitochondrial dysfunction 
ATP, adenosine triphosphate; DNA, deoxyribonucleic acid; e
-
, electrons; O2, oxygen; O2
-
, 
oxide ion; ROS, reactive oxygen species. 
Damage to the electron transport chain leads to leakage of electrons and increased 
production of reactive oxygen species.  The ROS cause damage to mitochondrial DNA, 
proteins, and lipids, perpetuating a destructive cycle of oxidative damage and 
mitochondrial dysfunction. 
Indicators of impaired mitochondrial respiration in PAD include prolonged 
post-exercise phosphocreatine (PCr) and ADP recovery rates and acyl-carnitine 
accumulation.  PCr and ADP are restored to pre-exercise levels using ATP generated 
mainly by oxidative phosphorylation, which occurs exclusively in the mitochondria 
113.  Using 31 magnetic resonance spectroscopy, it was found that post-exercise PCr 
and ADP recovery rates were prolonged in PAD skeletal muscle 114,115.  
Acylcarnitine Accumulation  
Carnitine serves as a buffer for the acyl-CoA pool through the reversible 
transfer of acyl groups (figure 2.9).  Changes in the distribution of total carnitine 
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between free carnitine and acylcarnitine reflects changes in the acyl-CoA pool and 
thus is an index of metabolic function 116.  Under conditions of metabolic stress, 
acetyl-CoA production may exceed utilization in the Kreb cycle leading to acetyl-CoA 
accumulation 117, which can inhibit pyruvate dehydrogenase leading to the 
production of lactate.  Transfer of the acetyl group from acetyl-CoA to carnitine to 
form acetyl-carnitine and CoA, decreases acetyl-CoA concentration alleviating the 
inhibition of pyruvate dehydrogenase.  During exercise the increase in lactate and 
acylcarnitine are closely related (Hiatt, 1992) and acylcarnitine accumulation occurs 
during high-intensity exercise exceeding the lactate threshold but not during low-
intensity exercise.   
 
 
Figure 2.9: The role of carnitine as a buffer for the acyl-CoA pool 
Carnitine buffers acetyl-CoA through the reversible transfer of acyl groups to produce 
acylcarnitine and CoA 
In PAD, the increase in muscle short-chain acylcarnitine concentration in the 
symptomatic limb during exercise was not related with the systemic lactate 
threshold or the change in muscle lactate content but was instead significantly 
related with exercise duration (r=0.82) 118.  In contrast, in the asymptomatic limb 
muscle short-chain acylcarnitine concentration significantly increased in participants 
who exceeded their lactate threshold only and the change in muscle short-chain 
acylcarnitine content was significantly related with peak blood lactate concentration 
(r=0.67, p<0.05), a response similar to healthy controls.  These findings indicate a 
Carnitine Acylcarnitine 
Acetyl CoA CoA 
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disruption in skeletal muscle intermediary metabolism during exercise in PAD.  In 
addition, there was an inverse relation between resting muscle short-chain 
acylcarnitine concentration and maximal walking time (MWT) (r=0.70, p<0.05) and 
VQO2peak (r=0.75, p<0.05) 
118 and between plasma short-chain acylcarnitine 
concentration and MWT (r=0.51, p<0.05) 119.  These associations were not observed 
in the asymptomatic limb or in healthy controls and indicate that the greater the 
accumulation of short-chain acylcarnitine at rest, the greater the functional 
impairment in individuals with PAD.  
The association between functional capacity and acylcarnitine concentration 
also indicates that individuals with PAD with more severe functional impairment 
have a greater accumulation of acylcarnitine.  In fact, individuals with severe PAD, 
Fontaine Stage III and IV, display carnitine deficiency 120, indicating that the more 
severe the ischemic disease, the greater the amount of carnitine required to buffer 
the excess acylCoA, which can ultimately lead to carnitine deficiency.  Carnitine 
deficiency has also been found in other ischemic conditions such as following an MI 
121.  Supplementation with L-carnitine and L-propionylcarnitine can improve walking 
performance in individuals with PAD compared with placebo 122,123.  L-carnitine 
therapy was associated with an increase in post-exercise lactate removal and an 
increase in lactate/pyruvate ratio during recovery, suggesting improved pyruvate 
utilization and oxidative phosphorylation efficiency 124.  This is further supported by 
the finding of increased short-chain acylcarnitine, implying that part of the 
supplemented carnitine was taken up by the muscle to buffer acyl-CoA.  
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Improvements in walking performance with L-carnitine were only evident in those 
with an abnormal plasma acylcarnitine responses to exercise 124 or carnitine 
deficiency 120. 
The functional impairment associated with PAD is not related to peripheral 
hemodynamics but is significantly related with acylcarnitine accumulation, which 
highlights the importance of the skeletal muscle myopathy in the pathophysiology of 
PAD.  Individuals with PAD are in double jeopardy; the blood and oxygen supply to 
the working muscles distal to the stenosis is compromised and the oxygen that is 
received by these muscles cannot be utilized to its maximum potential.   
Alterations in Skeletal Muscle Histology  
In addition to the metabolic myopathy evident in skeletal muscle, PAD is also 
associated with alterations in skeletal muscle morphology and function.  Ischemia-
reperfusion injury can result in denervation, fiber and muscle atrophy, and changes 
in muscle fiber type distribution that may contribute to the functional impairment 
associated with PAD 125.    
Neuropathy 
Chronic ischemia and I-RI can result in tissue damage including damage to 
nerve tissue.  Nerve conduction and EMG studies have reported evidence of 
neurological abnormalities in individuals with PAD.  The incidence of neurological 
abnormalities is significantly related to the severity of ischemia.  Findings of 
prolonged motor and sensory nerve conduction velocities, prolonged distal motor 
 35
latencies, and small amplitude of the compound muscle action potential suggest 
axonal degeneration and demyelination in PAD 126.  Histological analysis of sciatic 
and sural nerves from amputated PAD limbs demonstrate both axonal degeneration-
regeneration and segmental demyelination-remyelination 127.   
Denervation may result due to distal motor axon and nerve twig injury from 
repeated exposure to ischemia-reperfusion.  Evidence of denervation in individuals 
with PAD includes the presence of angular or target fibers, muscle fiber atrophy, 
muscle fiber grouping, and longer duration motor unit action potentials 126,128.  
Denervation can result in a decrease in excitatory and trophic effects of motor 
neurons, rendering them unable to maintain normal muscle fiber structure.  The 
muscle fibers are paralyzed in a flaccid state and begin to lose their contractile 
elements leading to muscle fiber atrophy unless reinnervated by a neighbouring 
motor neuron.   
Impaired lower extremity motor nerve innervation to skeletal muscles can 
result in muscle weakness, either directly or through muscle atrophy, and 
consequently contribute to functional impairment.  In men with unilateral IC, a 
significant relation has been found between walking performance and the number of 
angular fibers in the anterior tibial muscle of the symptomatic limb 129.  Peroneal 
nerve function, measured by electroneurography, was significantly related with calf 
muscle cross-sectional area (CSA), 6 minute walk test distance (6MWD), usual- and 
fast-paced 4 m walking velocity, and short physical performance battery (SPPB) score 
(a functional performance measure of leg strength and balance, that combines data 
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from usual paced 4 m walking velocity, time to rise and stand from a seated position 
5 times, and standing balance) in 413 men and women with PAD, but not in 271 age- 
and gender-matched controls 130.  The relation between nerve function and 
functional performance was attenuated after adjustment for calf muscle CSA.   
Muscle Atrophy 
Denervation and I-RI associated with PAD can lead to fiber and muscle 
atrophy.  Clyne et al., (1985) found that the CSA of both type I and II muscle fibers 
are significantly smaller in men and women with PAD than in healthy controls 131.  It 
was speculated that the smaller CSA was due to reduced mobility in patients with 
PAD.  However, when physical activity levels were matched among 14 men and 
women with PAD and 8 age-matched controls, both type I and type II muscle fiber 
area were still significantly smaller in PAD patients than controls, suggesting that the 
muscle atrophy is caused by PAD rather than disuse 132.  Type II fiber CSA has also 
been found to be smaller in symptomatic limb of men with unilateral PAD compared 
with the asymptomatic and activity-matched control limbs 128.   
Ischemia-reperfusion is associated with an inflammatory response and 
markers of inflammation are significantly related to calf muscle characteristics in 
PAD.  McDermott et al., (2007) found a significant inverse relation between calf 
muscle area and blood levels of CRP, interleukin-6 (IL-6), sVCAM-1, and D-dimer and 
between calf muscle density and blood levels of D-dimer, sVCAM-1, and 
homocysteine among 423 men and women with PAD 133.  These associations were 
generally unchanged after adjustment for physical activity levels.  There was a 
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significant inverse relation between sVCAM-1 and plantar flexion strength, which 
was attenuated after additional adjustment for calf muscle area, calf muscle 
percentage fat, and calf muscle density, indicating that calf muscle characteristics 
are involved in the association between inflammation and muscle function.   
Inflammation can directly alter muscle homeostasis by inhibiting muscle 
repair and promoting muscle proteolysis 134.  In men with unilateral IC substantial 
muscle fiber damage has been found in the anterior tibial muscle of the 
symptomatic limb compared with the asymptomatic limb and healthy controls 129.  
Morphological abnormalities included centrally localized nuclei, single fibers 
undergoing necrosis with and without phagocytosis, infiltrates of inflammatory cells 
between fibers, increased connective tissue, and focal and extensive Z-line 
streaming. 
Muscle atrophy in PAD may be related to the degree of ischemia.  A lower 
ABI has been associated with smaller calf muscle CSA, independent of physical 
activity 130.  A recent study by Parmenter et al., (2013) found a significant relation 
between ABI and bilateral hip extensor strength (r=0.54) and whole body strength 
(r=0.44) among 22 men and women with IC 135.  Bilateral hip extensor strength was 
also significantly related to 6MWD (r=0.75) and SPPB score (r=0.75), suggesting the 
presence of a pathway from a decrease in ABI to muscle atrophy and weakness, 
functional impairment and reduced ambulatory capacity.  
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Muscle Fiber Type Shift 
Type II muscle fibers may be more susceptible to ischemic damage than type 
I fibers.  In addition, denervation-reinnervation and physical inactivity may lead to 
changes in myosin isoforms resulting in fiber type transitions.  PAD appears to be 
associated with a muscle fiber type shift towards type I fibers, however the research 
is inconsistent with the shift to type I fibers reported in most 128,136 but not all studies 
132.  Controversial findings are likely due to variability in populations studied, in 
terms of disease severity, comorbidities, and physical activity level, the methods 
used for fiber type determination, and the fiber type composition of the control 
population.  
Fiber type alteration in PAD appears to be related to disease severity, with 
progressive increases of the relative amount of myosin heavy chain 1 (MHC I) with 
increasing ischemia.  Steinacker et al., (2000) determined the proportion of MHC 
isoforms in 13 PAD patients with varying degrees of PAD severity and 5 age-matched 
controls 136.  There was no difference in the proportion of MHC isoforms between 
participants with Fontaine stage II PAD and controls.  Individuals with Fontaine stage 
III PAD had a significantly reduced proportion of MHC IIb isoforms and a 
corresponding significant increase in the percentage of MHC I compared with 
controls.  In Fontaine stage IV, there was a significant decrease in MHC IIa compared 
with controls, resulting in a remarkably high MHC I content and the ratio of MHC I/II 
demonstrated a shift towards the more oxidative type I fiber.  
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Daily Physical Activity in Peripheral Arterial Disease  
Intermittent claudication severely limits mobility and functional capacity, 
with impairments in walking speed and distance 29,137.  This ambulatory limitation 
significantly reduces daily physical activity levels and in a destructive cycle, low daily 
physical activity leads to further impairments in functional capacity 138.  Low daily 
physical activity is a risk factor for the development of PAD.  A sedentary lifestyle 
was associated with a 1.46-fold increased risk of developing PAD 139.  Daily physical 
activity has been found to be significantly lower in individuals with PAD than healthy 
controls.  In a study by Sieminski et al., (1997), energy expenditure and step count, 
measured by accelerometer and pedometer, were significantly lower in 85 
participants with IC compared with 59 healthy controls 140. Women with IC have 
been shown to be less physically active than their male counterparts 141,142 and 
individual with IC who smoke are less physically active than non-smokers 143.   
The lower daily physical activity levels observed in individuals with PAD are 
due to both less time spent walking and fewer strides taken, especially at medium 
and high cadences.  The pattern of ambulatory activity was compared in 98 men and 
women with PAD and 129 age- and gender-matched controls, using a step activity 
monitor, worn for 7 d, by Gardner et al., (2007) 144.  Participants with PAD took fewer 
total strides.d-1 and fewer strides at medium, 15-30 strides.min-1 and high, >30 
strides.min-1, cadence than controls.  A higher percentage of the PAD patient’s 
strides were at a low cadence, <15 strides.min-1.  The average daily cadence and the 
peak activity index (average stride rate for the highest 30 min of the day) were 
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significantly lower in the PAD group than controls and participants with IC had a 
significantly slower ambulation at paces characteristics of bursts of activity and 
ambulation at sustained endurance activities than controls. The total time spent 
ambulating per day was significantly lower in the PAD group than controls, but there 
was no difference in sedentary time between groups.   
The fragmented nature of ambulation in individuals with IC was objectively 
quantified using an ActivPAL™ physical activity monitor by Clarke et al., (2013) 145.  
Thirty men and women with IC and 30 age- and gender-matched controls wore the 
monitor for 7 d and the ratio of the number of walking events to upright events was 
taken as an event-based claudication index (EBCI).  There was no difference in the 
number of upright events between groups, whereas the number of walking events 
and therefore the EBCI was significantly higher in participants with IC than controls, 
reflecting the need to stop and start more frequently due to claudication pain.  To 
achieve the same step count, participants with PAD would require more walking 
events per upright event.   
Daily Physical Activity and Disease Severity  
Daily physical activity has been found to be significantly related with PAD 
severity.  Sieminski et al., (1997) found a significant relation between ABI and 
physical activity determined by both accelerometer (r=0.41) and pedometer (r=0.41) 
140.  For every 0.10 decrease in ABI, daily activity was 42 kcal.d-1 or 612 steps.d-1 
lower.  Gardner et al., (1999) found no relation between energy expenditure of 
physical activity (EEPA), determined using both doubly-labelled water (DLW) and 
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indirect calorimetry, and markers of macrocirculation, ABI and calf blood flow 146.  
There was, however, a significant relation between EEPA and markers of 
microcirculation, calf transcutaneous heating power at rest (r=-0.41), after post-
occlusion reactive hyperemia (r=-0.38), and after maximal exercise (r=-0.46).   
Daily Physical Activity and Functional Capacity 
Daily physical activity is significantly related with functional capacity in 
individuals with PAD.  Gardner et al., (1998) reported a significant association 
between EEPA, measured using DLW and indirect calorimetry, and maximal walking 
distance (MWD) (r=0.47) and 6MWD (r=0.63) 147.  Functional capacity is associated 
with both the duration and intensity of physical activity.  Gardner et al., (2008) found 
a significant relation between MWD and total daily strides (r=0.31), total activity 
time (r=0.21), strides at medium (r=0.26) and high cadence (r=0.34), time at medium 
(r=0.28) and high cadence (r=0.31), average cadence (r=0.31), and peak activity index 
(r=0.47) 148.  Pain-free walking distance (PFWD) was associated with physical activity 
intensity rather than duration.  There was a significant relation between PFWD and 
average cadence (r=0.19) and peak activity index (r=0.31), indicating the onset of 
claudication limits the intensity of physical activity.  
Daily physical activity is also associated with functional decline in PAD.  In a 
cohort of 417 men and women with PAD followed for a median of 36 months, those 
who reported walking for exercise ≥3 d.wk-1 had a significantly smaller average 
annual decline in 6MWD, usual-paced 4 m walking velocity and fast-paced 4 m 
walking velocity than those who exercised less frequently 149.  Similar findings were 
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observed with accelerometer-measured physical activity.  Higher baseline 
accelerometer-measured physical activity was significantly associated with less 
average annual decline in 6 MWD, 4 m walking velocity, and SPPB score in 203 men 
and women with PAD followed for an average of 33.6 months 138.   
Greater sedentary time is associated with accelerated functional decline.  
Greater self-reported hours spent sitting per day and greater self-reported total 
sedentary time were associated with faster average annual decline in 6MWD, and 
usual-paced and fast-paced 4 m walking velocity in 384 men and women with PAD 
followed for a median of 47 months 150.  
Daily Physical Activity and CV Risk Factors  
Gardner et al., (2013) reported a significant association between hs-CRP and 
the total number of daily strides (r=0.30), total daily ambulatory time (r=0.28), daily 
average cadence (r=0.19), and peak activity index (r=0.24) in 134 men and women 
with IC 151.  An impaired endogenous fibrinolytic profile has been shown in sedentary 
individuals with PAD compared with their physically active counterparts.  Gardner et 
al., (2002) classified 106 men and women with IC into low, moderate, and high 
tertiles of physical activity based on data from Caltrac accelerometers worn over 2 
weekdays 141.  Tissue plasminogen activator activity was significantly lower and 
plasminogen activator inhibitor activity was significant higher in the low physically 
active group than the moderate and high groups.  There was no difference in 
fibrinolytic profile between the moderate and high activity groups.  Expending <175 
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kcal.d-1 in physical activities is associated with impaired endogenous fibrinolysis in 
individuals with PAD and increases the risk of having a prothrombotic state.     
Daily Physical Activity and Mortality  
Low physical activity is associated with increased risk of CV morbidity and 
mortality in healthy individuals 152,153.  Individuals with PAD are already at an 
increased risk of mortality 3,40 and a sedentary lifestyle further compounds this risk.  
Higher physical activity, determined using an accelerometer worn over 7 d, was 
associated with lower all-cause mortality after adjustment for confounders in 460 
men and women, mean age 71.9 ± 8.4 yr, with PAD at 57 month follow-up 154.  Those 
in the lowest activity quartile had a 3.48 fold higher mortality rate than those in the 
highest quartile.  In a retrospective, natural history follow-up study, men and women 
with IC were classified as physically active (n=135) or sedentary (n=135) using the 
Johnson Space Centre physical activity scale 155.  At follow-up, median 5.0 yr, the risk 
of mortality was significantly lower in the physically active than sedentary (hazard 
ratio = 0.51).  Physical activity status was an independent predictor of mortality.  
Participants who engaged in any amount of physical activity exceeding light intensity 
had a lower risk of mortality than the sedentary individuals who performed either no 
or only light-intensity physical activity.   
Sedentary Behaviour 
Moderate to vigorous physical activity (MVPA) has established health 
benefits and low levels of MVPA are associated with CVD, type 2 diabetes mellitus 
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(T2DM), obesity, and some site specific cancers 152,153.  Over the last decade, 
evidence has emerged suggesting that excessive sedentary behaviour has 
deleterious CV and metabolic effects, independent of physical activity levels.  The 
term inactivity physiology was proposed in 2004 to describe the research on the 
potential causal role of sedentary behaviour in the development of CV and metabolic 
diseases and to distinguish it from exercise physiology 156.  The effects of inactivity 
may not simply be a mirror image of the effects of activity or reflect the bottom end 
of the physical activity continuum.  There may be potentially unique molecular, 
physiologic, and clinical effects of too much sitting compared with too little exercise 
157. 
Epidemiological Evidence 
Epidemiological studies have provided a wealth of information on the 
association between sedentary behaviour and cardiometabolic risk.  In the 
Australian Diabetes, Obesity and Lifestyle Study (AusDiab) of 11 247 men and 
women aged ≥25 yr, self-reported TV viewing time and overall sitting time and/or 
accelerometer-derived sedentary time were significantly related with body mass 
index (BMI), blood pressure (BP), total cholesterol, HDL-C, low-density lipoprotein 
cholesterol (LDL-C), triglycerides (TGs), impaired fasting glucose (IFG), impaired 
glucose tolerance (IGT), 2-h plasma glucose, fasting insulin, insulin resistance, 
clustered metabolic risk score, and the metabolic syndrome, independent of physical 
activity 158–163.  In NHANES, self-reported total TV and computer time was 
significantly associated with the metabolic syndrome 164,165 and accelerometer-
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derived sedentary time demonstrated a detrimental linear association with waist 
circumference, HDL-C, TGs, CRP, insulin, B-cell function, and insulin sensitivity 6.  
Similarly, Henson et al., (2013) reported detrimental linear associations of 
accelerometer-derived sedentary time with 2-h plasma glucose, TGs, and HDL-C, 
among 878 men and women with a mean age of 58.4 ± 13.8 yr 166.  
In the EPIC-Norfolk study of 14189 men and women, mean age 60.5 ± 9.0 yr, 
TV viewing time was significantly associated with BMI, waist to hip ratio, percentage 
body fat, BP, total cholesterol, LDL, HDL, TGs, and HbA1c 
167.  In the ProActive UK trial 
involving 258 overweight men and women, mean age 40.8 ± 6.4 yr, with a family 
history of T2DM, accelerometer-measured sedentary time was significantly 
associated with insulin resistance 168.  There was a significant association between 
TV viewing time and the risk of T2DM among 37918 men and 50277 women in the 
Health Professionals Follow-up Study 169 and the Nurses’ Health Study 170, 
respectively. 
High levels of TV viewing time can have detrimental effects on 
cardiometabolic health even in individuals meeting the current physical activity 
recommendations.  Among 4064 participants in the AusDiab study who reported 
≥2.5 h.wk-1 of MVPA, there was a significant dose-response association between TV 
viewing time and waist circumference, SBP, and 2-h plasma glucose in men and 
women, and FPG, TG, and HDL in women 171.  
In a prospective study, the change in TV viewing from baseline to 5 yr follow-
up was significantly associated with changes in waist circumference, insulin 
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resistance, fasting serum insulin, and β-cell function in men and women, 2-h plasma 
glucose in men, and FPG and DBP and clustered metabolic risk score in women, 
independent of baseline and change in physical activity 172 
Sedentary behaviour has also been associated with CV events and mortality.  
In the EPIC-Norfolk study, there was a significant association between TV viewing 
time and incident total CVD, non-fatal CVD and CHD at 6.9 ± 1.9 yr follow-up 173.  In 
123216 US men and women, mean age 63.6 ± 6.0 yr, self-reported sitting time was 
associated with all-cause and CVD mortality at 14 yr follow-up 174.  In 4,512 Scottish 
men and women, mean age 57.8 ± 14.2 yr, screen-based entertainment time was 
significantly associated with all-cause mortality and CVD events at 4.3 ± 0.5 yr follow-
up 175.  Time spent riding in a car and a combination of TV and car time were 
significantly associated with CVD mortality in 7744 men aged 20-89 years at 21 yr 
follow-up 176.  
In the Canada Fitness Survey, there was a dose-response association between 
levels of sitting time and risk of all-cause and CV mortality in 17013 men and women 
aged 18-90 yr at mean follow-up of 12.9 yr 177.  In 83034 Japanese men and women 
aged 45-76 yr, there was significantly greater all-cause mortality at mean follow-up 
of 8.7 yr in men, but not women, who reported sitting for ≥8 h.d-1 compared with <3 
h.d-1 178.  In the AusDiab study, each 1 h.d-1 increase in TV viewing time was 
associated with hazard ratios of 1.11 and 1.18 for all-cause and CVD mortality, 
respectively at a median follow-up of 6.6 yr 179.  All these associations were 
independent of physical activity.  
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Breaks in Sedentary Time 
In addition to the detrimental effects of total sedentary time, the manner in 
which it is accumulated is of clinical relevance.  Breaking up sedentary time may 
have a beneficial effect on cardiometabolic risk, independent of total sedentary 
time.  In the AusDiab Study, breaks in sedentary time, defined as interruptions in 
sedentary time of >100 accelerometer counts.min-1, were inversely associated with 
waist circumference, BMI, TGs, and 2-h plasma glucose, independent of total 
sedentary time, MVPA, and the mean intensity of breaks 7.  Similarly, in the NHANES 
study there was a significant beneficial association between breaks in sedentary time 
and waist circumference, CRP, and FPG, independent of total sedentary time 6.  
Henson et al., (2013) found inverse associations between breaks in sedentary time 
and measures of adiposity, BMI and waist circumference, among 878 men and 
women, mean age 58.4 ± 13.8 yr, independent of total sedentary time 166. 
Mechanisms  
The mechanisms through which sedentary behaviour is associated with 
cardiometabolic risk are yet to be determined.  Both physiological and behavioural 
mechanisms have been proposed.  Behaviours associated with TV viewing time such 
as increased snacking have been suggested.  It is worth noting that the association 
between TV viewing time and cardiometabolic risk markers remains significant after 
adjustment for dietary intake.  Physiologically, inactivity may have unique negative 
effects on specific cellular and molecular processes important for disease-related 
proteins 156.  Findings from bed rest studies may provide insight but need to be 
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inferred with caution because these studies usually involve lying down for several 
days.  In an animal study, just 12 h of immobilization was associated with changes in 
expression of 63 genes and 58 expressed sequence tags compared with controls 
performing normal spontaneous standing and light ambulation 180.  There is limited 
evidence that inactivity activates specific molecular responses leading to impaired 
lipid metabolism by suppression of skeletal muscle lipoprotein lipase (LPL) activity 
181,182.  Lipoprotein lipase is among the first proteins directly involved in lipid 
metabolism to be studied at the cellular level during physical inactivity and has 
served as the prototype for understanding the impact of inactivity on metabolic 
health and highlighting the distinct cellular responses of activity and inactivity.   
Lipoprotein Lipase 
Lipoprotein lipase is a plasma enzyme synthesized primarily by muscle cells 
and adipocytes 183.  When present on the vascular endothelium, LPL binds to 
circulating lipoproteins and mediates TG lipolysis.  A reduction in LPL activity impairs 
tissue-specific uptake of lipoprotein-derived fatty acids and may contribute to the 
impaired lipid metabolism evident in obesity, T2DM, and CVD.  Even a small 
reduction in LPL activity with specific polymorphisms is associated with a significant 
increase in the risk of CVD and mortality compared with healthy individuals 184.   
The amount of LPL activity in skeletal muscles is extremely sensitive to 
physical inactivity and activity.  Bey and Hamilton (2003) reported a significant 
reduction in heparin-releasable LPL activity in rodent skeletal muscle after both 
acute, 12 h, and chronic, 10 h.d-1 for 11 d, hindlimb unloading compared with 
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ambulating controls 181.  Lipoprotein lipase activity began to decline after just 4 h of 
inactivity.  Following acute unloading, a recovery period of 4 h of normal cage 
activity and low-intensity treadmill walking was sufficient to reverse the LPL activity 
reduction.  The inactivity-induced decrease in LPL activity was localized to the 
immobilized skeletal muscle.  There was no decrease in LPL activity in the diaphragm 
or cardiac muscle, which continued contractile activity, or in the contralateral limb 
during unilateral limb unloading.  This suggests the decrease in skeletal muscle LPL 
activity is associated with the loss in local contractile activity and not a generalized 
response to a decrease in systemic energy demands.   
The decrease in LPL activity was in association with a significant decrease in 
[3H]TG-derived fatty acid uptake locally in hindlimb muscles and a significant 
decrease in HDL-C concentration after both acute and chronic unloading.  The 
decrease in LPL activity occurred in the absence of a change in LPL mRNA 
concentration.  Instead there was a significant decrease in heparin-releasable and 
total LPL protein mass.  The decrease in heparin-releasable LPL protein mass was 
significant after just 6 h compared with 12 h for total LPL protein mass, indicating 
that the LPL protein at the endothelium and other heparin binding sites is depleted 
before the larger intracellular pool.  This suggests a possible posttranslational 
regulation of the distribution of LPL.  Actinomycin D (ActD) is a potent global 
inhibitor of transcription and has been shown to raise LPL activity without raising LPL 
mRNA concentration.  Intraperitoneal injection of ActD immediately prior to 
unloading prevented the decrease in heparin releasable LPL activity.  Actinomycin D 
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infusion did not change LPL activity in ambulatory controls or during the reloading 
phase, suggesting the presence of a short-lived and potent inhibitor protein for 
posttranslational regulation of LPL induced by physical inactivity. 
In a subsequent rodent study, intraperitoneal administration of nicotinic acid 
completely prevented the inactivity-induced decrease in heparin-releasable LPL 
activity 182.  Nicotinic acid was administered at a dose known to acutely impede the 
appearance of plasma TG from the liver and FFA from adipose tissue.  In contrast to 
inactivity, nicotinic acid had no effect on heparin-releasable LPL activity in control 
rats with normal standing and ambulatory activity, indicating that the sensitivity of 
LPL activity to circulating plasma lipids is heightened by low contractile activity.  
Research on the effects of LPL activity during run training in rodents 183 
permits the comparison of the effects of activity and inactivity on LPL activity and 
highlights that the effects of inactivity are not simply the opposite of activity.  Firstly, 
the magnitude of the LPL activity response to activity and inactivity differs greatly.  
After just 10 h of inactivity, LPL activity was 10 fold lower compared with a ≥2.5 fold 
increase after 14-20 d of run training.  Secondly, the muscle fiber types affected 
differ.  Running was associated with a significant increase in LPL activity in glycolytic 
fibers only, whereas inactivity was associated with a greater decrease in LPL activity 
in oxidative fibers.  The higher sensitivity of oxidative fibers to inactivity compared 
with glycolytic fibers may be because oxidative fibers are generally recruited during 
standing, for example in postural muscle.  Lastly, run training is associated with a 
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significant increase in LPL mRNA compared with no change in LPL mRNA during 
inactivity.   
Insulin Action 
Epidemiological studies have reported a positive association between 
sedentary time and insulin resistance and the risk of T2DM.  Prolonged muscular 
unloading by hind limb suspension in rodents and bed rest in humans can decrease 
insulin-mediated glucose uptake 185,186.  Brooke et al., (2011) investigated the effect 
of 1 day of sitting on insulin action in 14 healthy men and women, mean age 26.1 ± 
4.5 yr 187.  Insulin action was measured during a continuous infusion of [6,6-2H]-
glucose the morning after three 24 h conditions: 1) an active, no sitting condition 
with a high energy expenditure of 2944 ± 124 kcal and a matched energy intake (NO-
SIT), 2) a sitting condition with low energy expenditure of 2195 ± 121 kcal and no 
reduction in energy intake (SIT), and 3) a sitting condition with low energy 
expenditure of 2139 ± 118 kcal and a reduction in energy intake to match 
expenditure (SIT-BAL).  Insulin action, defined as whole-body rate of glucose 
disappearance normalized to mean plasma insulin, was decreased by 39% in the SIT 
(p<0.001) and by 18% in the SIT-BAL group (p=0.07) compared with the NO-SIT 
group.  Insulin action was significantly lower in the SIT group than the SIT-BAL group.  
One day of sitting substantially reduced insulin action; this effect was attenuated, 
but not prevented, when energy intake was decreased to match expenditure.  These 
findings suggest that energy surplus is central to the acute metabolic response to 
sitting but other factors are also involved.  There was no significant difference in 
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fasting glucose, hepatic insulin action, or fatty acid oxidation between groups, 
suggesting the effect of prolonged sitting may be mediated in skeletal muscle and 
may be related to reduced skeletal muscle insulin sensitivity.  The factors responsible 
for this response are unknown but potential factors include greater circulating levels 
of counterregulatory hormones (e.g., glucagon, epinephrine, cortisol) or 
hemodynamic changes, including decreased insulin-mediated muscle blood flow and 
capillary recruitment. 
Breaking up sedentary time has a beneficial effect on insulin.  In a study by 
Dunstan et al., (2012), 19 sedentary overweight men and women, mean age 53.8 ± 
4.9 yr, performed either 5 h uninterrupted sitting, or 5 h sitting with 2 min bouts of 
light (3.2 km.h-1) or moderate-intensity (5.8-6.4 km.h-1) treadmill walking every 20 
min.  There was a significant reduction in both the glucose and insulin positive 
incremental area under the curve following the interrupted conditions compared 
with the uninterrupted condition.  Interrupting with light or moderate-intensity 
exercise lowered glucose and insulin by a similar extent.  
Low Energy Expenditure  
The associations between sedentary behaviour and cardiometabolic risk are 
independent of MVPA.  There is little or no relation between sedentary time and 
MVPA time 158.  On average only ~4% of waking hours are spent in MVPA, with the 
majority spent in either sedentary or light-intensity activity 162.  The deleterious 
health effects of sedentary behaviour are therefore not the result of sedentary 
behaviour replacing MVPA but may arise from sedentary behaviour replacing light-
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intensity activity.  Sedentary time and light-intensity time are strongly inversely 
related 162,163. 
Light-intensity activity consists of unintentional or non-exercise behaviours.  
This “active living” increases skeletal muscle energy demand and effects whole body 
metabolic rate.  Non-exercise activity thermogenesis (NEAT) typically accounts for a 
much greater portion of total energy expenditure than structured exercise 157, can 
be sufficient to prevent diet-induced obesity 188 and may prevent the negative 
molecular impact of inactivity.  Contractile activity through non-exercise activity may 
signal biochemical and molecular processes to prevent the effects of inactivity.  For 
example, rats performing normal cage activity and low-intensity ambulation did not 
experience the decrease in LPL activity of sedentary counterparts 181.  Maintaining a 
high level of daily low-intensity activity may be important for metabolic risk, 
independent of MVPA.   
Management of Peripheral Arterial Disease 
The primary goals of treatment for PAD are to prevent the progression of the 
disease, prevent a coronary or cerebrovascular event, and for individuals with 
symptomatic PAD to relieve symptoms, and improve functional capacity and quality 
of life (QOL) 81.  A number of treatment strategies are utilized in PAD, including risk 
factor modification, pharmacotherapy, revascularization, and exercise rehabilitation.  
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Exercise Rehabilitation  
Exercise was originally recommended by Erb in 1898 as a treatment modality 
for patients with PAD 189.  The concept was reintroduced by Foley in 1957 190 and in 
1988, Housley 191 summarized the treatment of PAD in the statement “stop smoking 
and keep walking”.  Exercise is a non-invasive, inexpensive, relatively safe, and 
effective treatment for PAD and the ACC/AHA recommend exercise as the first-line 
of treatment for the majority of patients 22.  The relatively benign natural history of 
PAD makes non-operative therapy such as exercise a viable and preferred approach 
to treating PAD.  Exercise training has been given a Class I recommendation by the 
ACC/AHA for the treatment of PAD, indicating the general agreement of its 
effectiveness, supported by Level of Evidence A arising from multiple RCTs and meta-
analyses 22.   
Exercise Rehabilitation and Walking Performance 
The improvement of walking performance is a primary objective for the 
treatment of individuals with PAD.  The effect of exercise rehabilitation on walking 
performance in patients with PAD has been extensively studied.  In 1998, Brandsma 
et al., conducted a systematic review of 10 randomized controlled trials (RCTs) 
investigating the effect of exercise on walking performance in individuals with IC 192.  
The methodological quality of the studies were scored and ranged from 47 to 75 
points out of a maximum 100, with a mean of 62.5 ± 8.5 193.  All studies reported that 
exercise had a positive effect on walking distance or walking time, despite the 
differences in demographic data, baseline characteristics, and exercise protocols 
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across the studies.  Improvements ranged from 28% to 210%, with a mean of 105% ± 
55.8%.  Gardner et al., (1995) included RCTs and non-randomized and uncontrolled 
trials in a meta-analysis of exercise trials in individuals with PAD 8.  In the 18 non-
randomized and uncontrolled trials, PFWD and MWD increased from baseline by 
179% and 122%, respectively.  In the RCTs, the exercise group had a 190% and 39% 
increase in PFWD and MWD, respectively, which were significantly greater than 
changes in the control group.   
A recent Cochrane review included 22 RCTs investigating the effect of 
exercise rehabilitation on relieving symptoms and improving walking ability in 
individuals with IC 9.  Exercise was concluded to be an effective therapeutic modality 
for the treatment of IC.  Fourteen of the twenty-two trials compared exercise with 
placebo or usual care and exercise significantly improved PFWD and MWD by 82.19 
m and 113.20 m, respectively.  The overall improvement in walking ability was 
between 50% and 200%.  In the majority of trials the data were not normally 
distributed demonstrating the individual variance in response to exercise.  
Differences in participant demographic and clinical characteristics, exercise 
programme components, training adherence, and outcome measures may account 
for the large range in the degree of improvement. 
The most recent meta-analysis by Fakhry et al., in 2012 included 25 RCTs 
examining the effect of supervised walking therapy as a treatment in individuals with 
IC 194.  There was a weighted mean difference of 128 m and 180 m in PFWD and 
MWD, respectively between exercise and control, in favour of exercise.   
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Exercise rehabilitation compared with usual care/placebo 
The first RCT to investigate the effect of an exercise intervention in PAD was 
performed in 1966 by Larsen and Lassen 195.  Fourteen men with IC were randomized 
to an exercise or placebo-controlled group for 26 weeks.  The exercise group was 
instructed to walk intermittently to near maximal claudication pain for 60 min daily.  
Pain free and maximal walking distance increased significantly from baseline by 
155% and 176%, respectively, whereas there was no change in walking performance 
in the control group.  The effect of supervised exercise therapy was first investigated 
in a RCT in 1974 by Dahllöf et al., 196.  Eighteen men and women with IC were 
randomly assigned to receive either supervised exercise training (dynamic leg 
exercises for 30 min to the onset of claudication pain 3 d.wk-1 for 26 weeks) or a 
placebo drug treatment.  Pain free and maximal walking distance increased by 191% 
and 120%, respectively in the exercise group.  Subsequently, numerous RCTs have 
confirmed the beneficial effect of exercise training compared with usual care on 
walking performance in individuals with PAD.  Table 2.4 provides a summary 
overview of these studies. 
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Table 2.4: RCTs examining the effect of exercise training on pain free walking time and maximum walking time in individuals with peripheral 
arterial disease 
Author n Mean age 
(yr) 
Duration 
(wks) 
Frequency 
(wk
-1
) 
Time 
(min) 
Mode Intensity Claudication 
pain end-point 
Results 
PFWT/PFWD MWT/MWD 
Allen et al., (2010) 
11
 
35 67 ± 2 12 3 30-40 ITW Workload to induce IC at 
baseline, progressed 
Moderately 
severe  
↑ by 138s  ↑ by 260s 
Cheetham et al., 
(2004) 
197
 
59 67 24 1 45 W + 
circuits 
Self-selected pace + 7 x 2 
min circuits  
Moderate to 
maximal  
 ↑ by 129% 
Crowther et al., 
(2008) 
198
 
21 69.2 ± 7.7 52 3 2540 ITW 3.2 kmh
-1
, progressed Near maximal  ↑ by 171% ↑ by 120% 
Dahllof et al., 
(1974) 
196
 
18 61.4 ± 1.7 26 3 30 DLE  Onset ↑ by 191% ↑ by 120% 
Dahllöf et al., 
(1976) 
199
 
34  26 3 30 DLE  Onset  ↑ by 172% ↑ by 128% 
Gardner et al., 
(2001) 
200
 
52 70.5 ± 1 24 3 1540 ITW ~2mph, grade at 50-80% 
max workload 
Near maximal ↑ by 134%  ↑ by 77% 
Helgerud et al., 
(2009) 
201
 
21 67.5 ± 6.5 16 3 4 x 4 min ITW + 
CE 
3.2 kmh
-1
, grade at 90-
95%HRpeak + CE at 55-65 
rpm and 80% max 
workload  
  ↑ by 35% 
Hiatt et al., (1990) 
101
 
19 60 ± 12.5 12 3 60 ITW 2mph, progressed  Moderately 
severe  
 ↑ by 117% 
Langbein et al., 
(2002) 
202
 
52 67.1 ± 7.8 24 3-5 3040-
60 
PS 60-80%VQO2peak   ↑ 51% 
Larsen & Lassen 
(1966) 
195
 
14 57.8 26 7 60 IW  Near maximal ↑ by 155% ↑ by 176% 
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Table 2.4 continued 
Author n Mean age 
(yr) 
Duration 
(wks) 
Frequency 
(wk
-1
) 
Time 
(min) 
Mode Intensity Claudication 
pain end-point 
Results 
PFWT/PFWD MWT/MWD 
McGuigan et al., 
(2001) 
203
 
20 69.5 ± 6 24 3  RT 2 sets of 8-15 reps of 8 
exercises 
 ↑ by 158%  
Mika et al., (2005) 
204
 
80 60.2 ± 6 12 3  ITW 3 x 85% PFWD at 3.2  
kmh
-1 
and 12° grade 
Pain-free ↑ by 119%   
Nicolai et al., 
(2010) 
205
 
304 66.2 ± 9.4 52 2-3 30 ITW  Near maximal  ↑ by 131% 
Patterson et al., 
(1997) 
206
 
55 69.1 ± 8.1 12 3 40 ITW + 
AE + LE 
To induce IC within 3-5 
min 
Onset ↑ by 315%  ↑ by 190% 
Stewart et al.,  
(2008) 
207
 
60 68 ± 8.3 12 2 60 Circuits 8 min x 5 stations  Maximal ↑ by 89%  ↑ by 93% 
Tew et al., (2009) 
208
 
51 69.5±8.5 12 2 10 x 2 
min 
AE 50 rpm at 60-70% max 
workload 
 ↑ by 53%  ↑ by 33% 
Tsai et al., (2002) 
209
 
53 76.2 ± 3.8 12 3 30 ITW 2 mph and 0% grade, with 
1% grade increase every 
10 min  
 ↑ by 88%  ↑ by 70% 
Wang et al., (2008) 
210
 
25 66.5±6.5 8 3 4 x 4 min CE 80% max workload   ↑ by 20% 
Womack et al., 
(1997) 
211
 
26 65.3 ± 7.9 16 3 15-30 ITW 2 mph, grade at 60-
70%VQO2peak 
Near maximal ↑ by 108%  
AE, arm ergometry; CE, calf ergometry; DLE, dynamic leg exercise; HR, heart rate; IC, intermittent claudication; ITW, intermittent treadmill 
walking; IW, intermittent walking; LE, leg ergometry; MWD, maximal walking distance; PFWT, pain-free walking time; PWD, pain-free walking 
distance; MWT, maximal walking time; PS, polestriding; RT, resistance training; W, walking 
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Exercise rehabilitation compared with surgery  
Surgery is an accepted treatment method for PAD 22, although it is not widely 
applied, perhaps because of the associated risks.  In contrast, exercise is a relatively 
safe therapeutic modality.  Research directly comparing exercise and surgery in PAD 
is limited.  In a large scale RCT, 264 men and women with IC were assigned to an 
exercise training, surgery, or control group 212.  Exercise training involved 30 min of 
supervised walking training 3 d.wk-1 for 6 months, and 2 d.wk-1 for a further 6 
months.  At 1 yr follow-up, MWD improved significantly in the surgery group only.  
The lack of improvement in walking performance in the exercise group is atypical 
and may be the result of poor training compliance as only 49% of the exercise group 
completed the training program.  Using the same training protocol, Lundgren et al., 
(1998) did find significant improvements in walking performance in the exercise 
group among 75 men and women with IC, randomized to receive surgery, surgery 
and exercise training, or exercise training only 213.  The improvement in the two 
surgery groups was significantly greater than in the exercise only group, although 
surgery was associated with more complications than exercise.  The combination of 
surgery and exercise had significantly greater improvements than both single 
treatment groups.  These findings were supported by a RCT by Badger et al., (2007), 
in men and women undergoing infrainguinal reconstructive surgery 214.  Patients 
randomized to receive exercise following surgery had a significant increase in MWD 
compared with those randomized to control following surgery.   
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Exercise rehabilitation compared with angioplasty 
The less invasive nature of angioplasty in comparison to surgery has made it 
an attractive and widely used treatment for PAD.  Low complication rates have been 
reported for percutaneous transluminal angioplasty (PTA) in PAD 215.  Research 
comparing exercise and PTA in the treatment of PAD is equivocal.  A recent 
systematic review 216 of all RCTs comparing PTA with exercise therapy in individuals 
with PAD could not conclude the superiority of one treatment option over the other.  
The heterogeneity of interventions, in particular the exercise therapy, baseline 
walking performance, lesion location and the assessment of outcomes made direct 
comparisons between studies impossible and a definitive conclusion could not be 
drawn.  In addition, the methodological quality of the studies was average, sample 
size was small, studies were underpowered and some were terminated prematurely.  
The first RCT to compare PTA and exercise therapy in PAD found an 
improvement in MWD in the exercise group only 217.  ABI improved in the PTA group 
only.  Revascularization was associated with a significant improvement in walking 
performance in a RCT by Murphy et al., (2012) 218.  However, improvements in MWT 
were still not to the same extent as with exercise.  In contrast, Hobbs et al., (2006) 
reported a superiority of PTA over exercise therapy in improving walking 
performance 219.  There was no significant improvement in walking performance 
with exercise therapy, which involved circuit training 2 d.wk-1 for 12 weeks.  This is 
an atypical finding and may be due to follow-up measures not being assessed until 3 
months after the cessation of the exercise program.  
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Revascularization may achieve more rapid improvements in walking 
performance in individuals with PAD, however the invasive nature and associated 
risks of revascularization must be considered and weighed-up against the non-
invasive and relatively safe treatment with exercise.  Furthermore, exercise is 
associated with additional benefits such as improved CV risk factors and CV fitness.  
Improvements with exercise take longer to achieve but may be more durable than 
with PTA.  Indeed, a 2000 Cochrane review of the effect of PTA on IC questioned the 
sustainability of the immediate improvements achieved in walking performance 220.  
In a RCT by Spronk et al., (2009), the initial advantage of PTA over exercise training in 
claudication symptoms was lost 221.  One week after the start of the exercise 
programme and after revascularization, there was a significantly greater 
improvement in clinical success rate, defined as an improvement by at least one 
category on the Rutherford scale, in the PTA group than the exercise group.  After 6 
months, there was no longer a significant difference between the groups. 
The combination of exercise and PTA may have additional benefits on 
walking performance in PAD.  Kruidenier et al., (2011) randomized 70 men and 
women with IC to receive PTA only or PTA plus supervised exercise (SE) 222.  There 
was a similar significant increase in MWD in both groups immediately following 
revascularization.  At 6 months, MWD remained the same as the postoperative level 
in the PTA only group, whereas the addition of SE increased MWD significantly above 
the postoperative level in the PTA + SE group.  Maximal walking distance was 
significantly greater in the PTA + SE group than the PTA only group.  Greenhalgh et 
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al., (2008) compared PTA + SE to SE only in men and women with PAD in a 
multicenter RCT 223.  After 6 months, MWD increased significantly from baseline in 
both groups, but to a significantly greater extent in the PTA + SE group.   
Mazari et al., (2010) compared the combination of PTA and exercise with 
each treatment alone in men and women with PAD 224.  Pain free and maximal 
walking distances were significantly increased above baseline in all 3 groups at 1, 3, 
6, and 12 month follow-up.  Analysis of clinical outcomes according to the 
International Society for Cardiovascular Surgery found that at 3 months follow-up 
62.7%, 66.6%, and 81.6% of patients improved following SE, PTA, and PTA + SE, 
respectively.  The improvements in the PTA + SE group were significantly greater 
than the PTA alone and SE alone, although this was not sustained at 12 months.  
Exercise rehabilitation compared with pharmacotherapy  
Pentoxifylline and cilostazol are the two drugs that have been approved by 
the US Food and Drug Administration (FDA) for the treatment of IC.  Pentoxifylline 
was FDA-approved in 1984 and believed to reduce blood viscosity.  Recent evidence 
suggests pentoxifylline is not significantly different from placebo in the treatment of 
IC 225.  The effect of pentoxifylline in comparison to exercise therapy for the 
treatment of IC has not been extensively studied.  A meta-analysis of controlled 
clinical trials investigating treatment strategies for IC included pentoxifylline trials 
and exercise trials 226.  The trials were classified based on the quality of design; level 
1, RCT with either double-blind or specified blind assessment; level 2, other RCTs; 
levels 3, nonrandomized controlled studies.  Compared with the placebo condition, 
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pentoxifylline increased PFWD by 21.0 m and MWD by 43.8 m in 6 level 1 studies.  In 
5 level 2 studies, exercise rehabilitation resulted in a significant increase in PFWD by 
139.0 m and MWD by 179.1 m compared with controls.  
The effect of pentoxifylline therapy and exercise rehabilitation in the 
treatment of IC was directly compared in a 3 month RCT by Ciuffetti et al., (1994) 227.  
Participants with IC were randomly assigned to receive pentoxifylline, 800 mg three 
times daily, or exercise therapy involving walking 3 d.wk-1 with an initial goal of 500 
m in 20 min, which doubled each week.  After 13 weeks, MWD increased 
significantly in both groups, with significantly greater improvements in the 
pentoxifylline group.  The administration of pentoxifylline in conjunction with 
exercise rehabilitation did not infer additional benefits in walking performance 
compared with exercise rehabilitation alone in a study by Scheffler et al., (1994) 228.  
Men and women with IC were randomized to receive 4 weeks of daily exercise 
therapy alone, or in combination with either pentoxifylline or prostaglandin E1 
(PGE1), administered as 200 mg and 40 μg, respectively, twice daily.  Pain free and 
maximal walking distance increased significantly in all 3 groups.  There was no 
difference in improvements between the exercise only and exercise and 
pentoxifylline groups.  However, the improvement in the exercise and PGE1 group 
was significantly greater than the other groups.  In contrast, iloprost, an analogue of 
PGE, has been shown to be less effective than exercise rehabilitation in improving 
walking performance in individuals with PAD 229.   
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Cilostazol, a phosphodiesterase 3 inhibitor, was FDA-approved in 1999 and is 
associated with significantly greater improvements in walking performance in 
individuals with IC than pentoxifylline or placebo 225.  The effect of cilostazol and 
supervised exercise on walking performance was directly compared in men and 
women with IC randomized in a 2 x 2 factorial design to receive best medical therapy 
(BMT) only, BMT + SE, BMT + cilostazol, or BMT + SE + cilostazol 230.  Cilostazol was 
administered at a dose of 100 mg twice daily and the SE involved circuit training 2 
d.wk-1 for 12 weeks.  Pain free and maximal walking distance significantly improved 
in the exercise and cilostazol groups and the improvement was similar between 
groups.   
The effect of antiplatelet therapy compared with exercise rehabilitation has 
also been investigated in men and women with PAD by Mannarino et al., (1991) 231.  
Thirty PAD patients were randomized to one of 3 groups.  Group 1 was administered 
dipyridamole 75 mg three times daily and aspirin 330 mg once daily.  Group 2 
performed physical exercise in the form of walking and dynamic leg exercise to the 
onset of pain daily and group 3 received both the antiplatelet and exercise therapy.  
After 6 months, PFWT and MWT improved significantly from baseline in all 3 groups.  
The improvements in both exercise groups were significantly greater than 
antiplatelet therapy alone.   
The effectiveness of exercise therapy in comparison to pharmacotherapy is 
relatively unknown due to the small number of trials conducted and the small 
number of participants within these trials.  Side effects of pentoxifylline include 
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abdominal bloating, diarrhea, flushing, and palpitations.  Side effects of cilostazol 
include diarrhea, headache, and palpitations 232.  Exercise is a safer and cheaper 
alternative that can provide additional health benefits.  However, exercise 
rehabilitation requires commitment and adherence can significantly impact upon the 
improvements obtained.  Exercise rehabilitation may not be suitable for all patients 
and individual patient characteristics and likelihood to adhere to exercise should be 
considered when deciding the course of treatment.  
There is evidence for the effectiveness of exercise, revascularization, and 
pharmacotherapy compared with usual care or placebo in the treatment of IC and 
current guidelines include all 3 as treatment options.  However, the relative benefits 
of these therapies are unknown, as no multicenter clinical trials have directly 
compared the 3 treatments.  The study of the comparative effectiveness of 
claudication treatments is ranked in the top 50 of all American health challenges by 
the Institute of Medicine 233.   
Exercise Rehabilitation and Quality of Life 
Intermittent claudication impairs functional capacity, which can have a 
detrimental effect on personal, social, and occupational aspects of daily living and 
severely diminish QOL 234–236.  Treadmill performance and ABI relate poorly to 
perceived functional capacity and health status measures in individuals with PAD 
237,238.  These commonly used objective outcome measures do not reflect a patient’s 
perceived QOL and do not directly define the degree of functional disability of a 
patient in the community setting.  In addition, QOL predicts long-term survival in 
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patients with PAD, independent of established prognostic risk factors 239.  The 
evaluation of the efficiency of treatment strategies now extends beyond objective 
measures of clinical symptoms to include the broader impact of the disease and 
treatment on the patient’s QOL and several studies have even proposed the use of 
QOL as a primary endpoint when determining treatment effects 235,238,240. 
Exercise rehabilitation can have a beneficial effect on QOL in individuals with 
PAD.  A recent systematic review identified 23 exercise trials, including 5 RCTs, 
measuring the impact on QOL in patients with IC 241.  Eleven studies used the 
Medical Outcomes Study Short Form (SF-36) and all found improvements in the 
physical functioning domain, with some also reporting improvements in the bodily 
pain, role functioning, vitality, general health and health transition domains.  
Improvements across a range of QOL domains also occurred in studies using a 
disease-specific questionnaire.  Using the Walking Impairment Questionnaire (WIQ), 
a number of RCTs have found significant improvements in walking distances and 
speeds, and ability to climb stairs following exercise rehabilitation 101,209.  In contrast, 
Gardner et al., (2001) failed to find an improvement in WIQ or SF-36 scores in 61 
men and women, mean age 70.5 ± 1 yr, with IC randomized to 24 weeks of exercise 
or control 200.  The training protocol used was similar to a study by Hiatt et al., 
(1990), which did find improvements in WIQ with exercise in 19 men, mean age 61 ± 
13 yr, with IC compared to age-matched controls 101.  Both studies reported 
improvements in treadmill walking performance, however VQO2peak improved in the 
study by Hiatt et al., only, perhaps suggesting a link between improvements in 
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aerobic fitness and QOL.  Participants in the study by Gardner et al., were also older 
and had a greater number of comorbidities.  These findings indicate that in elderly or 
chronically ill individuals, ambulatory function may be only one of many factors 
influencing QOL. 
Taft et al., (2001) compared the effects of exercise rehabilitation and surgery 
on QOL in 264 men and women with IC 242.  Compared with exercise, surgery was 
associated with significantly greater improvements in disease-specific symptoms and 
complaints during walking and Sickness Impact Profile – Intermittent Claudication 
scores.  Spronk et al., (2005) pooled data from 8 trials using a random-effects model 
and weighted mean to compare QOL results between exercise and angioplasty 
treatment 243.  At 3 months there were significant improvements in SF-36 physical 
function and bodily pain domain scores in the exercise group and in the physical role 
functioning and general health in the PTA group.  There was no significant difference 
in the change in QOL between groups.  Although a combination of exercise and 
revascularization has been suggested to have added benefit in improving walking 
performance over either treatment alone, this may not apply for QOL 222,224,244.   
Exercise Rehabilitation and Daily Physical Activity 
The ambulatory limitation associated with IC places individuals with PAD at 
the extreme low end of the physical activity spectrum. Exercise rehabilitation is 
effective at improving claudication symptoms and ambulatory capacity in individuals 
with PAD and therefore, may remove the limitations preventing individuals with PAD 
from leading physically active lives.  Studies investigating the effects of exercise 
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rehabilitation on free-living daily physical activity have produced inconsistent 
findings.  Following 6 months of intermittent treadmill walking (ITW) training to 
near-maximal claudication 3 d.wk-1, Gardner et al., (2000) reported a significant 
improvement in daily physical activity, determined by both a Caltrac accelerometer 
worn over 2 d and the Minnesota LTPA questionnaire, in individuals with PAD 245.  
The change in accelerometer-derived physical activity, but not self-reported physical 
activity, was significantly related with the change in PFWD and MWD.  In a 
subsequent RCT using the same exercise protocol, Gardner et al., (2001) found a 
significant increase in accelerometer-derived physical activity, but no change in self-
reported physical activity in individuals with PAD compared with controls 200.  These 
findings suggest the increase in physical activity was primarily unstructured activity, 
such as walking around the home.  
In contrast, a study including both symptomatic and asymptomatic PAD 
patients found no significant improvement in accelerometer-derived daily physical 
activity, following either ITW or lower extremity resistance training (RT) for 6 months 
246.  It is possible that the lack of impairment in functional capacity experienced by 
asymptomatic participants at baseline may explain the findings.  Despite significant 
improvements in PWFT and MWT, Crowther et al., (2008) found no improvement in 
daily step count, determined by pedometer over 7 d, in men and women with IC 
following supervised treadmill walking training to near-maximal or maximal pain 3 
d.wk-1 for 12 months 198.  Similarly, improvements in treadmill walking performance 
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following both SE and stent revascularization did not translate to improvements in 
community-based step activity in a study by Murphy et al., (2012) 218.   
Exercise Rehabilitation and CV Risk Factors 
Risk factor modification is central to the treatment of PAD.  It can prevent the 
progression of atherosclerotic disease and prevent CV events.  In healthy individuals, 
exercise is an established therapy for risk factor reduction 153.  The functional 
limitations imposed by IC may restrict individuals with PAD from achieving sufficient 
exercise volume or intensity to induce risk factor modification.  The findings are 
inconsistent.  In a nonrandomized-controlled trial specifically addressing the effect of 
exercise rehabilitation on CV risk factors, Izquierdo-Porrera et al., (2000) found a 
significant reduction in total cholesterol, LDL-C and SBP following 6 months of 
supervised ITW 3 d.wk-1 in 34 men and women with IC 247.  There was no change in 
lipids or BP in 14 age-matched controls with IC.  However, between group 
differences were not significant and lipid profile and BP remained abnormal in both 
groups.  The findings from several additional studies investigating the effect of 
exercise training on lipid profiles, WBCs, haematocrit, fasting glucose, fibrinogen, hs-
CRP, plasminogen, platelet count, prothrombin time, and activated partial 
thromboplastin time in individuals with PAD have been equivocal 248–251. 
Exercise Rehabilitation and Cardiovascular Events 
Cardiovascular causes are the primary cause of mortality in individuals with 
PAD.  Individuals with PAD are at a 2-3 fold increased risk of fatal or non-fatal MI or 
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stroke 3,40,72.  Sakamoto et al., (2009) found that completing an exercise programme 
may reduce mortality rates in individuals with PAD 252.  In a retrospective cohort 
study, 118 men and women with PAD were assigned to a 12-week supervised 
exercise programme involving ITW 3 d.wk-1 and the long-term outcomes of 64 
participants who completed the training programme were compared with 54 
participants who did not.  At mean follow-up of 5.7 ± 3.9 yr, CV death-free and 
event-free rates were significantly higher in completers than non-completers.  
Completing the programme reduced CV mortality and morbidity by 52% and 30%, 
respectively.  Completion of the training programme was an independent predictor 
of CV mortality. 
Exercise Prescription  
A meta-analysis of 21 exercise trials in individuals with PAD investigated the 
components of exercise programmes that were most effective in alleviating 
symptoms and improving walking ability 8.  There were significantly greater 
improvements when walking was the sole mode of exercise compared with a 
combination of exercises and when exercise was performed to near-maximal IC 
compared with the onset of IC, for >30 min compared with ≤30 min, for ≥3 
sessions.wk-1 compared with <3 sessions.wk-1, and for ≥6 months compared with <6 
months.  Increases in PFWD and MWD were independently related to claudication 
pain endpoint used during training, duration of the training programme, and mode 
of exercise.  Collectively these 3 exercise components explained 89% and 87% of the 
variance in the increases in PFWD and MWD, respectively.  
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Intensity 
Claudication pain endpoint, the pain threshold to which participants exercise 
explained 55% and 40% of the variance in the increases in PFWD and MWD, 
respectively, making it the most important programme component for determining 
improvements in walking performance 8.  The greatest improvement in walking 
performance occurred when exercise was performed to near-maximal IC compared 
with the onset of IC.  This may be a consequence of greater local ischemia, which 
may lead to greater hemodynamic and metabolic adaptations.  The TASC-II working 
group currently recommends walking to a moderate-high level of claudication pain 
as a treatment for IC 30. 
To date only one study has directly compared training protocols to varying 
claudication pain intensities 250.  Fifty-two men and women with IC were randomized 
to either an onset of IC or moderate IC group.  Both groups performed ITW to their 
designated IC end-point at 3.2 km.h-1 and a grade to induce IC within 3-5 min, 3 d.wk-
1 for 12 weeks.  Pain free and maximal walking time improved significantly and 
similarly in both groups.  
Exercise intensities based on maximal exercise capacity rather than 
claudication pain have been compared in other studies.  Gardner et al., (2005) 
randomized 64 men and women with IC to walk at 40% or 80% of the maximal grade 
achieved during a baseline test 253.  Both groups performed ITW to near-maximal IC 
at ~3.2 km.h
-1, 3 d.wk-1 for 24 weeks.  The low-intensity training (LIT) group 
accumulated 15 min of walking initially and progressed to 40 min, whereas the 
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walking duration of the high-intensity training (HIT) group was shorter to match the 
caloric expenditure of the LIT group.  Pain free and maximal walking distance, 6MWD 
and VQO2peak increased significantly in both groups.  Walking economy, measured 
during a submaximal constant load treadmill test, and fractional utilization of oxygen 
also increased significantly in both groups.  The changes in each measure were 
similar between groups.  
In contrast, Slørdahl et al., (2005) reported a difference in outcomes between 
LIT and HIT in men and women with IC 100.  Participants randomized to both groups 
performed treadmill walking 3 d.wk-1 for 8 weeks.  The LIT group exercised at 
60%VQO2peak and walked continuously for 30 min or if IC became intolerable, they 
walked intermittently and accumulated the 30 min of exercise.  The HIT group 
exercise at 80%VQO2peak and performed 8 x 2 min bouts of exercise, interspersed 
with 3 min of passive recovery.  Maximal walking distance was increased significantly 
in both groups.  The improvements were significantly greater in the HIT than LIT 
group.  VQO2peak was significantly increased in the HIT group only. 
Recently, a pain-free model of exercise training for individuals with IC has 
been proposed.  Some studies have shown that exercise to maximal claudication 
pain can induce an inflammatory response and may be associated with potentially 
harmful systemic effects associated with I-RI.  Exercise to maximal claudication pain 
can lead to elevated plasma markers of oxidative stress 14, oxidative damage 95, and 
inflammation 17,254,255.  Improvements in walking performance in the absence of an 
inflammatory response have been reported using a pain-free training model in 
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individuals with PAD 204.  In a RCT, the training group performed 3 bouts of treadmill 
walking to 85% of their PFWD, 3 d.wk-1 for 12 weeks.  Pain free walking distance 
increased significantly in the training group compared with controls.  There was no 
significant increase in neutrophil count, WBC count, or microalbuminuria with 
exercise.  
Barak et al., (2009) 256 employed a different pain-free training protocol 
involving continuous treadmill walking at ≤2.4 km.h-1 for 2-3 min, with subsequent 
increases in velocity every 1-2 min.  If IC symptoms occurred, velocity was decreased 
until symptoms subsided, before being increased again gradually for a total duration 
of 25 min.  Participants trained 2 d.wk-1 for 6 weeks.  The walking distance, walking 
time, and walking rate during a training session increased significantly from the first 
to the last session.  There were also significant increases in the estimated relative 
VQO2 consumption, mean METs, estimated total energy expenditure, and estimated 
rate of energy expenditure from the first to the last training session.  
Duration 
Exercise programme duration explained 22% and 28% of the variance in the 
increases in PFWD and MWD, respectively in individuals with PAD 8.  Improvement in 
walking performance was significantly greater when participants exercised for ≥6 
months compared with <6 months.  In contrast, a recent RCT investigating the 
optimal exercise programme duration for individuals with PAD, found that 
improvements in PFWD and MWD are achieved rapidly within the first 2-4 months, 
with no further improvement from 4-6 months 257.  Similar findings have been 
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reported in other studies, whereby improvements in walking performance are 
achieved rapidly and further exercise maintains but does not enhance these 
improvements 258,259.  Improvements in walking performance in individuals with PAD 
have been found after as little as 2 weeks of exercise training 229,260.  However the 
exercise training protocols in these studies were intensive, involving several hours of 
exercise daily.  Other studies involving less intense protocols have found 
improvements in walking performance in individuals with PAD after 3-4 weeks 
202,261,262.   
A number of studies have shown continuous improvements in walking 
performance in individuals with PAD with prolonged exercise training 263–265.  
However, if the continuous improvements are expressed relative to the volume and 
intensity of exercise completed during training, a trend of diminishing returns may 
be evident.  More prolonged exercise training programmes may be required to 
achieve additional benefits, such as improvements in CV fitness, and to maintain 
improvements in walking performance.  Improvements can be maintained even 
when the frequency of training sessions is reduced 266 or supervised training is 
followed by an unsupervised training period 207.   
Mode 
Walking is the most commonly used mode of exercise prescribed in PAD 
rehabilitation and is central to the ACC/AHA guidelines for the management of PAD 
22.  Numerous RCTs have confirmed the effectiveness of walking exercise to improve 
walking performance in individuals with PAD 101,200 198.  A recent systemic review of 
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RCTs concluded that aerobic modalities other than walking appear equally beneficial 
for improving walking performance in individuals with PAD, although the data is 
limited 267.  The efficiency of alternative modes of exercise to improve walking 
performance may require a cross-transfer effect, possibly through central and/or 
peripheral adaptations.  Additional aims of PAD treatment are to prevent the 
progression of the disease, prevent CV events and improve QOL.  Alternative modes 
of exercise may be effective in achieving these aims.   
Ergometry 
Lower-limb Ergometry  
Leg ergometry induces similar acute physiological responses to walking in 
individuals with PAD 268.  However, the primary exercise-limiting symptom and the 
post-exercise hemodynamic response in the lower extremity differ between the 2 
modes.  The effects of chronic leg ergometry and walking training on walking 
performance also differ.  In a RCT, men and women with IC performed 6 weeks of 
either treadmill training (TM) or lower-limb ergometry (LLE), matched for volume 
and intensity 269.  Pain free and maximal walking time significantly increased in the 
TM group only and this was significantly greater than the change in the LLE and 
control groups.  Maximal cycle time significantly increased in the LLE group only and 
the change was significantly greater than the change in the control group, but not 
the change in the TM group.  Claudication pain in the calf and quadriceps were the 
most commonly cited symptoms during TM and LLE training, respectively, and the 
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difference in location of the ischemic pain between the 2 modes may explain the 
absence of a cross-transfer effect. 
Calf ergometry utilizes the muscle groups most commonly affected by 
claudication pain during walking and exercise-induced muscle ischemia may 
stimulate local skeletal muscle adaptations and hence may improve walking 
performance.  In addition, decreasing the muscle mass used in exercise increases the 
rate of muscle blood flow and metabolic extraction 270.  Wang et al., (2008) found 
significant improvements in MWT and VQO2peak following 8 weeks of plantar flexion 
training compared with controls.  The fact that there was no change in cardiac 
output (Q) or stroke volume (SV) measured at VQO2peak, would indicate that the 
improvements in MWT and VQO2peak were attributable to peripheral adaptations.  
Plantar flexion power output increased significantly in the exercise group, suggesting 
enhanced metabolic capacity.   
Improvements in Q and SV were found when calf training was combined with 
walking training in individuals with IC 201.  A combination of lower-extremity 
ergometry and walking training may be required to attain both central and 
peripheral adaptations.  Concurrent calf ergometry and walking training has been 
found to improve PFWT, MWT, and VQO2peak 
271,272. 
Upper-limb Ergometry 
Upper-limb ergometry has been proposed as an alternative mode of exercise 
training to allow individuals with PAD to exercise 
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claudication pain, which may increase exercise adherence.  It may also potentially 
increase the intensity of training an individual can achieve, thereby resulting in 
greater potential for improvements in cardiorespiratory fitness.  The cross-transfer 
effect of aerobic exercise training represents a potential mechanism by which upper-
limb ergometry may lead to improvements in walking performance.  Tew et al., 
(2009) found significant improvements in PFWT, MWT and VQO2peak following 12 
weeks of upper-limb ergometry training in men and women with IC compared with 
controls 208.   
In a RCT, Walker et al., (2000) compared upper- and lower-limb ergometry 
training in men and women with IC 273.  Both groups performed 10 x 2 min bouts at 
50 rpm and ~85-95% of limb-specific VQO2peak, interspersed with 2 min passive 
recovery.  After 6 weeks, PFWD, MWD, and QOL increased significantly in both 
exercise groups.  The change did not differ between groups.  There was no change in 
the control group.  Using the same training protocol, Zwierska et al., (2009) 
compared the effects of 24 weeks of upper- and lower-limb ergometry training in 
men and women with PAD 264.  There was a significant improvement in PFWD and 
MWD in both groups, with no difference between groups and no change in controls.  
Quality of life also improved in both exercise groups 274.  
Upper-limb ergometry may result in improvements in walking performance 
similar to walking training.  Treat-Jacobson et al., (2009) randomized 41 men and 
women with IC to either a treadmill, arm-ergometry, combination, or control group 
275.  Participants in all 3 exercise groups performed 60 min of intermittent exercise 3 
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d.wk-1 for 12 weeks.  The combination group performed 20 min of arm-ergometry 
exercise, followed by 40 min of ITW.  MET-minutes of exercise training per session 
were similar between all exercise groups.  Pain free and maximal walking distance 
increased significantly in all exercise groups.  There was no change in controls.  The 
change in MWD did not differ between exercise groups.  The change in PFWD was 
significantly different from controls in the arm-ergometry group only.  
Upper-limb ergometry training also improved cardiorespiratory function to a 
similar extent as treadmill training in individuals with PAD.  Submaximal rate of VQO2, 
rate pressure product (RPP), O2 uptake kinetics, minute ventilation, VQO2 at the 
anaerobic threshold, and VQO2peak significantly improved in those randomized to the 
arm-ergometry group and treadmill training group compared with the control group 
276.  There was no significant difference between the exercise groups.  
Polestriding 
Polestriding is a modified form of walking that incorporates the use of 
handheld walking sticks.  The additional muscle recruitment associated with the 
upper-body work during polestriding has been found to significantly increase heart 
rate (HR), VQO2, RER and caloric expenditure compared with walking without poles in 
healthy individuals 277 and in individuals with PAD 278, in the absence of increased 
RPE.  Walking with poles can acutely improve PFWT, MWT, and perceived leg pain in 
individuals with IC 278.  The use of poles may also increase walking speed, stride 
length, and stance time, and reduce vertical ground and knee joint reaction forces 
279.  Greater stance time provides longer relaxation time between “toe off” and “heel 
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strike” in the non-weight bearing leg, which theoretically, may allow greater limb 
perfusion.  In addition, reduced ground reaction forces lead to less tension in 
antigravity muscles contracting to balance forces, thus potentially slowing the 
accumulation of metabolic by-products and extending exercise duration.   
Langbein et al., (2002) investigated the potential of polestriding training to 
improve functional capacity in individuals with PAD 202.  In a RCT, the polestriding 
group performed interval training to maximal or near-maximal IC at 60-80% VQO2peak 
to accumulate 30 min initially and eventually 40-60 min of exercise.  After 24 weeks, 
there was a significant improvement in MWT, VQO2peak and QOL in the polestriding 
group compared with controls.  Polestriding was also associated with an 
improvement in clinical indicators of CV fitness.  The change in the slope of the 
relation between SBP, HR, RPP, VQO2, and leg pain measured over time was 
significantly greater in the polestriding group than controls 280.   
The effect of walking with and without poles in individuals with PAD was 
examined by Collins et al., (2012) 281.  Randomized participants followed identical 
training programs, which involved interval training with combinations of light-, 
moderate-, and high-intensity exercise, 3 d.wk-1 for 12 weeks.  Maximal walking time 
increased in both groups, but to a greater extent in the traditional walking group.  
Pain free walking time increased significantly in the traditional walking group only, 
but there was no difference between groups.  The greater improvements in the 
traditional walking group may be due to greater peripheral adaptations in the 
skeletal muscle of the lower limb.  Time to nadir StO2 was significantly increased in 
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the calf muscle of the traditional walking group only.  Exercise training were 
matched for intensity based on HR and the addition of upper-body work in 
polestriding contributes to exercise intensity, resulting in less work being performed 
by the lower limbs.  
Stair-climbing 
Stair-climbing exercise evokes similar acute responses to walking in 
individuals with PAD.  Oxygen consumption, time to the onset of IC and to maximal 
IC, foot transcutaneous oxygen tension, ankle SBP, and ABI were similar between 
acute walking and stair-climbing over a range of intensities 282.  However, responses 
to chronic exercise differ between these modalities.  Jones et al., (1996) randomized 
12 men and women with IC to either stairmaster (SM) or treadmill (TM) training 283.  
Both groups performed intermittent exercise to severe IC to accumulate 60 min of 
exercise, 2 d.wk-1 for 12 weeks.  Pain free walking time significantly improved with 
training in both groups on both a treadmill test and stair-climbing test.  However, 
greater improvement occurred with the apparatus on which they trained.  
Improvements in MWT were training-mode specific.  The TM group increased MWT 
on the treadmill test only and the SM group improved on the stair-climbing test only.  
Resistance Training 
Muscle strength and endurance is decreased in individuals with PAD 128.  
Histological changes in PAD skeletal muscle include denervation, muscle fiber 
atrophy, and alterations in myosin heavy chain isoforms 128,136.  The reduced muscle 
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strength is related to disease severity 102 and functional performance 128.  There is 
therefore a strong rationale for RT as a successful training modality for individuals 
with PAD. 
McGuigan et al., (2001) found significant improvements in walking 
performance and lower-extremity strength following 24 weeks of RT in men and 
women with IC compared with controls 203.  The RT programme involved 2 sets of 8-
15 repetitions of 8 exercises for upper- and lower-body strength, 3 d.wk-1.  There 
were significant increases in PFWT, MWT, 6MWD, 10 RM leg press strength, and 10 
RM calf press strength in the RT group only.  Biopsies of the medial head of the 
gastrocnemius muscle showed a significant increase in the percentage of type IIA 
fibers and the CSA of all 3 fiber types and a significant decrease in the percentage of 
MHC IIB and the percentage of type IIB/AB fibers in the RT group.  Capillary density 
increased significantly in the RT group only.  There was no change in fiber type 
distribution, CSA, or capillary density in controls.  Walking performance and leg 
strength were also significantly improved in individuals with PAD following 8 weeks 
of maximal leg press RT 284.  Participants performed 4 sets of 5 repetitions of leg 
press at 85-90%1RM, with 4 min rest between sets.  There was a significant 
improvement in MWT, walking economy, 1 RM leg press and the dynamic rate of 
force development.   
The effect of RT in comparison to walking training in individuals with PAD has 
been examined in a number of RCTs.  McDermott et al., (2009) randomized 156 men 
and women with asymptomatic or symptomatic PAD to a treadmill exercise, lower 
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extremity RT, or control group 246.  The two exercise groups trained 3 d.wk1 for 6 
months.  The TM group performed ITW to near maximal IC or to a level between 12 
and 14 on the Borg RPE scale (asymptomatic participants) to accumulate 15 min 
initially and gradually increasing to 40 min.  The RT group performed 3 sets of 8 
repetitions of 3 leg exercises at 50%1RM initially, increasing gradually to 80%1RM 
and 3 sets of 8 reps of body-weight squat and toe rise exercises.  Maximal walking 
time increased significantly in both exercise groups compared with controls.  Pain 
free walking time and 6MWD improved in the TM group only compared with 
controls.  The improvements in MWT and 6MWD were significantly greater in the 
TM group than the RT group.  Maximum isometric knee extension strength improved 
in the RT group compared with the TM and control groups.  Quality of life improved 
significantly in both exercise groups compared with controls.   
Similar improvements in walking performance between modalities was found 
when the exercise training was matched for intensity 285. Thirty men and women 
with IC were randomized to perform 30 min of either ITW or RT at an RPE of 11-13, 
with 30 min passive recovery, 2 d.wk-1 for 12 weeks.  The ITW group performed 15 x 
2 min bouts at an intensity to induce IC in the last 30 s of each bout, with 2 min 
passive recovery.  The RT group performed 3 sets of 10 repetitions of 8 exercises, 
with 2 min recovery between sets.  There was a significant improvement in PFWD 
and MWD in both exercise groups, with no between group differences.  Resting and 
exercise CV responses also improved significantly and similarly following training in 
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both groups.  There was a significant reduction in resting SBP, HR, and RPP, and 
submaximal SBP and RPP 286.  
Hiatt et al., (1994) compared the effect of walking and RT in individuals with 
PAD and then investigated the effect of a combined programme 263.  Twenty-nine 
men with IC were randomized to a TM, RT, or non-exercising control group for 12 
weeks.  In the second phase of the study (i) the TM group continued training for an 
additional 12 weeks, (ii) the RT group crossed-over to 12 weeks of treadmill training 
to determine if an initial period of muscle strengthening would augment the training 
benefits of walking and (iii) participants originally assigned to the control group 
undertook 12 weeks of a combined programme of treadmill walking and RT.  All 
exercise groups trained 3 d.wk-1.  The TM group performed 50 min of ITW to 
moderate IC at an intensity that induced IC pain within 3-5 min.  The RT group 
performed 3 sets of 6 repetitions of 5 leg exercises at 6 RM.  The combined 
programme involved 50 min of ITW and 3 RT exercises.   
There was a significant improvement in MWT after 12 weeks in the TM group 
(74%) and RT group (36%).  The difference in the improvement between groups did 
not reach statistical significance.  Pain free walking time and VQO2peak were 
improved in the TM group only.  There were no changes in any measure in the 
control group after 12 weeks.  After an additional 12 weeks of TM training, the 
original TM group had further significant increases in MWT and PFWT compared 
with baseline and week 12.  Both the original RT group who undertook 12 weeks of 
TM training and the combination group significantly increased MWT compared with 
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baseline and week 12, but did not improve PFWT or VQO2peak.  Gastrocnemius 
muscle strength increased in the RT group only after week 12, but these 
improvements were lost when the group crossed to TM training.  The combination 
group had no improvement in calf muscle strength. 
Quality of life improved significantly in the TM and RT groups at week 12 and 
week 24 with no improvements in the control or combination group 287.  There was a 
significant increase in daily physical activity levels, measured using the PAR 
questionnaire and a Vitalog activity monitor, in the TM group at week 12 and week 
24.  There was no change in daily physical activity in the control or combination 
group or the RT group until they crossed to TM training.  The finding that a 
combination of modalities do not appear to be associated with additive benefits, 
suggests that the total volume of exercise is more important than the mode in 
determining functional improvements.  
Supervised versus Non-supervised Exercise Rehabilitation 
In 2006, a Cochrane review evaluated the effects of supervised versus non-
supervised exercise therapy on walking performance in individuals with IC 265.  Eight 
randomized and controlled trials were included in the analysis.  Although, 
heterogeneity existed among the studies with regard to exercise training protocols, 
there was a significantly greater improvement in PFWD and MWD with supervised 
exercise compared with non-supervised, with overall effect sizes of 0.61 and 0.58, 
respectively, at 3 month follow-up. Only 2 of the trials monitored compliance with 
non-supervised exercise training 197,288 and the results were inconsistent.  Quality of 
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life was significantly different between groups in only 3 of the trials, bringing into 
focus the clinical, as opposed to the statistical, relevance of the results.   
Wind et al., (2007) conducted a systematic review of 5 RCTs comparing 
supervised to non-supervised exercise in individuals with IC 289.  The weighted 
difference in PFWD and MWD was 143.81 m and 250.40 m, respectively, in favour of 
supervised exercise.  
Structuring unsupervised exercise programs can result in greater 
improvements in walking performance than traditional home-based exercise or “go 
home and walk” advice.  In a non-randomized study, 143 men and women with IC 
undertook 6 months of traditional home-based free walking exercise (Tr-E) or test in-
train out (Ti-To) exercise 290.  The Tr-E group was advised to perform intermittent 
walking at a self-selected pace to IC tolerance for 20-30 min ≥6 d.wk-1.  The Ti-To 
group performed 2 daily 10 min interval walking sessions, involving 1 min at maximal 
asymptomatic velocity with 1 min passive recovery, 6 d.wk-1.  Maximal asymptomatic 
velocity was determined monthly during a hospital visit and converted into a walking 
cadence and followed at home using a metronome.  The Tr-E group also attended 
monthly assessments of functional capacity to ensure similar motivation between 
groups.  Pain free and maximal walking distance, and self-reported claudication 
symptoms improved significantly in both groups, with significantly greater 
improvement with Ti-To.  
Using a monitoring device during home-based exercise can achieve 
improvements in walking performance similar to supervised exercise.  Gardner et al., 
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(2011) randomized 119 men and women with IC to a home-based exercise program, 
supervised exercise program, or usual-care control 291.  Both exercise groups 
performed intermittent walking to near-maximal IC 3 d.wk-1 for 12 weeks and wore a 
step activity monitor during each session.  The supervised group walked at 2.0 mph 
and 40% of maximal baseline grade and accumulated 15 min for the first two weeks, 
progressing by 5 min biweekly thereafter up to 40 min duration.  The home-based 
group was instructed to walk 5 min extra in an attempt to match the programs on 
total volume of exercise.  The home-based group reported to the laboratory 
biweekly to receive feedback from their step activity monitor.  The adherence to the 
exercise programs was similar between groups and was >80%.  The home-based 
group exercised for a longer duration but at a lower cadence, resulting in similar 
total exercise volume.  After 12 weeks, PFWT and MWT increased significantly in 
both groups and there was no significant difference between groups. Daily average 
cadence increased in the home-based group only and this was significantly different 
from the supervised group.  There were no changes in walking performance or daily 
physical activity in the control group. 
Mechanisms of Exercise Rehabilitation 
Although the beneficial effect of exercise rehabilitation on functional capacity 
in individuals with PAD is well established, the mechanisms underlying these 
improvements are not fully understood.  It is likely that the physiological, metabolic, 
and mechanical alterations that occur with exercise training induce an adaptive 
response that decreases IC symptoms, improving ambulatory capacity.  Several 
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potential mechanisms for such benefits have been proposed, including the 
formation of collateral vessels and improvements in endothelial function, 
hemorheological properties, muscle metabolism, walking economy, and muscle 
strength.   
Improvement in Endothelial Function 
Endothelial dysfunction is a primary event in the pathogenesis of 
atherosclerosis.  A feature of endothelial dysfunction is an imbalance in the 
regulation of vascular tone, which is due, at least in part to a reduction in level of 
endothelial-derived nitric oxide (NO).  In PAD, the delivery of blood flow to the lower 
limbs depends not only on the severity of the stenosis but also on the regulatory 
mechanisms that control blood flow, specifically vascular tone 292.  Vascular 
reactivity, assessed non-invasively by brachial artery flow-mediated dilation (FMD), 
is impaired in individuals with PAD compared with healthy controls 293–297.  There is 
no impairment in glyceryl trinitrate (GTN)-mediated dilation, indicating that the 
impairment in FMD is due to endothelial dysfunction and not smooth muscle cell 
(SMC) dysfunction.  Flow-mediated dilation is an independent predictor of short- and 
long-term CV events in individuals with PAD 298,299 and can add to the prognostic 
value of ABI, the most consistent and powerful prognostic indicator in PAD 300,301.  It 
may also serve as an indicator of subclinical coronary artery abnormalities 302. 
An association between FMD and the severity of PAD has been found in some 
294,303,304 but not all studies 296,297.  The studies reporting a relation between FMD and 
the severity of PAD have involved asymptomatic or symptomatic participants.  In 
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studies involving participants at more advanced stages of PAD, such as CLI, FMD is 
associated with the presence but not the severity of PAD, suggesting that endothelial 
dysfunction is not linearly related to the severity of the disease. 
Impaired FMD in PAD has been attributed to various mechanisms.  A 
decrease in NO bioavailability may be caused by a decrease in endothelial nitric 
oxide synthase (eNOS) expression, insufficient L-arginine or cofactor 
tetrahydrobiopterin for eNOS, presence of eNOS inhibitors (e.g. asymmetric 
dimethylarginine (ADMA)), impaired eNOS activation, or increased NO degradation.  
Plasma concentrations of ADMA have been shown to be elevated above the normal 
range and urinary excretion rates of nitrate and cyclic guanosine monophosphate 
(cGMP), indices of systemic NO production, below the normal range in individuals 
with IC 305.  Treatment with L-arginine improves FMD in individuals with PAD and is 
associated with a significant increase in the L-arginine/ADMA ratio, which suggests 
improved eNOS substrate availability.  L-arginine treatment was also associated with 
a significant increase in urinary nitrate and cGMP excretion rates.  The change in the 
L-arginine/ADMA ratio and urinary excretion rates were related to improvements 
walking performance.  
Oxidative stress, which impairs eNOS activation and increases NO 
degradation, is elevated in patients with PAD 306 and is significantly inversely related 
with FMD, plasma levels of nitrites and nitrates and walking performance in 
individuals with PAD 306,307.  Antioxidant supplementation reduces the level of 
oxidative stress and is associated with increased NO bioavailability, FMD, and MWD.  
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Inflammation is a major determinant of endothelial dysfunction 308.  Significant 
inverse relations have been reported between FMD and plasma levels of CRP, 
fibrinogen, and soluble intercellular adhesion molecule-1 (sICAM-1) in individuals 
with PAD 294,303,309,310.  Finally, CV risk factors, the prevalence of which is high in PAD, 
may also contribute to impairment in endothelial function, although the findings of 
an association with FMD are inconsistent 60,296. 
Flow-mediated Dilation and Exercise in Peripheral Arterial Disease  
Cross-Sectional Studies 
In a cross-sectional study, Payvandi et al., (2009) investigated the association 
between FMD and daily physical activity levels, measured over a 7 d period using 
both an accelerometer and pedometer, in 111 men and women with PAD 311.  After 
adjustment for confounding factors, there was a significant positive relation 
between daily physical activity, measured by both the accelerometer and step 
counter, and both absolute and percent change in brachial artery diameter.  
Acute Exercise 
Acute exercise has been found to transiently impair FMD in individuals with 
PAD.  Andreozzi et al., (2007) found a significant reduction in FMD following an acute 
bout of treadmill walking to maximal IC in 22 men with IC 12.  The impairment in FMD 
with acute exercise in PAD is dependent upon the degree of ischemia produced in 
the diseased limb during exercise.  In a RCT, Silvestro et al., (2002) found a significant 
decrease in FMD following acute treadmill exercise to maximal IC, but no change 
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following exercise to the onset of IC and exercise in healthy age- and gender-
matched controls 14.  Exercise-induced changes in FMD differed significantly 
between treatment conditions.  Endothelial-independent dilation was unaffected by 
acute exercise.  There was a significant difference in post-exercise plasma levels of 
thiobarbituric acid-reactive substances (TBARS), an index of oxidative stress, and 
sICAM-1 between groups.  Plasma levels TBARS and sICAM-1 increased significantly 
following exercise to maximal IC, and remained unchanged following exercise to the 
onset of IC and in controls.  There was no significant relation between increases in 
TBARS and changes in FMD and sICAM-1.  However, the impairment in FMD and 
elevation of sICAM-1 were eliminated by administration of an antioxidant, vitamin C.  
The acute exercise-induced impairment in FMD is also eliminated by PLC 
administration, which exerts both antioxidant and anti-inflammatory effects 15.  
Flow-mediated dilation was significantly reduced following acute treadmill exercise 
to maximal claudication in 40 men and women with IC.  Participants were 
subsequently randomized in a double-blind fashion to receive either placebo or PLC, 
administered as 600 mg in a single bolus followed by an infusion of 1.0 mg.kg-1.min-1 
for 60 min.  Following treatment, FMD continued to decrease significantly post-
exercise in the placebo group, but not in the PLC group.  However, the difference 
between the 2 treatments did not reach statistical significance.  There was a 
significant inverse relation between the post-exercise decrease in FMD before 
treatment (Δ% FMD1) and the difference between post-exercise change in FMD after 
PLC (Δ% FMD2) and Δ% FMD1, indicating the greater the post-exercise decrease in 
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FMD at baseline, the greater the benefit attained from PLC treatment.  
Subsequently, the data of participants with a post-exercise decrease in FMD ≥45% 
(the median FMD decrease) at baseline were analyzed.  In this cohort, there was a 
significant protective effect on post-exercise FMD with PLC compared with placebo.  
The time course of the changes in FMD following acute exercise in men and 
women with IC was examined by Joras and Poredos (2008) 16.  Flow-mediated 
dilation was determined before and 30 min, 2 h and 4 h after a constant load 
treadmill test to maximal claudication for PAD participants and for 10 min for 
controls.  Following exercise, FMD decreased significantly from baseline at 30 min 
and 2 h post-exercise in participants with IC, before returning to baseline values at 4 
h post-exercise.  Controls experienced a slight non-significant increase in FMD post-
exercise.  In comparison with controls, FMD was significantly lower in participants 
with IC at 30 min, 2 h and 4 h post-exercise.  The difference between groups in the 
change in FMD over time was significant.  
Chronic Exercise  
In contrast to the detrimental effect of acute exercise on FMD in PAD, chronic 
exercise has been found to have a positive effect.  The majority of studies 
investigating the effects of acute exercise on FMD in PAD have involved exercise to 
ischemia-inducing maximal IC, whereas the majority of exercise training studies have 
involved submaximal exercise protocols.  Acute exercise to submaximal claudication, 
unlike exercise to maximal claudication, does not lead to transient impairment of 
endothelial function 14.  The moderate hemodynamic stress associated with 
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submaximal exercise may in fact lead to improvements in endothelial function, 
through ischemic preconditioning.   
In a study by Andreozzi et al., (2007) 12 22 participants with IC performed ITW 
to 60-70% of maximal walking ability to accumulate 1-2 km, 3 d.wk-1.  After 6 weeks, 
there was a significant improvement in pre-exercise FMD.  Post-exercise FMD 
significantly increased from pre-training levels, but was still significantly reduced 
compared with pre-exercise.  Exercise training was also associated with significant 
improvements in MWD and ABI.   
The effect of a longer duration exercise programme on FMD in PAD was 
considered by Brendle et al., (2001) 13.  Nineteen overweight men and women with 
IC performed a 6 month aerobic exercise programme involving 3 d.wk-1 of ITW to 
near-maximal IC at 2.0 mph and a grade equivalent to 50-80%HRpeak.  Participants 
accumulated 15 min of walking initially and gradually progressed to ≥30 min.  
Following the program, there was a significant improvement in FMD, PFWT, MWT 
and maximal calf blood flow.  There was a significant relation between change in 
FMD and reactive hyperemic blood before and after the exercise programme and 
maximal blood flow at baseline, indicating those with the lowest calf blood flow 
experienced the least improvement in FMD.  
Improvements in FMD are likely due to an increase in NO bioavailability.  
Exercise training is associated with exposure to repeated episodes of increased shear 
stress, which upregulates the mRNA expression of eNOS, consequently increasing 
NO production and improving endothelial function 312.  Allen et al., (2010) 
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investigated the response of NO bioavailability and FMD to exercise training in 35 
men and women with IC 11.  Participants were randomized to either a supervised or 
home exercise group for 3 months.  The supervised exercise involved ITW to 
moderately severe IC, accumulating 30-40 min, 3 d.wk-1.  The home exercise group 
was instructed to walk for 30 min 3 d.wk-1.  At baseline, plasma nitrite concentration 
(a surrogate measure of NO bioavailability) was significantly lower in PAD 
participants than 41 healthy controls following an acute bout of maximal exercise.  
Following the supervised exercise program, plasma nitrite concentration after 
maximal exercise no longer differed from controls and plasma nitrite flux became 
positive rather than negative.  Flow-mediated dilation improved significantly in the 
supervised group only.  There was also a significant improvement in PFWT, MWT and 
VQO2peak in the supervised exercise group only.  The change in PFWT was 
significantly related to the change in plasma nitrite flux for both the supervised 
exercise group and the home exercise group, individually and combined, suggesting 
that the degree of change in the onset of ischemia is related to the change in NO 
bioavailability.   
The effect of the intensity of exercise training on FMD in PAD was 
investigated by Mika et al.,(2012) 313.  Fifty-two men and women with symptomatic 
PAD were randomized into either a pain-free training (PFT) or moderate pain training 
(MT) group.  Both groups performed ITW at 3.2 km.h-1 and a grade to induce IC 
within 3-5 min to accumulate 35-60 min, 3 d.wk-1 for 12 weeks.  The PFT group 
exercised to the onset of IC and the MT group exercised to moderate IC.  Following 
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training, FMD increased by 36% and 56% in the PFT and MT groups, respectively.  
There was no difference between groups.  There was no change in plasma levels of 
hs-CRP and fibrinogen in either group following the training programme.  There were 
also significant and similar improvements in PFWT and MWT in both groups.  
The effect of different training modalities on FMD was evaluated by 
McDermott et al., (2009) in 156 men and women with asymptomatic or symptomatic 
PAD 246.  Participants were randomized to a treadmill exercise, lower extremity RT, 
or control group.  The two exercise groups trained 3 d.wk1 for 6 months.  Compared 
with controls, FMD improved significantly in the treadmill exercise group, but not 
the RT group.  There were also significant improvements in MWT in both exercise 
groups compared with controls. However, PFWT and 6MWD improved in the 
treadmill exercise group only compared with controls.   
Formation of Collateral Vessels  
Arteriogenesis refers to the increase in diameter of pre-existing arterioles 314.  
It can result in the formation of mature arteries and the development of collateral 
circulation to supply the tissues distal to a stenotic occlusion.  This process is not a 
passive dilation but involves active proliferation and remodelling.  The primary 
stimulus for arteriogenesis is likely increased shear stress resulting from increased 
blood flow 315.  Shear stress triggers a complex cascade of molecular and cellular 
events resulting in the enlargement of the vessel lumen and wall thickness (figure 
2.10).  
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Figure 2.10:The process of arteriogenesis 316 
EC, endothelial cell; ECM, extracellular matrix; EEL, external elastic lamina; FGF, 
fibroblast growth factor; FSS, fluid shear stress; MCP-1, monocyte chemoattractant 
protein; MMP, matrix-metalloproteinase; PDGF, platelet-derived growth factor, PIGF, 
placenta growth factor; SMC, smooth muscle cells; TGF-β, transforming growth factor 
beta; TIMP, tissue inhibitor of metalloproteinase; VEGF, vascular endothelial growth 
factor 
FSS triggers EC activation, which is associated with the upregulation of chemotactic 
factors, in particular, MCP-1.  This results in the recruitment of monocytes, which 
release proteases such as MMP.  These proteases degrade surrounding structures such 
as the internal elastic lamina and extracellular matrix, creating space for the expanding 
vessel and remodelling the structure of the vessel itself.  Monocytes also release growth 
factors essential for vascular remodelling.  The vascular growth begins with endothelial 
proliferation, followed by that of SMCs to the subendothelial space, where they exhibit 
a “synthetic” phenotype, characterized by production of ECM, collagen and elastin to 
form a new internal elastic lamina, ultimately producing a mature artery.   
In PAD, a pressure gradient develops between the regions proximal and distal 
to the stenotic occlusion, resulting in increased blood flow and thus shear stress 317.  
Arteriogenesis may be a compensatory adaptation in PAD.  Exercise results in 
increased blood flow to the active muscles, rendering it a source of shear stress, 
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which may accelerate compensatory arteriogenesis in PAD leading to increased 
collateral blood flow and ultimately improved walking economy.  Exercise training is 
associated with collateral vessel development in animal models of PAD.  Following 
femoral artery ligation in rodents, collateral vessel wall CSA, maximal luminal 
diameter, and total hindlimb blood flow increased in both sedentary and exercise 
trained animals, but to a significantly greater extent in the trained animals 318.  The 
improvements in total hindlimb blood flow are associated with improved exercise 
tolerance 319,320.  Exercise accelerated the time course of the developments in 
collateral circulation.  Maximal luminal diameter increased significantly in exercised 
rodents 1 week in advance of significant improvements in sedentary rodents 318.  
Restoration of blood flow by collaterals was incomplete as calf muscle blood flow in 
the exercise animals still remained at ~60% that of the nonoccluded control group.  
Arteriogenesis is a self-limiting process.  Since shear stress is inversely proportional 
to the cube of the vessel radius there will be a decrease in shear stress and 
consequently a decrease in arteriogenesis following the initial vessel enlargement.   
The effect of exercise training on collateralization in human studies of PAD is 
equivocal.  Collateralization in human studies is not measured directly, but inferred 
from lower limb hemodynamic measures including calf blood flow and ABI.  The 
majority of studies have found no improvement in calf blood flow following exercise 
training, despite significant improvements in walking capacity.  A 2010 systematic 
review of RCTs using an exercise intervention for the treatment of IC, reported small 
and insignificant effect sizes for resting and reactive hyperemic blood flow 321.  Hiatt 
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et al., (1990) did find moderate increases in maximal calf blood flow, measured using 
venous occlusion plethysmography, in 19 men with PAD following 12 weeks of ITW 3 
d.wk-1 compared with age-matched PAD controls.  The changes in maximal calf blood 
flow were not related to changes in MWT.  In contrast, Gardner et al., (2001)200 
found a significant relation between the change in maximal calf blood flow, 
measured using venous occlusion plethysmography, and the change in both PFWD 
and MWD in men and women with IC following 24 weeks of ITW 3 d.wk-1 200.  
However, in a 12 month continuation of this study, in which training frequency was 
reduced to 2 d.wk-1, the improvements in maximal calf blood flow decreased, 
despite continued improvement in PFWD and MWD.   
The disconnect between improvements in walking performance and 
improvements in blood flow is also evident in revascularization studies.  
Improvements in ABI following PTA did not translate to improvements in walking 
performance 217 or were not related to improvements in walking performance 213.  
The apparent contradiction between findings of collateral development in animals 
but not humans may be explained by a number of factors 322.  Firstly, animal models 
may not reflect the disease process in humans with regard to the location of the 
occlusion, level of ischemia, and rate of onset.  In humans, the ischemia associated 
with PAD is intermittent, the onset of the occlusion is gradual, and the disease is 
often multilevel, which impairs the development of an effective collateral circuit 
because of the increasingly lower perfusion pressure at each level 323.  Secondly, 
shear stress is the primary stimulus of arteriogenesis and the endothelial dysfunction 
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evident in individuals with PAD may inhibit vascular remodelling.  Finally, more 
sophisticated measures of collateralization such as magnetic resonance imaging or 
computed tomography may be necessary to detect changes in humans.   
Improvement in Hemorheological Properties 
Hemorheology refers to the study of the deformation and flow of blood and 
its formed elements and their interaction with other tissues 324.  Hemorheological 
properties are a determinant of blood flow in the macro- and microcirculation, 
especially in low flow states such as PAD 325, and hence significantly affect tissue 
perfusion.  Abnormal hemorheology has been reported in individuals with PAD, 
specifically increased blood and plasma viscosity, increased RBC aggregation and 
decreased RBC deformability 326–328.  Blood viscosity refers to the resistance of blood 
to flow.  Under low-shear conditions such as in PAD the tendency of RBCs to 
aggregate increases 329 and RBC aggregation is a main cause of increased blood 
viscosity 330.  RBC aggregation is influenced by plasmatic factors, including fibrinogen 
concentration, and cellular factors such as I-RI 331.  Red blood cell deformability 
refers to ease of deformation of blood cells by external force.  Deformability allows 
RBC to change shape and traverse microcirculation 332 and the loss of deformability 
decreases microcirculation blood flow and consequently tissue perfusion 333.  
The degree of hemorheological abnormality in PAD may be related to disease 
severity.  Blood viscosity, hematocrit, hematocrit-corrected blood viscosity, plasma 
viscosity, fibrinogen, leukocyte elastase, and uric acid have been found to be 
significantly related to ABI and the presence of IC 328.  Blood viscosity and fibrinogen 
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were identified as independent predictors of ABI.  In addition, plasma viscosity 334 
and RBC deformability 335 are significantly lower in patients with CLI compared with 
those with IC.  Abnormal hemorheology may have prognostic value for PAD.  
Dormandy et al., (1973) found a significant relation between progressive 
deterioration of peripheral blood flow and initial blood viscosity and plasma 
fibrinogen levels 336.  Abnormal hemorheology may also be regarded as a risk factor 
for PAD.  Impaired blood viscosity in individuals aged 45-65 years doubled the risk of 
developing arterial occlusive disease in the following 2 years, independent of classic 
CV risk factors 337.   
Exercise training can potentially normalize hemorheology in individuals with 
PAD.  In a study by Ernst and Matrai (1987), 42 men and women with IC were 
assigned to an exercise or control group 327.  The exercise group performed 
supervised continuous treadmill walking to maximal IC twice per day, 5 d.wk-1 for 8 
weeks.  At baseline, there was a significant difference in blood and plasma viscosity, 
blood cell filterability, and cell aggregation between all PAD patients and 40 healthy 
matched controls.  After 8 weeks, there was a significant difference for blood and 
plasma viscosity, blood cell filterability, red cell aggregation, PFWD, and MWD 
between the exercise and PAD control group and the exercise group no longer 
differed from healthy controls.  Similarly, Mika et al., (2006) found significant 
improvements in RBC deformability following 12 weeks of ITW 3 d.wk-1 in individuals 
with IC compared with usual care controls 338.  These improvements were 
accompanied by significant improvements in PFWT and MWT in the training group. 
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Häfner et al., (2009) found a significant inverse relation between the change 
in PFWD and the change in plasma viscosity following 12 months of pedal 
dynamometry in men and women with IC 272.  In contrast, Tan et al., (2000) reported 
no change in plasma viscosity following 12 weeks of walking for 60 min to maximal IC 
5 d.wk-1 in men and women with IC, despite a significant improvement in MWD 339. 
The mechanisms through which exercise leads to the normalization of 
hemorheology are not fully understood.  In healthy individuals exercise produces an 
increase in plasma volume 340, which may explain the decrease in blood and plasma 
viscosity.  However, hematocrit was unchanged, although exercise may have 
stimulated erythropoiesis.  A decrease in plasma fibrinogen is also a potential 
contributor to the improvement in blood and plasma viscosity.  Plasma fibrinogen is 
elevated above the normal range in individuals with PAD and is significantly related 
to blood viscosity 326.  
An improvement in the resistance of blood to flow would theoretically 
improve macro- and microcirculation and thus tissue perfusion, especially in low 
flow states such as PAD.  Blood viscosity is related to exercise performance 341 and 
improvements in viscosity are associated with improvements in walking 
performance in individuals with PAD.  However, the association is weak and 
improvements in walking performance can occur in the absence of improvements in 
hemorheological properties, indicating that hemorheological adaptations are not the 
primary mechanisms responsible for improvements in walking performance with 
exercise rehabilitation in PAD.   
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Improvement in Muscle Metabolism 
Chronic exposure to I-RI leads to significant oxidative damage to the 
mitochondria of skeletal muscle distal to the stenosis in PAD.  This results in 
diminished activity of oxidative enzymes and consequently impaired mitochondrial 
respiration 96.  Improved muscle metabolism is a common adaptive response to 
exercise training in healthy individuals and may, at least in part, explain the 
beneficial response to exercise rehabilitation in individuals with PAD.  An 
improvement in mitochondrial respiration in PAD skeletal muscle would yield greater 
oxygen extraction per unit of blood delivered, leading to improvements in exercise 
performance without the need for improvements in limb hemodynamics.   
In PAD, skeletal muscle acylcarnitine accumulation is inversely related with 
exercise performance and it is believed to be an indicator of impaired mitochondrial 
respiration.  Hiatt et al., (1990) found a significant decrease in plasma concentration 
of short-chain acylcarnitines following 12 weeks of ITW training in men with PAD 
compared with PAD controls 101.  There was also a significant decrease in the ratio of 
plasma short-chain acylcarnitine concentration to the total acid-soluble carnitine 
concentration, an index of the distribution of total carnitine between free and acyl 
carnitines.  This ratio was strongly inversely related with the increase in MWT.  In a 
subsequent study Hiatt et al., (1996) randomized 26 men with PAD to a TM, RT or 
control group 105.  There was no significant change in plasma or muscle 
concentrations of carnitine or acylcarnitines in any group.  However, the change in 
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the ratio of plasma short-chain acylcarnitines to total acid-soluble carnitine was 
significantly related with the increase in MWT.   
Improvement in muscle metabolism with exercise rehabilitation may be 
attributable to a number of factors including an increase in the activity of oxidative 
enzymes, increased capillary density and consequently O2 extraction, and alterations 
in muscle fiber properties.   
Increased Oxidative Enzyme Activity 
The effect of exercise rehabilitation on oxidative enzyme activity in PAD 
skeletal muscle has not been extensively investigated and the findings are 
inconclusive.  Duscha et al., (2011) 261 found no change in citrate synthase (CS) 
activity in men and women with PAD randomized to 12 weeks of supervised or 
unsupervised exercise training.  An increase in CS activity is a normal training 
response in healthy individuals.  The absence of an increase in CS activity in PAD 
patients may be due to concomitant denervation with exercise, which has been 
shown to decrease the activities of a variety of oxidative enzymes 342, or due to a 
number of other insults to oxidative metabolism.  Hiatt et al., (1996) also failed to 
find a significant change in CS activity in men with PAD randomized to a TM, RT or 
control group for 12 weeks 105.  However, there was a significant increase in 
phosphofructokinase activity in the TM group, which may suggest a larger 
dependence on glucose than fatty acids under conditions of limited oxygen delivery.  
In a RCT involving 26 weeks of supervised exercise training in men and women with 
IC Dahllöf et al., (1974) found a significant increase in the muscle contents of 
 103
cholesterol and phospholipids and the incorporation rate of glucose-carbon in 
glycogen, lipids, and CO2 and a significant decrease in the incorporation of glucose-
carbon into lactate 196.  Succinic oxidase activity was significantly increased and the 
change in the pattern of metabolic activity was significantly related with the 
improvement in walking performance.   
In a study by Lundgren et al., (1989), 33 participants with IC were randomized 
to receive surgery, combined surgery and exercise, or exercise only 107.  Cytochrome-
c oxidase activity increased significantly in the exercise only group.  The increase was 
significantly related with the improvement in PFWD.  The absence of an 
improvement in oxidative enzyme activity in the combined surgery and exercise 
group, in which blood flow was restored, suggests that both exercise and a reduced 
calf blood flow are necessary for positive enzymatic adaptation.   
Increased Capillary Density 
Increased capillary density enhances diffusion capacity through increased 
diffusion surface area and decreased diffusion distance.  This leads to increased O2 
extraction and consequently increased mitochondrial respiration, despite no change 
in limb blood flow 343.  It is a common adaptive response to exercise training in 
healthy individuals and represents a potential mechanism through which exercise 
training increases functional capacity in individuals with PAD.  It occurs through 
angiogenesis, the formation of new blood vessels from pre-existing vessels.  
Angiogenesis is a complex process depending on the balance of multiple stimulating 
and inhibiting factors (figure 2.11).  
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Figure 2.11: The process of angiogenesis 344 
EC, endothelial cell; ECM, extracellular matrix 
Angiogenesis begins with the production of angiogenic factors.  Vascular endothelial 
growth factor (VEGF) is the primary angiogenic factor and the most powerful stimulus 
for VEGF expression is hypoxia, which upregulates VEGF primarily through increased 
hypoxia-inducible factor I (HIF-1)-mediated transcription.  VEGF-A exerts its biological 
effects via interaction with receptors located on EC membranes.  Selected ECs, known 
as “tip-cells”, react to the VEGF gradient that specifies the direction of their migration 
and hence the direction of capillary growth.  “Tip-cells” undergo phenotypic change 
acquiring invasive and migratory properties and activate secreted or cell surface 
proteases for partial degradation of the adjacent basement membrane.  Proliferation 
and migration of ECs localized in the growing capillary branch progress the formation 
of the new capillary.  Vessel maturation begins with the fusion of the newly formed 
capillary with other capillaries and the formation of the vessel lumen.  The emerging 
blood flow removes the hypoxia stimulus for VEGF expression, which ceases EC 
proliferation.  Recruitment of mural cells, pericytes and SMCs, form the walls of 
capillaries and immature blood vessels, and mature blood vessels, respectively.  
Pericytes, in turn, exert a stabilizing effect on the newly formed vessels, halting their 
growth and aiding the transition to a quiescent, mature state.   
Vascular endothelial growth factor (VEGF) is the primary angiogenic factor 
and the most powerful stimulus for VEGF expression is hypoxia.  In healthy 
individuals, exercise under conditions of restricted blood flow result in a significantly 
greater increase in VEGF mRNA expression than exercise under normoxic conditions 
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345.  Therefore, PAD represents a prime condition for increasing VEGF expression 
with exercise.  In a RCT, Sandri et al., (2005) found a significant increase in 
investigated VEGF expression in individuals with PAD following ischemic but not non-
ischemic exercise training 346.  Ischemic training involved treadmill walking to 
maximal IC.  The non-ischemic group walked to 75% of MWD.   Both exercise groups 
performed 2 bouts of treadmill walking at 3.5 km.h-1 and 12% grade, 6 times daily, 5 
d.wk-1 for 4 weeks.  Ischemia appears to be a prerequisite to enhance VEGF 
expression. Additional studies employing submaximal exercise programmes have 
reported no change in VEGF expression 347,348.  
Increased capillary density has been found after both endurance and 
resistance training in individuals with PAD 203,261.  Wang et al., (2009) found a 
significant relation between the change in the number of capillaries in contact with 
type IIx and IIa muscle fibers and the increase in PFWT following 12 weeks of ITW 
training in individuals with IC 349.  Duscha et al., (2011) found that improvements in 
capillary density preceded improvements in VQO2peak with supervised exercise 
training in men and women with PAD 261.  There was a significant increase in 
gastrocnemius muscle capillary density after 3 weeks of training, although there was 
no significant improvement in VQO2peak until week 12.  Capillary density was related 
to VQO2peak at baseline and week 12.  Enhanced perfusion may be first required 
before improvements in mitochondrial function become evident.   
Increased capillary density enhances diffusion capacity leading to increased 
O2 extraction.  Numerous studies have investigated the effects of exercise training 
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on calf muscle StO2 in individuals with PAD.  Exercise training has been associated 
with significant increases in calf muscle oxygenation at rest, dynamic muscle 
perfusion during exercise 350, time to nadir StO2 
208,281 and significant decreases in 
popliteal 351 and femoral venous StO2 during exercise 
352 in individuals with PAD.  
Transcutaneous oxygen tension appears unchanged with exercise training in 
individuals with PAD 231,272,283.   
Manfredini et al., (1991) found that calf O2 consumption at rest and dynamic 
muscle perfusion during exercise in men and women with PAD approached the 
stable values of untrained healthy participants following exercise training 350.  In a 
study by Sørlie et al., (1978) the decrease in popliteal StO2 was accompanied by a 
decrease in lactate release, indicating less reliance on anaerobic glycolysis and 
improved oxidative capacity, despite no change in limb blood flow 351.  The 
improvements in O2 extraction are associated with improvements in walking 
performance.  Collins et al., (2012) found a significant relation between the 
reduction in time to nadir StO2 and improvements in PFWT and MWT 
281. 
Alterations in Muscle Fiber Properties  
A recent non-randomized controlled trial found that exercise rehabilitation 
may result in a shift in skeletal muscle fiber properties towards a more oxidative 
fibre type 353.  Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), a significant increase in MHC I expression was found in the symptomatic 
gastrocnemius muscle of 27 men and women with IC following 12 weeks of circuit 
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training compared with 11 IC control patients.  There was a significant relation 
between the percentage increase in MWD and the increase in MHC I expression.   
Myosin heavy chain is a key determinant of skeletal muscle metabolism.  An 
increase in the proportion MHC I increases oxidative capacity and reduces the 
reliance of claudicants on anaerobic glycolysis, thereby decreasing the painful 
accumulation of lactate.  Pervious research using immunohistochemistry has 
measured the effect of exercise rehabilitation on fiber type composition and fiber 
type area and found no significant change 105,261,349. 
Improvement in Walking Economy 
Walking economy is impaired in individuals with PAD.  During constant-load 
exercise at high-intensity, VQO2 continues to rise with exercise duration in individuals 
with PAD rather than remaining steady-state as in healthy controls 354.  Impaired 
walking economy in combination with the low VQO2peak evident in individuals with 
PAD results in ambulation at a given pace being performed at a higher relative 
metabolic cost than in healthy individuals.   
Exercise rehabilitation is associated with an improvement in walking 
economy in individuals with PAD 101,200,253,263,276,280,285,355.  Studies have shown 
significant decreases in VQO2, HR, RER, and ventilation during submaximal constant-
load treadmill tests.  Improvement in walking economy decreases the metabolic cost 
at a given workload, which would allow the activity to be maintained for a longer 
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duration.  In claudication, this would allow individuals to walk for longer before 
developing an oxygen supply-demand mismatch and consequently claudication pain.   
Although improvements in walking economy with exercise training are 
evident in the vast majority of trials, a significant relation between the change in 
walking economy and the change in PFWT and MWT has not always been reported.  
The absence of a significant relation between the change in walking economy and 
the change in PFWT and MWT tends to occur in studies measuring walking economy 
as VQO2 during the first stage of treadmill testing 
101,263,285.  When walking economy is 
measured as VQO2 at the beginning of the final min of treadmill walking, a significant 
relation between the change in walking economy and a change PFWT, MWT, and 
6MWD has been reported 200,245,253.  Fractional utilization (walking 
economy/VQO2peak) has been identified as an independent predictor of PFWT and 
MWT, suggesting that improvements in walking performance is due, at least in part, 
to combined changes in VQO2peak and walking economy
253 .   
Measuring changes in VQO2 at one time-point during exercise does not 
highlight whether improvements in walking economy are due to decreased steady-
state VQO2 or a decrease in the slow component of VQO2 or both.  Womack et al., 
(1997) measured VQO2 at the third min and final min of a submaximal exercise test in 
26 men and women with IC before and after a 4 month supervised exercise 
programme 211.  There was a significant increase in exercise time, a significant 
decrease in end-exercise VQO2, and no change in VQO2 during the third min of 
submaximal exercise.  The increase in VQO2 from the third min to the end of 
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submaximal exercise bout (the slow component of VQO2) present at baseline was 
eliminated with training.   
The mechanisms through which exercise rehabilitation improves walking 
economy in individuals with PAD remain unclear, although a number of potential 
mechanisms have been proposed.  Increased lower limb perfusion would reduce 
reliance on anaerobic metabolism, however change in limb perfusion is an 
inconsistent finding in PAD.  Increased local skeletal muscle metabolism through 
increased mitochondrial content, oxidative enzyme activity, and capillary density 
would reduce the VQO2 at a given workload.  Improvements in lower extremity 
strength have also been associated with improved walking economy.  Following 12 
weeks of RT, Ritti-Dias et al., (2010) found a significant improvement in walking 
economy in 15 men and women with IC 285.  There was a significant inverse relation 
between the change in VQO2 at the first stage of the treadmill test and the change in 
strength in the leg with lower ABI and the change in the sum of strength of both legs.  
Another potential mechanism through which exercise rehabilitation improves 
walking economy is improvements in biomechanical efficiency.  Individuals with 
claudication may respond to exercise-induced pain in the lower extremities by 
altering their gait.  Using this compensatory or protective mechanism, individuals 
with IC favor stability at the expense of speed by reducing both stride length and 
stride frequency and by spending a lower percentage of the gait cycle in the swing 
phase and more in the stance phase 356,357.  Within the stance phase, claudicants 
spend less time in single stance and more in double stance.  Self-selected walking 
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pace is typically the most energy efficient, yielding the lowest O2 consumption per 
meter travelled, and velocities above or below self-regulated pace are performed at 
a higher energy cost 358.  Individuals with IC may alter their gait in response to lower 
extremity pain by transferring the work to unaffected muscles, which may result in a 
less energy efficient gait.  In fact, walking economy is further impaired after the 
onset of claudication pain 359.  
Exercise rehabilitation may improve the biomechanical efficiency of 
ambulation, thereby improving walking economy.  Following 6 weeks of supervised 
exercise training, Hiatt et al., (1990) found a significant decrease in VQO2, minute 
ventilation, and HR during a submaximal exercise test in 10 men with IC compared 
with 9 age-matched controls 101.  This improvement occurred in the absence of a 
change in VQO2peak but fewer participants experienced claudication pain during the 
submaximal test following training.  A reduction in claudication pain may allow 
participants to select a more natural, energy-efficient gait.   
Crowther et al., (2008) directly assessed the effects of exercise rehabilitation 
on gait parameters in individuals with IC and found no change in any of the 
temporal-spatial gait parameters measured, despite significant improvements in 
PFWT and MWT 198.  However, gait parameters were measured during pain-free 
walking only. 
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Improvement in Muscular Strength 
Histological changes in PAD skeletal muscle including denervation, muscle 
fiber atrophy, and alterations in myosin heavy chain isoforms contribute to reduced 
muscle strength in individuals with PAD, which is related to functional performance 
128.  Ritti-Dias et al., (2010) found a significant relation between improvements in 
lower extremity strength and improvements in walking performance following 12 
weeks of RT in 15 men and women with IC 285.  There was a significant relation 
between the change in knee extension strength in the higher ABI limb and PFWT and 
between both the change in the knee extension strength in the lower ABI limb and 
the change in the sum of strength in both limbs and the change in VQO2 during the 
first stage of the treadmill test.  Similarly, Wang et al., (2010) found a significant 
relation between the increase in 1 RM leg press and the improvement in walking 
economy in IC patients following 8 weeks of supervised maximal strength training 
284.  The improvement in walking economy was also significantly related with the 
improvement in MWT.   
The mechanisms through which improvements in lower extremity strength 
may potentially improve walking performance in individuals with PAD have not been 
fully investigated.  An increase in muscle strength would decrease the relative load 
placed on the muscle during submaximal efforts.  Individuals with PAD may alter 
their gait in favour of stability 357 and a reduced relative load could improve stability 
and decrease the O2 cost of walking.  The improvements in strength occurred in the 
absence of increases in body weight, which may suggest the role of neural 
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adaptations, for example increased neural drive leading to increased frequency of 
motor unit stimulation and increased number of motor units recruited.  An increase 
in the rate of force development would result in longer relaxation periods between 
contractions and potentially increased muscle perfusion 360.   
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Chapter III 
STUDY 1 
SEDENTARY PATTERNS AND THEIR IMPACT IN PERIPHERAL ARTERIAL DISEASE 
Rationale 
The ambulatory limitation caused by PAD-associated intermittent 
claudication significantly reduces daily physical activity levels, placing these 
individuals at the extreme low end of the physical activity spectrum.  A low level of 
physical activity is a risk factor for the development of PAD 139,361.  Recent 
epidemiological studies in the general population have found significant associations 
between sedentary time and cardiometabolic biomarkers, independent of physical 
activity 6,162.  Even in adults meeting the current physical activity recommendations, 
high levels of sedentary behaviour can have a detrimental effect on cardiometabolic 
health 171.  In addition to the detrimental effects of total sedentary time, the pattern 
of its accumulation may also be of clinical relevance.  Prolonged sedentary bouts 
appear particularly detrimental to health and breaking up sedentary time can have a 
beneficial effect on metabolic biomarkers, independent of total sedentary time 7.   
The mechanisms responsible for the adverse cardiometabolic effects 
associated with prolonged sedentary behaviour are not fully understood.  Chronic 
unbroken periods of muscular unloading may have deleterious biological 
consequences.  The loss of contractile stimulation induced through sitting may lead 
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to the suppression of LPL activity leading to impairment in lipid metabolism 181.  In 
contrast, standing involves isometric contraction of the antigravity muscles and 
produces changes in skeletal muscle LPL activity.  Other potential mechanisms 
include the reduction of insulin action 187 and the replacement of light-intensity 
physical activity 157.  Interrupting sedentary time with light or moderate-intensity 
exercise has been shown to lower glucose and insulin 362. 
Several studies have measured the physical activity levels of individuals with 
PAD 140,144.  However, to our knowledge no study has directly and objectively 
measured total daily sedentary time and the duration of sedentary bouts in 
individuals with PAD.  Thresholding of accelerometer data classifies low counts as 
sedentary behaviour, which misleadingly classifies standing as a sedentary 
behaviour.  ActivPAL3™ triaxial physical activity logger is an inclinometer-based 
motion sensor that measures sedentary behaviour using postural orientation.  It can 
differentiate between standing and sitting/lying 363 and is a valid measure of 
sedentary behaviour in adults 364.   
Previous research has reported a significant inverse relation between daily 
physical activity levels and mortality 154, disease severity 140, CV risk factors 151, 
functional capacity 148, and functional decline 138 among individuals with PAD.  The 
purpose of this study was to measure total sedentary time and the number and 
duration of sedentary bouts in men and women with PAD and to determine the 
relation between sedentary time and patterns and CV risk factors, disease severity, 
functional capacity, and endothelial function. 
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Study Aims 
1. To determine total daily sedentary, standing, and ambulating time in men 
and women with PAD 
2. To determine the number and duration of sedentary bouts in men and 
women with PAD 
3. To examine the relation between activity and sedentary time and patterns 
and disease severity, functional capacity, CV risk factors, endothelial function 
and QOL in men and women with PAD 
Study Hypotheses 
1. The majority of the day will be spent sedentary in men and women with PAD 
2. The majority of daily sedentary time will be spent in bouts >60 min in men 
and women with PAD 
3. There will be a significant relation between sedentary time and the duration 
of sedentary bouts and CV risk factors, disease severity, functional capacity, 
endothelial function, and QOL in men and women with PAD 
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Methodology 
Participants 
Eighteen men and five women with documented PAD were recruited. 
Peripheral arterial disease was confirmed by an ABI <0.90 at rest or a decrease in 
ankle systolic pressure ≥30 mmHg after exercise.  Participants were excluded if they 
had ischemic rest pain, ulceration or gangrene, unstable angina, uncontrolled 
hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure 
>100 mmHg), resting tachycardia, or unstable or acute heart failure.  Participants 
were also excluded if their exercise tolerance was limited by factors other than 
intermittent claudication or if they were unable to walk on a treadmill at a velocity 
≥3.2 km.h-1.  Participants were fully informed of the experimental procedures and 
provided with a plain language statement before giving written informed consent in 
accordance with the Research Ethics Committee at Dublin City University (appendix 
A).  
Overview of Study Design 
Research Design 
Participants visited the Vascular Research Unit in DCU on 2 separate 
occasions and then wore an ActivPAL3™ triaxial physical activity logger for 7 d.  The 
first laboratory visit was used to screen potential participants and during the second 
visit endothelial vasomotor function, walking performance, ABI, and QOL were 
assessed and a blood sample was taken.   
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Visit 1 
Participants were fully informed of the experimental procedures and 
provided with a plain language statement before giving written informed consent.  
Participants completed a general health questionnaire (appendix B), a physical 
activity readiness questionnaire (PAR-Q) (appendix C), and had their blood pressure, 
height, and body mass measured.  
Visit 2 
An overview of visit 2 is outlined in figure 3.1.  Participants arrived at the 
Vascular Research Unit following an 8 h overnight fast.  Water consumption was 
permitted during the fasting period and where possible, all vasoactive medications 
were withheld for at least 4 half-lives.  Participants refrained from strenuous physical 
activity for 24 h and from substances that may affect FMD such as caffeine, vitamin 
C, and tobacco for 6 h prior to the visit.  Since the female participants were post-
menopausal there was no need to control for menstrual cycle phase.   
Following a 10 min rest period in a quiet, temperature-controlled room, a 
blood sample was drawn, and endothelial function was assessed.  The participants 
then rested for a further 10 min in a supine position after which resting ABI was 
measured.  Post-exercise ankle pressure was measured immediately after a treadmill 
walking test.  Participants then completed the Peripheral Artery Questionnaire (PAQ) 
and finally performed a 6MWT.  
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Figure 3.1: An overview of visit 2 
Blood Pressure 
Resting blood pressure was taken from an upright sitting position using a 
mercury sphygmomanometer (Dekamet Model Accoson Sphygmomanometers, 
Harlow Essex) and stethoscope (Classic II 3M Littmann, St. Paul, MN). 
Anthropometric Characteristics 
Height and body mass were measured using a wall stadiometer and 
electronic balance, respectively (Seca 797, USA).  Footwear was removed prior to 
measurement.  Height was measured to the nearest 0.1 cm and body mass was 
measured to the nearest 0.1 kg. 
Blood Sampling and Storage 
Participants rested in a seated position for 5 min with legs uncrossed in order 
to minimize plasma volume shifts.  Blood samples were drawn from the antecubital 
vein.  Serum vacutainers were allowed to stand for 30 min before centrifugation at 
3000 rpm (1600 g) for 15 min at 4°C.   
Supine Rest  
Blood 
Sample 
Resting 
ABI 
Treadmill 
Test 
Post-
exercise 
ankle SBP 
60 s 
PAQ 6MWT 
30 min 
Endothelial 
Function 
(10 min) 
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Biochemical Analysis 
Serum triglycerides, total cholesterol, HDL-C, LDL-C, CRP, and creatine kinase 
(CK) were determined using spectrophotometric assays, performed on an 
automated bench-top clinical chemistry system (ACE®, Alfa Wassermann B.V., 
Netherlands) using the appropriate reagents, calibrators and controls (Randox 
Laboratories, UK).  Concentration of haematocrit, haemoglobin and circulating 
leukocytes were determined from an EDTA whole blood sample using an automated 
haematology analyzer (AcTdiff2, Beckman Coulter, USA).   
Endothelial Function 
Overview of Endothelial Function Assessment 
Brachial artery FMD was determined using high-resolution ultrasonography 
365.  Measurements were performed by the same investigator using a SonoSite, 
MicroMaxx® (Sonosite Inc., Bothell, Washington, US) ultrasound system with a linear 
array transducer, operating at a frequency of 12.0 MHz (figure 3.2).  The investigator 
displayed reliability in the use of ultrasonography to assess brachial arterial diameter 
(r=0.81, p<0.1). 
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Figure 3.2: Sonosite MicroMaxx® ultrasound system and 12.0 MHz linear array 
transducer 
All brachial artery images were acquired with the participants in a supine 
position in a quiet, temperature-controlled room with their right arm rested on an 
examination table perpendicular to the bed and extended and externally rotated to 
permit imaging of the right brachial artery.  An automated pneumatic cuff was 
placed on the right forearm, distal to the brachial artery (figure 3.3) and electrodes 
for a 3-lead ECG were placed on the chest.  The ECG tracing was activated on the 
ultrasound system and settings adjusted to ensure clear identification of the R wave, 
which corresponds to the end of diastole in the cardiac cycle.  
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Figure 3.3: Arm position and cuff placement 
Ultrasound Technique and Image Acquisition 
Anatomic landmarks such as veins and fascial planes were noted and used to 
ensure that all M-mode images and Doppler measurements were recorded at the 
same site.  A longitudinal image of the brachial artery was obtained using B mode 
ultrasound.  The brachial artery was insonated 3-7 cm above the antecubital crease.  
Great care was taken to ensure that the anterior and posterior intimal interfaces 
between the lumen and the arterial wall were clearly visible.  Depth and gain 
settings were optimized to delineate the lumen-arterial interface optimally on both 
the near (anterior) and far (posterior) wall.  The boundaries were clearly visualized 
with the angle of insonation perpendicular to the vessel.  It is recommended that the 
imaging plane should bisect the vessel in the longitudinal direction to ensure that 
diameter measurements obtained from the images reflect the true diameter of the 
vessel 366.  Images were magnified using a “zoom” function.  
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M Mode Imaging 
The brachial artery was imaged using M mode function to facilitate arterial 
diameter measurements at appropriate time points (figure 3.4).  Brachial artery 
images were named and saved for subsequent off-line analysis of arterial diameter.  
Each image acquired incorporated a minimum of 2 and a maximum of 3 consecutive 
ECG R waves, which represent the end of diastole in the cardiac cycle.  The brachial 
artery diameter measurements were obtained at cross sections corresponding to the 
R waves, a process referred to as gating.  The mean of the 2-3 measurements was 
taken as the brachial artery diameter.   
 
Figure 3.4: M mode ultrasound image of the brachial artery 
Doppler Imaging 
Doppler imaging was used to measure blood flow velocity (cm.s-1) in the 
brachial artery.  The Doppler scale was adjusted to accommodate the spectral signal 
and the expected increase in blood flow following cuff release.  The scale was 
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maintained at the minimum range to decrease measurement error.  The Doppler 
gate was set to minimum (1.5 mm) and was positioned in the center of the artery 
lumen.  The Doppler gate was aligned with the direction of flow and the transducer 
was adjusted to achieve an angle of insonation of 60° 367.  The insonation angle 
between the pulsed-wave Doppler beam and the vessel walls was adjusted by 
manipulation of the transducer, to allow the beam to be steered and the angle 
corrected in alignment with the vessel orientation/parallel, and blood flow axis at a 
discrete segment of vessel 60° 367.  The Doppler function traced the spectral 
waveform (figure 3.5).  The image was frozen and peak systolic velocity was 
manually measured using the in-built ultrasound calipers (SonoSite MicroMaxx®). 
 
Figure 3.5: Frozen screen shot of a Doppler image 
Endothelial-Dependent Dilation  
Figure 3.6 illustrates the endothelial-dependent dilation assessment 
procedure.  Following a 10 min rest period, the brachial artery was identified.  M 
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mode images were recorded for the measurement of baseline artery diameter and 
baseline systolic velocity was measured using Doppler.  The pneumatic cuff was 
inflated to 250 mmHg for 5 min 366.  Following 5 min of occlusion, the cuff was 
rapidly deflated resulting in reactive hyperemia and a subsequent increase in 
brachial artery blood flow.  Post-deflation peak systolic velocity was measured using 
Doppler within 15 s of cuff release.  M-mode images of the brachial artery were 
named and recorded every 30 s post-deflation for 5 min.  Brachial artery diameter 
was analyzed off-line.  
 
Figure 3.6: Overview of endothelial-dependent dilation assessment 
Endothelial-Independent Dilation 
Figure 3.7 illustrates the endothelial-independent dilation assessment 
procedure.  Participants rested for 15 min to eliminate endothelium-dependent 
effects on the brachial artery diameter.  Following this period, a new baseline 
brachial artery image was recorded.  Gylceryl trinitrate (GTN; 400 µg) was then 
administered sublingually.  M-mode images were named and recorded every 30 s for 
5 min following GTN administration, for the off-line analysis of brachial artery 
diameter.  
  
Rest in supine position 
(10 min) 
Cuff occlusion 
(5 min) 
Baseline Doppler 
Post-occlusion diameter 
(Every 30 s for 5 min) 
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Figure 3.7: Overview of endothelial-independent dilation assessment 
Off-line Arterial Measurement Software 
Brachial artery diameter was determined by the off-line analysis of 
ultrasound images using a custom-designed, semi-automated ultrasound arterial 
measurement software 368.  Measurements were performed in a blinded fashion.  
Images were selected for analysis using a standard dialog box (figure 3.8).  For each 
image, the artery was located and the area between the anterior and posterior 
arterial walls was manually selected.  The software used this point to segment the 
arterial boundary using a constrained region-growing algorithm, and the result was 
depicted visually in that the segmented arterial lumen was highlighted using grey 
shading.  The segmentation of the artery was updated in real-time.  The automated 
values could be overridden by selecting a new seed point or by using a slider to 
adjust the threshold intensity values of the segmentation until a satisfactory 
diameter estimate was obtained.  Gated measurements of the brachial artery 
diameter were recorded using a minimum of 2 and maximum of 3 consecutive R 
waves on the ECG tracing.  The mean of the 2-3 measurements was taken as the 
brachial artery diameter.  
  
Post-occlusion interval 
(15 min) 
New 
Baseline 
GTN 
Post-GTN diameter 
(Every 30 s for 5 min) 
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Figure 3.8: Standard dialog box 
Resting Ankle Brachial Index 
Ankle brachial index was measured in accordance with recommendations 
from the AHA 35 (figure 3.9).   
 
Figure 3.9: Overview of the ankle brachial index procedure 
Following 10 min of supine rest, blood pressure cuffs were placed on both 
arms, just above the antecubital fossa, and both ankles, just above the malleolus.  
  
 127
Ankle and brachial systolic blood pressures were measured using a hand-held 
Doppler device (Elite 100™, Nicolet) with an 8 MHz pencil probe (figure 3.10).  The 
Doppler device was used to detect the pulse.  A sphygmomanometer was used to 
inflate the cuff to 20 mmHg above SBP.  The cuff was then slowly deflated and the 
first reappearance of the pulse was recorded as the systolic pressure.   
 
Figure 3.10: Nicolet Elite 100™ hand-held Doppler device with an 8 MHz pencil 
probe 
Systolic blood pressures were measured in the right brachial artery, and the 
posterior tibial artery and dorsalis pedis artery of the right ankle followed by the left 
brachial artery and the posterior tibial artery and dorsalis pedis artery of the left 
ankle.  This process was repeated and the average of the two pressures for each 
artery was taken.  If any pair of values differed by more than 6 mmHg, repeat 
pressures were taken.  Ankle brachial index was calculated by dividing the highest 
ankle artery pressure in the more severely diseased lower limb by the highest 
brachial artery pressure.  
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Post-Exercise Ankle Pressure 
Immediately following the treadmill exercise, participants returned to a 
supine position and SBP was measured within 60-150 s using a hand-held Doppler 
device (Elite 100™, Nicolet) in the artery yielding the highest resting pressure, in the 
more severely diseased lower limb.   
Treadmill Walking Capacity 
Walking capacity was assessed on a treadmill (Marquette 2000, General 
Electric, USA) using an incremental protocol of 3.2 km.h-1 and 0% grade, with a 
subsequent 2% increase in grade every 2 min to maximal claudication 369.  Pain free 
walking time and maximal walking time were recorded.  Respiratory metabolic 
measures were monitored continuously throughout the test and VQO2peak was 
determined by averaging the 3 highest consecutive 20 s values.  Heart rate was 
recorded continuously throughout the test using telemetry (Polar Vantage NV™ 
Polar, Port Washington, NY). 
Cardiorespiratory and Metabolic Measures 
Respiratory metabolic responses were determined using standard open-
circuit spirometry techniques (Sensormedics Vmax 229, SensorMedics Corp., CA).  
Prior to testing, the gas analyzers were calibrated with standard gases of known 
concentration.  A mass flow sensor (Sensormedics, Loma Linda, CA, USA) was used to 
collect breath-by-breath measurement of ventilation.  A 3 L volume syringe 
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(Sensormedics, Loma Linda, CA, USA) was used to calibrate the mass flow sensor 
prior to each test.   
Mass Flow Sensor Heated Wire Anemometer – Mode of Operation 
The mass flow sensor is a low resistance tube with a tapered internal 
diameter extending from both ends of a laminar flow throat.  A cold and hot 
stainless steel wire electrically heated to -180°C and -240°C respectively, are 
centered in the flow stream.  These wires are elements in a servo-controller bridge 
circuit that maintain the resistance ratio of the two wires at a constant value.  If only 
the temperature of the inspired gases changes, then both wires lose heat at the 
same rate and no current change is required to keep the bridge balanced.  As air 
flows across the wires, the hot air loses heat more rapidly than the cold air and 
current must be added to keep the bridges balanced at a 3:4 ratio. The amount of 
current required is proportional to the mass flow of the gas.  This method ensures 
that the sensor measures only the heat loss from the molecular convection of the 
moving gas stream, and not the artifact due to cooling of the gas as it passes 
through a breathing assembly.   The mass flow meter responds to instantaneous 
flow rates between 0-16 L.s-1 and integrated flow between 0-350 L.min-1 with flow 
resistance <1.5 cmH2O.L
-1.s-1.  The mass flow sensor was outputted to the analyzer 
module of the Vmax 229 and was sampled at a rate of 125 Hz.  
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Mass Flow Sensor Calibration 
A 3 L volume syringe (Sensormedics, Loma Linda, CA, USA) was connected to 
the mass flow sensor and stroked four times in order to measure inspired and 
expired volumes.  The volumes were calculated by expressing 3 L as a fraction of 
each measured inspired and expired volume achieved during calibration.  An 
average correction factor was calculated for inspired and expired volumes, and used 
to fine-tune the volume measurement.   
A verification procedure was performed. This involved stroking the 3 L 
volume syringe four times.  Inspired and expired volumes were measured using the 
newly calculated correction factors.  In order to pass the calibration procedure, one 
of the four strokes had to have an average flow rate <0.5 L.s-1 and at least one of the 
four strokes had to have an average flow >3.0 L.s-1.  
Gas Analyzers 
The Vmax 229 utilizes a rapid response infrared measurement technique.  An 
O2 and CO2 analyser is integrated with the Vmax 229.  A small sample of inspired air 
is drawn through a sample cell and exposed to an infrared light through an optical 
that is passed through a band pass filter and the sample cell.  An infrared detector 
responds to the amount of infrared light that passes through the sample cell.  The 
amount of light that passes through the sample cell varies according to the 
concentration of CO2 in the sample cell.  Based on measured levels of infrared light 
intensity, the analyzer computes the PCO2 in the gas sample.  The CO2 analyzer is 
 131
linearly scaled across the 0-100% range with a resolution of 0.01% CO2 and a 
response time of <130 ms (10-90%) at 500 ml.min-1 flow.  The O2 analyzer is based 
on the high paramagnetic susceptibility of O2.  A diamagnetic glass dumbbell 
suspended in a magnetic field rotates in proportion to the PO2.  The analyzer is 
linearly scaled across the 0-100% range with a resolution of 0.01% O2 and a response 
time of <130 ms (10-90%) at 500ml.min-1 flow.  
Calibration of CO2 and O2 Analyzers 
The gas analyzers were calibrated with standard gases of known 
concentration (BOC gases, Dublin, Ireland).  The first calibration gas contained 26.00 
± 0.02% O2 and the balance nitrogen (N2).  The second calibration gas contained 4.00 
± 0.02% CO2, 16.00 ± 0.02% O2, and the balance N2.  A small bore drying tube 
connected to the CO2 and O2 analyzers sampled the calibration gases.  The 
absorption and evaporative properties of the drying tube ensured that the relative 
humidity of the calibration gas was equilibrated to ambient conditions prior to 
sampling by the O2 and CO2 analyzers.  The calibration gas was sampled at a rate of 
125 Hz. The response time was similar between O2 and CO2 analyzer.  
The Peripheral Artery Questionnaire 
The PAQ is a self-administered, 20-item questionnaire, encompassing 6 
domains concerning; physical function, symptom stability, symptom 
frequency/burden, treatment satisfaction, quality of life, and social function 
(appendix D) 370,371.  The PAQ is scored by allocating 1 point to the response 
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signifying the most limited function and an additional point for each higher 
response.  Domain scores were calculated by summing the individual items within 
the domain and subtracting the lowest possible score for that domain, dividing by 
the range of that domain and multiplying by 100.  Domain scores ranged from 0 to 
100, and a lower score indicated greater limited function.  A summary score was 
generated by averaging the scores from the physical function, symptom 
frequency/burden, social function, and quality of life domains. 
Six Minute Walk Test 
Prior to the test, participants rested for 10 min in a seated position.  The test 
was performed along a flat, enclosed 30 m corridor with a hard surface, according to 
ATS Guidelines 372.  No warm up was permitted and participants were instructed to 
walk as far as possible, turning 180° every 20 m in the allotted time of 6 min.  The 
total distance walked was measured to the nearest metre, and recorded.  Heart rate 
was recorded throughout the test using telemetry (Polar Vantage NV™ Polar, Port 
Washington, NY). 
Activity and Sedentary Behaviour 
The ActivPAL3™ triaxial physical activity logger (PAL Technologies Ltd., 
Glasgow, UK) (figure 3.11) is a single unit triaxial accelerometer measuring 53 x 35 x 
7 mm and weighing approximately 15 g.  The device samples at 10 Hz and measures 
bodily accelerations using a triaxial accelerometer.  An inbuilt inclinometer is used to 
identify the posture of the wearer.  The data was allocated into 15 s epochs of 
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sitting/lying, standing, and stepping using the on-board microprocessor.  Proprietary 
algorithms provided outputs including time spent sitting/lying, standing, stepping, 
step counts, cadence and activity counts.   
 
 
 
 
Figure 3.11: ActivPAL3™ triaxial physical activity logger 
Each participant was provided with an ActivPAL3™ and given a verbal 
description and written demonstration of its use.  Participants were instructed to 
wear the device continuously for 7 d, except during water activity periods.  The 
ActivPal3™ was worn on the midpoint of the anterior aspect of the right thigh and 
attached using a Tegaderm™ film adhesive frame dressing (3M Health Care, Neuss, 
Germany) (figure 3.12).  If required, an elastic tube bandage was worn over the 
device for further stability.  After 7 d, the ActivPAL3™ was retrieved and the data was 
downloaded to a PC via a USB interface.  
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Figure 3.12: ActivPAL3™ placement  
Data Processing 
For data to be included in the analysis, participants were required to provide 
≥4 valid days, including one weekend day, where a valid day was defined as ≥600 
min of recording during daytime hours, i.e., 7 am to 11 pm 373. Non-wear time was 
defined as ≥60 min of continuous unbroken zero counts from the output data file 363.  
Recorded data was accessed using the ActivPAL™ proprietary software (ActivPAL™ 
Professional VX) and exported to a Microsoft Excel format file (Microsoft Excel 2010, 
Microsoft Corporation, WA, USA).  Data was displayed as the number of seconds 
that the participants engaged in sitting/lying, standing, and stepping for each 15 s 
epoch.  Values over 24 h were summed to provide the total time spent sitting/lying, 
standing and stepping and the average daily time spent in these behaviour 
categories during the recording period were calculated.   
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A technical issue occurred during the analysis of accelerometer counts to 
identify MVPA.  Step cadence was subsequently used to identify MVPA, which is 
robustly defined as >25 steps.epoch-1.  Moderate-to-vigorous physical activity was 
also classified using the definition of >16 steps.epoch-1 to account for the ambulatory 
limitation associated with PAD.   The treadmill velocity used by Gardner et al., (1991) 
to test functional capacity in individuals with PAD is equivalent to a cadence of 16 
steps.epoch-1 369. 
Sedentary behaviour characteristics were examined by processing the 
ActivPAL™ data output files using a customized MATLAB® (version 7.0.1, Mathworks 
Inc, Natick, MA, USA) computer software programme 363.   
Number and Duration of Sedentary Bouts 
The customized MATLAB® programme examined the ActivPAL™ output file 
epoch-by-epoch and binary coded each epoch.  A sedentary epoch was categorized 
as an epoch spent entirely sitting/lying, i.e., a full 15 s (code = 1) and a non-
sedentary epoch was categorized as an epoch containing >0 s of standing or stepping 
or <15 s of sitting/lying (code = 0) 374.  A sedentary epoch identified the start of a 
sedentary bout and the last consecutive sedentary epoch marked the end of the 
sedentary bout.  The number and mean duration of sedentary bouts per day were 
calculated.  Sedentary bouts were categorized by specific durations, namely <5 min, 
5-10 min, 11-20 min, 21-30 min, 31-40 min, 41-60 min, >60 min, >90 min, >2 h, >3 h, 
and >4 h.  The number of sedentary bouts and total duration spent in sedentary 
bouts in each category were calculated.   
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Breaks in Sedentary Behaviour 
Breaks in sedentary behaviour were defined as time spent standing or 
stepping that lasted ≥15 s 363.  The total number of breaks in sedentary behaviour, 
and the number of these breaks that involved ambulation was calculated.   
Statistical Analysis 
Prior to statistical analysis the data were checked for normality using the 
Shapiro-Wilks test.  Pain-free and maximal walking time data was log transformed to 
log10 to normalize data.  Univariate analysis was undertaken using both the Pearson 
product-moment correlation (r) (parametric) and the Spearman correlation (rs) (non-
parametric).  Statistical significance was accepted at the p<0.05 level of confidence.  
SPSS for Windows statistical software (V21.0, SPSS Inc, IL) was used to perform the 
statistical analysis.  
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Results 
Participant Characteristics 
Participant’s physical and biological characteristics are summarized in table 
3.1.  One participant provided <4 valid days of ActivPAL data and was excluded from 
the analysis.  Based on BMI and blood pressure data the participants were on 
average overweight and stage I hypertensive 375.  Total cholesterol, LDL-C, and HDL-C 
were within the normal range and triglyceride levels were above the normal range 
376.   
Table 3.1: Physical and biological characteristics of participants (n=22)  
Age (y) 68.95 ± 8.43 
Height (cm) 167.83 ± 8.18 
Body mass (kg) 80.11 ± 17.07 
BMI (kg.m-2) 28.28 ± 4.97 
Systolic blood pressure (mmHg) 156.52 ± 19.35 
Diastolic blood pressure (mmHg) 83.94 ± 14.83 
Ankle brachial index  0.73 ± 0.18 
Post-exercise change in ankle SBP (mmHg) -33.71 ± 23.74 
Total cholesterol (mmol.L-1) 4.83 ± 1.16 
HDL-cholesterol (mmol.L-1) 1.17 ± 0.25 
LDL-cholesterol (mmol.L-1) 1.76 ± 0.65 
Triglycerides (mmol.L-1) 2.04 ± 2.14 
Values are means ± SD 
Table 3.2 summarizes the medications taken by the study participants.  
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Table 3.2: Medications taken by study participants 
Drug class N % 
Statins 18 82 
Anti-platelet 16 73 
Beta blocker 7 32 
Angiotensin-converting-enzyme inhibitor 7 32 
Proton pump inhibitors 7 32 
Nonsteriodal anti-inflammatory drugs 7 32 
Calcium channel blocker  6 27 
Diuretic 6 27 
Angiotensin II receptor blockers 6 27 
Hypoglycemic  6 27 
Antipasmodic 2 9 
 
Activity and Sedentary Behaviour  
The daily activity and sedentary behaviour of the participants is outlined in 
figure 3.13.  Participants spent a mean of 18.9 ± 2.1 h (79.0%) of the total day 
sedentary, 3.9 ± 1.8 h (16.1%) standing, and 1.2 ± 0.6 h (4.9%) ambulating.   
 
Figure 3.13: Total daily time (h) spent sedentary, standing, and ambulating  
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Figure 3.14 outlines the sedentary, standing and ambulating behaviours 
during waking hours.  Participants spent 67.6 ± 13.3%, 24.9 ± 11.0%, and 7.6 ± 3.5% 
of the waking day sedentary, standing, and ambulating, respectively.  The mean step 
count was 5575.0 ± 3197.3 steps.d-1.  A total of 0.24 ± 0.30 h.d-1 was spent in MVPA, 
defined as >25 steps.epoch-1.  When the definition of MVPA was altered to >16 
steps.epoch-1 to account for the ambulatory limitation associated with PAD, the value 
was 0.50 ± 0.38 h.d-1. 
 
Figure 3.14: Percentage of the waking day spent sedentary, standing, and 
ambulating 
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Sedentary Behaviour Characteristics  
The characteristics of the participant’s sedentary behaviour are outlined in 
figure 3.15.  The majority of sedentary bouts were <5 min, however the greatest 
duration of sedentary time was spent in bouts >60 min.  A mean of 4.0 ± 2.3 h.d-1 
was spent in sedentary bouts >60 min.  This represented 35.6% of the total waking 
sedentary time.  
 
Figure 3.15: Characteristics of sedentary behaviour  
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Breaks in Sedentary Time 
Figure 3.16 outlines the breaks in sedentary time.  Participants broke 
sedentary time on a mean of 39.1 ± 11.0 occasions daily.  The majority of these 
breaks, 91.1 ± 4.5%, involved ambulation.   
 
Figure 3.16: Total number of breaks in sedentary time and the number of 
ambulatory and non-ambulatory breaks 
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Relation between activity and sedentary behaviour and cardiovascular risk factors 
Sedentary time characteristics were associated with CV risk factors.  
Prolonged sedentary bouts were significantly related to cardiometabolic risk factors.  
There was a relation between DBP and the number of sedentary bouts >60 min 
(rS=0.57, p<0.05) and the total duration spent in sedentary bouts >60 min (rs=0.60, 
p<0.01) (figure 3.17).  Total serum cholesterol was significantly related with the 
number of sedentary bouts >3 h and >4 h and the total duration spent in sedentary 
bouts >3 h and >4 h (table 3.3).  The mean circulating level of CRP was 3.75 ± 3.16 
mg.L-1 and CRP levels were related to the number of sedentary bouts >4 h and the 
total duration spent in sedentary bouts >4 h (table 3.3).   
  
Figure 3.17: Relation between diastolic blood pressure and (A) the number of 
sedentary bouts >60 min and (B) total duration spent in sedentary 
bouts >60 min 
Table 3.3: Relation between CV risk factors and sedentary bouts >3 h  
Sedentary bouts CRP Total Cholesterol 
Total number of bouts >3 h ns rs=0.45, p<0.05 
Total duration in bouts >3 h ns rs=0.45, p<0.05 
Total number of bouts >4 h rs=0.44, p<0.05 rs=0.48, p<0.01 
Total duration in bouts >4 h rs=0.44, p<0.05 rs=0.48, p<0.01 
ns, non-significant 
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There was a positive relation between BMI and the number of non-
ambulatory breaks (r=0.53, p<0.05) and the percentage of non-ambulatory breaks 
(r=0.57, p<0.01) and an inverse relation between BMI and the percenatge of 
ambulatory breaks (r=0.57, p<0.01) (figure 3.18).  Body mass was also positively 
related with the percentage of non-ambulatory breaks (r=0.44, p<0.05) and inversely 
associated with the percentage of ambulatory breaks (r=0.44, p<0.05). 
 
 
Figure 3.18: Relation between BMI and (A) the number of non-ambulatory breaks, 
(B) the percentage of non-ambulatory breaks, and (C) the percentage of 
ambulatory breaks 
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Relation between activity and sedentary behaviour and disease severity 
Resting ABI was related with MVPA defined as >25 steps.epoch-1 (rs=0.44, 
p<0.05) (figure 3.19).  The post-exercise change in ankle SBP was inversely related 
with total sedentary time (r=0.49, p<0.05) and positively related with total standing 
time (r=0.46, p<0.05) (figure 3.20).  The post-exercise change in ankle SBP was also 
associated with the characteristics of sedentary time (figure 3.21).  It was positively 
related with the total number of sedentary bouts (r=0.49, p<0.05) and the number of 
sedentary bouts <5 min (rs=0.60, p<0.01) and inversely related to the number of 
sedentary bouts >60 min (rs=0.48, p<0.05).   
 
Figure 3.19: Relation between resting ABI and MVPA (>25 steps.epoch-1) 
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Figure 3.20:  The relation between the post-exercise change in ankle systolic blood 
pressure and (A) total sedentary time and (B) total standing time 
 
 
 
Figure 3.21: The relation between the post-exercise change in ankle systolic blood 
pressure and (A) the total number of sedentary bouts, and the number 
of sedentary bouts (B) <5 min and (C) >60 min 
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Relation between activity and sedentary behaviour and walking performance 
The mean PFWT and MWT were 4 min 18 s and 7 min 7 s, respectively.  The 
mean 6MWD was 377.95 ± 77.57 m.  There was no significant relation between 
walking performance and any measure of activity or sedentary behaviour.   
Relation between activity and sedentary behaviour and endothelial function 
Endothelial-dependent dilation in response to reactive hyperemia was 4.54 ± 
4.62%.  Endothelial-independent dilation in response to GTN administration was 
16.96 ± 7.35%.  There was a relation between endothelial-dependent dilation and 
MVPA defined as >25 steps.epoch-1 (r=0.43, p<0.05) (figure 3.22). 
 
Figure 3.22: The relation between endothlial-dependent dilation and moderate-to-
vigorous physical activity defined as >25 steps.epoch-1 
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Relation between activity and sedentary behaviour and quality of life 
Table 3.4 summarizes the association between PAQ scores and activity and 
sedentary behaviour.  The PAQ summary score was significantly related with total 
sedentary, standing, and ambulating time; step count, and MVPA (figure 3.23).  The 
social function domain was significantly related with total sedentary, standing, and 
ambulating time; step count, and MVPA (table 3.4).  The quality of life domain was 
significantly related with total sedentary and standing time.  There was a significant 
relation between the physical function domain and measures of activity, i.e. total 
stepping time, step count, and MVPA.  Treatment satisfaction was significantly 
related with MVPA, defined as >25 steps.epoch-1.  There was no relation between 
activity and sedentary behaviour and the symptom stability or symptom 
frequency/burden domains of the PAQ. 
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Figure 3.23: The relation between the Peripheral Artery Questionnaire summary 
score and (A) total sedentary time, (B) total standing time, (C) total 
ambulating time, (D) step count, and moderate-to-vigorous physical 
activity defined as both (E) >25 and (F) >16 steps.epoch-1 
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Table 3.4: The relation between PAQ scores and activity and sedentary behaviour 
PAQ Domain Sedentary time Standing time Ambulating time Step count MVPA 
(>25 steps
.
epoch
-1
) 
PAD MVPA 
(>16 steps
.
epoch
-1
) 
Physical function ns ns rs=0.58, p<0.01 rs=0.52, p<0.01 rs=0.43, p<0.05 rs=0.48, p<0.01 
Treatment satisfaction  ns ns ns ns rs=0.50, p<0.05 ns 
Quality of life rs=-0.44, p<0.01 rs=0.44, p<0.05 ns ns ns ns 
Social function r=-0.74, p<0.01 r=0.71, p<0.01 rs=0.70, p<0.01 rs=0.65, p<0.01 rs=0.53, p<0.05 rs=0.49, p<0.05 
Summary score r=-0.54, p<0.01 r=0.51, p<0.05 rs=0.61, p<0.01 rs=0.56, p<0.01 rs=0.49, p<0.05 rs=0.48, p<0.05 
ns, non-significant 
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Summary of Results 
Participants spent 79.0%, 16.1%, and 4.9% of the total day sedentary, 
standing, and ambulating, respectively.  The greatest duration of sedentary time was 
spent in bouts >60 min; 36% of the total daily waking sedentary time was spent in 
sedentary bouts >60 min.  Excessive sedentary time and prolonged sedentary bouts 
were related to PAD severity.  Prolonged sedentary bouts were also related to CV 
risk factors.  Breaking up sedentary time and having numerous and short sedentary 
bouts was found to have a beneficial effect on PAD severity and CV risk factors.  
Quality of life was associated with overall daily activity and sedentary behaviours in 
PAD. 
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Chapter IV 
STUDY 2 
EFFECT OF ACUTE INTERMITTENT EXERCISE ON ENDOTHELIAL FUNCTION IN 
PERIPHERAL ARTERIAL DISEASE 
Rationale 
In the pathophysiology of PAD the delivery of blood flow to the peripheral 
tissues depends not only on the severity of the stenotic occlusion but also on the 
regulatory mechanisms that control blood flow, including vascular tone 292.  Vascular 
tone is regulated by the endothelium and endothelial dysfunction represents one of 
the earliest events in the pathogenesis of atherosclerosis 377.  The ability of large 
conduit vessels to dilate in response to a brief period of occlusion is termed 
endothelial-dependent dilation (EDD) and is commonly used to non-invasively assess 
endothelial function 365.  Impairment in EDD is well established in individuals with 
PAD, whereas there is no change in endothelial-independent dilation (EID) 
294,296,297,303, signifying that the impairment in vasodilation is due to endothelial 
dysfunction.  In addition to being an early event in the development of PAD, 
endothelial dysfunction can be exacerbated by chronic exposure to I-RI in PAD.   
Improvement in endothelial function is proposed as a mechanism through 
which exercise rehabilitation relieves symptoms and enhances functional capacity in 
individuals with PAD 10.  Previous research has found significant improvements in 
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EDD with exercise rehabilitation in individuals with PAD 11–13.  However, acute 
exercise is associated with a transient impairment in EDD in individuals with PAD 
12,14–17.  This is in contrast to significant increases in EDD following acute exercise in 
healthy individuals 18 and individuals with CAD 19.  The impairment in EDD in 
individuals with PAD is dependent upon the degree of ischemia produced in the 
diseased limb during exercise and occurs following exercise to maximal claudication 
but not exercise to the onset of claudication 14.  Exercise to maximal claudication is 
also associated with an acute inflammatory response in individuals with PAD 14,17. 
Previous studies have employed acute exercise protocols consisting of a 
single short continuous bout of exercise, ranging in duration from approximately 2 
min to 10 min.  Current American College of Sports Medicine (ACSM) physical activity 
guidelines for adults, older adults, and adults with a clinically significant chronic 
condition or functional limitation recommend a minimum of 30 min moderate-
intensity aerobic physical activity on 5 d.wk-1 or a minimum of 20 min vigorous-
intensity aerobic physical activity on 3 d.wk-1 378,379.  Activity can be accumulated 
from bouts of ≥ 10 min.  The functional limitation associated with intermittent 
claudication means that exercise rehabilitation programs designed for individuals 
with PAD often employ intermittent walking consisting of multiple exercise bouts to 
allow participants to accumulate minutes of exercise.  A similar approach has been 
adopted in research studies investigating the effects of chronic exercise in 
individuals with PAD.  
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In addition, all but one of the previous studies investigating the effects of 
acute exercise in individuals with PAD have failed to measure EID, which prohibits 
conclusions being drawn that the observed impairment in vasodilation is 
endothelial-dependent.  The purpose of this study was to determine and compare 
the effect of acute intermittent exercise to the onset of claudication (OC) and 
maximal claudication (MC) on endothelial function and inflammatory markers in 
men and women with PAD.    
Study Aims 
1. To determine the effect of an acute bout of intermittent walking to the onset 
of claudication on endothelial-dependent and endothelial-independent 
dilation and inflammation in men and women with PAD 
2. To determine the effect of an acute bout of intermittent walking to maximal 
claudication on endothelial-dependent and endothelial-independent dilation 
and inflammation in men and women with PAD 
3. To compare the effects of an acute bout of intermittent walking to the onset 
of claudication and maximal claudication on endothelial-dependent and 
endothelial-independent dilation and inflammation in men and women with 
PAD 
Study Hypotheses  
1. There will be no significant change in endothelial-dependent or endothelial-
independent dilation, or inflammation following an acute bout of 
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intermittent walking to the onset of claudication in men and women with 
PAD 
2. There will be a significant decrease in endothelial-dependent dilation and 
increase in inflammation following an acute bout of intermittent walking to 
maximal claudication in men and women with PAD 
3. There will be a significant decrease in endothelial-dependent dilation and 
increase in inflammation following an acute bout of intermittent walking to 
maximal claudication compared with an acute bout of intermittent walking to 
the onset of claudication in men and women with PAD 
  
 155
Methodology 
Participants 
Ten men and five women with documented PAD were recruited.  Two 
participants from Study 1 participated in Study 2.  Peripheral arterial disease was 
confirmed by an ABI <0.90 at rest or a decrease in ankle systolic pressure ≥30 mmHg 
after exercise.  Participants were excluded if they had ischemic rest pain, ulceration 
or gangrene, unstable angina, uncontrolled hypertension (systolic blood pressure 
>180 mmHg and/or diastolic blood pressure >100 mmHg), resting tachycardia, or 
unstable or acute heart failure.  Participants were also excluded if their exercise 
tolerance was limited by factors other than intermittent claudication or if they were 
unable to walk on a treadmill at a velocity of 3.2 km.h-1.  Participants were fully 
informed of the experimental procedures and provided with a plain language 
statement before giving written informed consent in accordance with the Research 
Ethics Committee at Dublin City University (appendix E).  
Overview of Study Design 
Research Design 
An overview of the study design is presented in figure 4.1.  Participants 
visited the Vascular Research Unit in DCU on 3 separate occasions.  The first visit was 
used to screen potential participants and measure treadmill-walking performance.  
During the second and third visit endothelial vasomotor function was assessed 
 156
before, and immediately and 1 h after an acute bout of intermittent treadmill 
walking to OC or MC. 
 
 
 
 
 
Figure 4.1: Overview of research design 
Visit 1 
Participants fasted for 4 h and refrained from strenuous physical activity for 
24 h prior to the visit.  They were fully informed of the experimental procedures and 
provided with a plain language statement before giving written informed consent.  
Participants completed a general health questionnaire (appendix B), a PAR-Q 
(appendix C), and had their blood pressure, height, and body mass measured.  
Following a 10 min rest period in a supine position, resting ABI was measured before 
and post-exercise ankle pressure was measured immediately after a treadmill 
walking test. 
Visit 1 Visit 2 Visit 3 
Screening Endothelial function before and after 
an acute bout of intermittent walking 
to: 
• onset of claudication or, 
• maximal claudication    
≥7 d 
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Visit 2 and Visit 3 
An overview of visits 2 and 3 is outlined in figure 4.2.  Both visits were 
identical except for the exercise endpoint – OC or MC.  The order of exercise 
endpoints was randomized.  Participants arrived at the Vascular Research Unit 
following an 8 h overnight fast.  Water consumption was permitted during the 
fasting period and where possible, all vasoactive medications were withheld for at 
least 4 half-lives.  Participants refrained from strenuous physical activity for 24 h and 
substances that may affect FMD such as caffeine, vitamin C, and tobacco for 6 h 
prior to the visit.  Since the female participants were post-menopausal there was no 
need to control for menstrual cycle phase.   
Following a 10 min rest period in a quiet, temperature-controlled room, a 
blood sample was drawn, and endothelial function was assessed.  Participants then 
undertook an acute bout of intermittent treadmill walking to either OC or MC to 
accumulate 30 min of exercise.  Within 5 min of exercise cessation a blood sample 
was taken and endothelial function was again assessed.  One hour after exercise 
cessation a blood sample was taken and endothelial function was assessed.   
 
Figure 4.2: Overview of visit 2 and visit 3 
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Blood Pressure  
As described in the methodology section of Chapter III 
Anthropometrics  
As described in the methodology section of Chapter III 
Resting Ankle Brachial Index 
As described in the methodology section of Chapter III 
Post-exercise Ankle Pressure 
As described in the methodology section of Chapter III 
Treadmill Walking Capacity 
Walking capacity was assessed on a treadmill (Marquette 2000, General 
Electric, USA) using an incremental protocol of 3.2 km.h-1 and 0% grade, with a 
subsequent 2% increase in grade every 2 min to maximal claudication (Gardner, 
1991).  Pain free walking time and maximal walking time were recorded.  Heart rate 
was recorded continuously throughout the test using telemetry (Polar Vantage NV™ 
Polar, Port Washington, NY). 
Blood Sampling and Storage 
Participants rested in a seated position for 5 min with legs uncrossed in order 
to minimize plasma volume shifts.  Blood samples were drawn from the antecubital 
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vein.  Serum vacutainers were allowed to stand for 30 min before centrifugation at 
3000 rpm (1600 g) for 15 min at 4°C.    
Biochemical Analysis  
Circulating leukocytes, haematocrit, RBC and haemoglobin concentrations 
were determined from an EDTA whole blood sample using an automated 
haematology analyzer (AcTdiff2, Beckman Coulter, USA).  Serum concentration of 
interferon gamma (INF-γ), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor 
necrosis factor alpha (TNF-α) were determined in duplicate using a 
electrochemiluminescent multi-spot quantitative sandwich immunoassay system  
(MSD, Maryland, USA).  Appropriate reagents and calibrators were used (MSD, 
Maryland, USA).  
Endothelial Function Assessment 
As described in the methodology section of Chapter III 
Acute Intermittent Exercise 
Participants performed intermittent treadmill walking to accumulate 30 min 
of exercise.  Treadmill intensity was self-selected by participants under instructions 
to select an intensity that induced the onset of claudication within 3-5 min (Norgren, 
2005).  Participants walked to either OC or MC.  The severity of claudication pain 
experienced by the patient was determined using an adapted version of the 
perceived claudication pain scale, where 0 = no symptoms, 0.5 = tiredness, 
heaviness, or tightness in legs without pain; 1 = onset of pain; 2 = mild pain; 3 = 
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moderate pain; 4 = maximal pain (Barak, 2009) (appendix F).  When participants 
reached the required point on the pain scale they rested seated until the pain 
subsided before continuing.  Participants were allowed to alter the treadmill velocity 
and grade during the first minute of each exercise bout.  The velocity control arrows 
were kept visible to allow participants alter the treadmill grade and velocity when 
signalled by the research assistant.  Participants continued in this fashion until 30 
min of walking had been accumulated.  Heart rate was recorded continuously 
throughout the test using telemetry (Polar Vantage NV™ Polar, Port Washington, 
NY). 
Statistical Analysis 
Prior to statistical analysis the data was checked for normality using the 
Shapiro-Wilks test.  A dependent t-test (parametric) and the Wilcoxon signed-rank 
test (non-parametric) were used to compare mean differences in exercise 
characteristics and physiological responses during exercise to OC and MC.  A 
condition (OC and MC) x time (baseline, immediately post-exercise, and 1 h post-
exercise) repeated measures ANOVA was used to compare mean differences in 
endothelial-dependent and –independent dilation and inflammatory markers within 
and between exercise conditions.  Significant main effects were probed using a 
Bonferroni post hoc test (parametric).  Statistical significance was accepted at the 
p<0.05 level of confidence.  SPSS for Windows statistical software (V19.0, SPSS Inc, 
IL) was used to perform the statistical analysis.  
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Results 
Participant Characteristics 
Four patients did not complete all 3 laboratory visits and were excluded.  Two 
completed the screening visit only, 1 was lost due to ill health and 1 due to a family 
bereavement.  Two did not complete the second exercise session, 1 due to vacation 
and 1 underwent revascularization.  One participant could not complete the 30 min 
of exercise during the exercise to OC session due to fatigue and was excluded.  
Participant’s physical characteristics are summarized in table 4.1.  Based on BMI and 
blood pressure data the participants were on average overweight and stage I 
hypertensive 375. 
Table 4.1: Physical characteristics of participants (n=10)  
Age (y) 70.40 ± 7.91 
Height (cm) 169.58 ± 8.04 
Body mass (kg) 72.75 ± 14.90 
BMI (kg.m-2) 25.24 ± 4.39 
Systolic blood pressure (mmHg) 141.29 ± 17.65 
Diastolic blood pressure (mmHg) 79.86 ± 11.88 
Ankle brachial index  0.71 ± 0.15 
Pain-free walking time (min:s) 7:36 ± 4:20 
Maximal walking time (min:s) 13:19 ± 3:41 
Values are means ± SD 
Acute Exercise Session 
The mean exercise characteristics and physiological responses during the 
exercise sessions to OC and MC are summarized in table 4.2.  The treadmill grade 
was significantly higher during the exercise session to MC than OC.  The bout 
duration was significantly longer and the number of exercise bouts was significantly 
lower in the MC condition than OC condition.  The recovery duration did not differ 
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between the two conditions.  The total recovery time and total session time was 
significantly longer in the OC condition than the MC condition.  The average heart 
rate and the percentage of HRpeak were significantly higher in the MC condition than 
OC. 
Table 4.2:  Average exercise characteristics and physiological responses during 
exercise to onset of claudication and maximal claudication 
 Exercise Condition 
 Onset of Claudication Maximal Claudication 
Treadmill velocity (km.h-1) 3.85 ± 0.67 4.05 ± 0.56 
Treadmill grade (%) 1.10 ± 1.64 1.99 ± 1.66* 
Number of bouts  6.10 ± 1.85 3.60 ± 1.78* 
Bout duration (min:s) 5:51 ± 3:23 13:03 ± 9:12† 
Recovery duration (min:s) 3:58 ± 1:18 4:07 ± 2:53 
Total exercise time (min:s) 30:26 ± 1:13 29:58 ± 0:50 
Total recovery time (min:s) 19:23 ± 9:03 10:59 ± 10:05* 
Total session time (min:s) 49:49 ± 9:20 40:57 ± 10:17* 
Heart rate (beats.min-1) 85.22 ± 14.67 98.32 ± 18.24† 
Percentage of treadmill test HRpeak (%) 74.62 ± 12.76 85.69 ± 12.79† 
Peak heart rate (beats.min-1) 105.90 ± 22.90 115.9 ± 22.37 
 Values are means ± SD, *p<0.05 vs. OC; †p<0.01 vs. OC 
Endothelial Function 
There was no significant main effect for time or condition and no significant 
time x condition interaction effect on endothelial-dependent (figure 4.3) or 
independent dilation.  There was no significant main effect for time or condition and 
no significant time x condition interaction effect on baseline or peak blood flow 
velocity or the change in blood flow velocity.   
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Figure 4.3:  The effect of acute intermittent exercise to the onset of claudication (OC) 
and maximal claudication (MC) on FMD 
Inflammatory Markers  
Compared with baseline there was a significant decrease in plasma 
concentration of INF-γ 1 h after acute exercise to both OC and MC (figure 4.12).  
There was no significant difference between conditions.  There was no significant 
change in TNF-α, IL-6, IL-1β, or lymphocytes following either condition(table 4.3).  
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Table 4.3:  Inflammatory markers during exercise to the onset of claudication and maximal claudication 
Values are means ± SD, †p<0.01 vs. baseline 
 Onset of claudication Maximal claudication 
 Baseline Immediately 
post exercise 
1 h post 
exercise 
Baseline Immediately 
post exercise 
1 h post 
exercise 
INF-γ (pg.mL-1) 20.94 ± 16.73 19.58 ± 15.12 17.85 ± 14.78† 21.41 ± 18.38 19.18 ± 16.49 18.15 ± 14.49† 
TNF-α (pg.mL-1) 24.75 ± 8.87 26.40 ± 7.50 24.04 ± 7.44 26.81 ± 7.71 25.30 ± 8.06 25.16 ± 8.86 
IL-6 (pg.mL-1) 4.14 ± 2.39 4.82 ± 2.81 4.46 ± 2.51 3.98 ± 1.62 4.06 ± 1.82 4.01 ± 1.36 
IL-1-β (pg.mL-1) 0.27 ± 0.58 0.15 ± 0.31 0.13 ± 0.30 0.13 ± 0.27 0.32 ± 0.54 0.25 ± 0.52 
WBCs (x10^3.uL-1) 7.63 ± 2.17 8.05 ± 2.86 7.18 ± 1.48 7.79 ± 2.44 8.45 ± 3.00 7.69 ± 2.64 
Lymphocytes (%) 27.43 ± 7.40 26.14 ± 8.36 25.40 ± 8.36 26.39 ± 9.21 25.36 ± 8.52 24.73 ± 8.55 
Lymphocytes (x10^3.uL-1) 2.06 ± 0.74 2.13 ± 1.00 1.91 ± 0.81 2.05 ± 1.01 2.22 ± 1.13 1.89 ± 0.94 
Monocytes (%) 6.58 ± 3.57 5.28 ± 1.70 5.23 ± 2.07 5.70 ± 3.06 5.56 ± 1.30 5.86 ± 2.31 
Monocytes (x10^3.uL-1) 0.49 ± 0.27 0.45 ± 0.25 0.37 ± 0.14 0.46 ± 0.30 0.45 ± 0.22 0.56 ± 0.34 
Granulocytes (%) 66.15 ± 5.83 68.50 ± 7.97 69.27 ± 8.28 74.49 ± 23.03 68.23 ± 8.74 70.48 ± 9.00 
Granulocytes (x10^3.uL-1) 7.77 ± 8.51 5.48 ± 2.02 9.62 ± 16.40 5.29 ± 1.86 5.80 ± 2.23 5.35 ± 1.97 
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Summary of Results  
Acute intermittent exercise to both OC and MC had no effect on either 
endothelial-dependent or endothelial-independent dilation.  There was no 
inflammatory response following either exercise condition.  Mean recovery time 
during the acute exercise bouts did not differ whether participants walked to OC or 
MC.  Fewer exercise bouts were required to accumulate 30 min and the overall 
session time was shorter when exercising to MC than OC.  
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Chapter V 
STUDY 3 
EFFECT OF A 12-WEEK COMMUNITY-BASED EXERCISE REHABILITATION 
PROGRAMME ON ENDOTHELIAL FUNCTION IN PERIPHERAL ARTERIAL DISEASE 
Rationale 
Exercise rehabilitation is a well-established treatment for PAD and is 
recommended by the ACC/AHA as the first-line of treatment for the majority of 
individuals with PAD 22.  The mechanism(s) through which exercise rehabilitation 
improves symptom severity and functional capacity in PAD is not fully understood.  A 
number of potential mechanisms have been proposed including the formation of 
collateral vessels and improvements in hemorheological properties, muscle 
metabolism, walking economy, muscular strength, and endothelial function.  
Endothelial function can be assessed non-invasively by measuring the ability of large 
conduit vessels to dilate in response to a brief period of occlusion 365.  Previous 
research has reported significant improvements in EDD following exercise 
rehabilitation in individuals with PAD 11–13,246,313.  The training protocols employed in 
previous studies have consisted of submaximal intermittent exercise.  To date, no 
published studies have evaluated the effect of exercise rehabilitation involving 
intermittent exercise to maximal claudication on endothelial function in individuals 
with PAD.  Findings from Study 2 found no adverse effect of acute intermittent 
 167
exercise to maximal claudication on endothelial function or inflammatory markers in 
PAD.  
Previous studies that have examined the effect of exercise training on 
endothelial function in PAD have employed hospital- or laboratory-based exercise 
rehabilitation programmes.  The growing epidemic of CVD and its escalating 
economic burden requires the employment of viable secondary prevention 
strategies.  Home- and community-based exercise rehabilitation programmes 
provide an alternative to hospital-based programmes for PAD.  It is however, first 
necessary to determine the efficacy of home- and community-based exercise 
rehabilitation programmes if their use is to become more widespread in the 
treatment of PAD.  The purpose of this study was to determine the effect of a 12-
week community-based exercise rehabilitation programme on endothelial function, 
disease severity, walking performance, daily physical activity and sedentary levels, 
and QOL in men and women with PAD.   
Study Aims 
1. To evaluate the effect of a 12-week community-based exercise rehabilitation 
programme on endothelial-dependent dilation in men and women with PAD  
2. To evaluate the effect of a 12-week community-based exercise rehabilitation 
programme on endothelial-independent dilation in men and women with 
PAD  
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3. To evaluate the effect of a 12-week community-based exercise rehabilitation 
programme on ABI, walking performance, daily physical activity and 
sedentary levels, and QOL in men and women with PAD  
Study Hypotheses 
1. There will be a significant increase in endothelial-dependent dilation after a 
12-week community-based exercise rehabilitation programme in men and 
women with PAD 
2. There will be no change in endothelial-independent dilation after a 12-week 
community-based exercise rehabilitation programme in men and women 
with PAD 
3. There will be a significant increase in walking performance, daily physical 
activity levels, and QOL, and a significant decrease in daily sedentary 
behaviour after a 12-week community-based exercise rehabilitation 
programme in men and women with PAD 
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Methodology 
Participants 
Eleven men and four women with documented PAD, who had been referred 
for exercise rehabilitation by vascular surgeons in Beaumont Hospital and the Mater 
Misericordiae Hospital, were recruited.  All Study 3 participants participated in Study 
1.  Two participants participated in all 3 studies.  Peripheral arterial disease was 
confirmed by an ABI <0.90 at rest or a decrease in ankle systolic pressure ≥30 mmHg 
after exercise.  Participants were excluded if they had ischemic rest pain, ulceration 
or gangrene, unstable angina, uncontrolled hypertension (systolic blood pressure 
>180 mmHg and/or diastolic blood pressure >100 mmHg), resting tachycardia, or 
unstable or acute heart failure.  Participants were also excluded if their exercise 
tolerance was limited by factors other than intermittent claudication or if they were 
unable to walk on a treadmill at a velocity ≥3.2 km.h-1.  Participants were fully 
informed of the experimental procedures and provided with a plain language 
statement before giving written informed consent in accordance with the Research 
Ethics Committee at Dublin City University (appendix A).  
Overview of Study Design 
Research Design  
An overview of the study design is presented in figure 5.1.  Participants 
visited the Vascular Research Unit in DCU on 3 separate occasions.  The first visit was 
was used to screen potential participants.  The second and third visits took place 
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before and after completing a 12 week community-based exercise rehabilitation 
programme, respectively.  Both visits involved taking blood samples and the 
assessment of endothelial function, walking performance, ABI, and QOL.  Following 
the second and third laboratory visits, participants wore an ActivPAL3™ triaxial 
physical activity logger for 7 d.  Participants did not begin the community-based 
exercise rehabilitation programme until after the 7 d physical activity recording 
period following the second laboratory visit.   
 
Figure 5.1: Overview of research design 
Visit 1 
Participants were fully informed of the experimental procedures and 
provided with a plain language statement before giving written informed consent. 
They completed a general health questionnaire (appendix B), PAR-Q (appendix C), 
and had their blood pressure, height, and body mass measured.  
Visit 2 and Visit 3 
An overview of visit 2 and visit 3 is outlined in figure 5.2.  Participants arrived 
at the Vascular Research Unit following an 8 h overnight fast.  Water consumption 
12-week community-based 
exercise rehabilitation programme 
Week 1 Week 12 
Visit 1 Visit 2 Visit 3 
 171
was permitted during the fasting period and where possible, all vasoactive 
medications were withheld for at least 4 half-lives.  Participants refrained from 
strenuous physical activity for 24 h and substances that may affect FMD such as 
caffeine, vitamin C, and tobacco for 6 h prior to the visit.  Since the female 
participants were post-menopausal there was no need to control for menstrual cycle 
phase.   
 
Figure 5.2: Overview of visit 2 and visit 3 
Following a 10 min rest period in a quiet, temperature-controlled room, a 
blood sample was drawn, and endothelial function was assessed.  The participants 
then rested for a further 10 min in a supine position after which resting ABI was 
measured before and post-exercise ankle pressure was measured immediately after 
a treadmill walking test.  Participants then completed the PAQ and finally performed 
a 6MWT. 
Blood Pressure  
As described in the methodology section of Chapter III 
Supine Rest  
Blood 
Sample 
Resting 
ABI 
Treadmill 
Test 
Post-
exercise 
ankle SBP 
60 s 
PAQ 6MWT 
30 min 
Endothelial 
Function 
(10 min) 
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Anthropometrics  
As described in the methodology section of Chapter III 
Blood Sampling and Storage 
As described in the methodology section of Chapter III 
Biochemical Analysis  
As described in the methodology section of Chapter III 
Endothelial Function Assessment 
As described in the methodology section of Chapter III 
Resting Ankle Brachial Index 
As described in the methodology section of Chapter III 
Post-exercise Ankle Pressure 
As described in the methodology section of Chapter III 
Treadmill Walking Capacity 
As described in the methodology section of Chapter III 
The Peripheral Artery Questionnaire 
As described in the methodology section of Chapter III 
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Six Minute Walk Test 
As described in the methodology section of Chapter III 
Activity and Sedentary Behaviour 
As described in the methodology section of Chapter III 
Participants continued to attend the exercise programme after the initial 12 
weeks.  Analysis of ActivPAL data was performed including and excluding the days 
participants attended the exercise programme. 
Exercise Programme  
A community-based exercise rehabilitation programme for individuals with 
PAD, known as SmartSteps, was established in conjunction with the School of Health 
and Human Performance in DCU, DCU Sport, Beaumont Hospital and the Mater 
Misericordiae Hospital.  Participants attended supervised exercise sessions 2 d.wk-1 
for 12 weeks.  The exercise sessions involved 5 min of warm-up exercises, 30 min of 
intermittent treadmill walking, 15 min of resistance training and 5 min of cool down 
exercises.  Participants were instructed to select a treadmill intensity that induced 
the onset of claudication after 3-5 min and walk to maximal claudication (Norgren, 
2005).  At maximal claudication participants rested in a seated position until the pain 
subsided before continuing.  This pattern was continued until participants 
accumulated 30 min of exercise.  Pain-free walking time and distance and maximal 
walking time and distance were recorded.  When participants could successfully 
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complete 10 min of continuous walking, the treadmill intensity was progressed by 
increasing velocity by 0.5 km.h-1 or grade by 1% as tolerated.   
Statistical Analysis 
Prior to statistical analysis the data was checked for normality using the 
Shapiro-Wilks test.  A dependent t-test (parametric) and the Wilcoxon signed-rank 
test (non-parametric) were used to compare mean differences in outcome variables 
at baseline and week 12.  Statistical significance was accepted at the p<0.05 level of 
confidence.  SPSS for Windows statistical software (V21.0, SPSS Inc, IL) was used to 
perform the statistical analysis.  
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Results 
Training Adherence 
Eleven participants completed the 12-week exercise programme.  Four 
participants were lost to follow-up; 2 due to illness, 1 underwent revascularization, 
and 1 due to lack of interest.  Training adherence for those who completed the 
programme was 83.9%. 
Participant Characteristics 
Participant’s physical and biological characteristics at week 1 and week 12 
are summarized in table 5.1.  Based on baseline BMI and blood pressure data the 
participants were on average overweight and stage I hypertensive 375.  Total 
cholesterol, LDL-C, HDL-C, and TGs were within the normal range 376.  Table 5.2 
summarizes the medications taken by the participants.  There was no change in body 
mass, BMI, BP, ABI, or blood lipids between week 1 and week 12.   
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Table 5.1:  Physical and biological characteristics of the participants at week 1 and 
week 12 (n=11) 
 Week 1 Week 12 
Age (y) 67.55 ± 9.20  
Height (cm) 166.12 ± 6.40  
Body mass (kg) 77.96 ± 18.85 78.08 ± 18.79 
BMI (kg.m-2) 28.13 ± 6.04 28.19 ± 6.11 
Systolic blood pressure (mmHg) 157.60 ± 20.19 151.09 ± 11.95 
Diastolic blood pressure (mmHg) 82.40 ± 14.66 79.00 ± 11.71 
Ankle brachial index  0.70 ± 0.16 0.69 ± 0.18 
Total cholesterol (mmol.L-1) 4.92 ± 1.23 4.91 ± 0.85 
HDL-cholesterol (mmol.L-1) 1.27 ± 0.19 1.26 ± 0.23 
LDL-cholesterol (mmol.L-1) 1.88 ± 0.59 1.92 ± 0.54 
Triglycerides (mmol.L-1) 1.38 ± 0.55 1.99 ± 1.54 
Values are means ± SD 
Table 5.2: Medications taken by participants 
Drug class N % 
Statins 8 73 
Anti-platelet 6 55 
Beta blocker 4 36 
Nonsterodial anti-inflammatory drugs 4 36 
Calcium channel blocker  4 36 
Angiotensin-converting-enzyme inhibitor 3 27 
Proton pump inhibitors 3 27 
Diuretic 2 18 
Angiotensin II receptor blocker 2 18 
Hypoglycemic  2 18 
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Endothelial Function 
There was a significant increase in the percentage change in brachial artery 
diameter from 2.71 ± 5.56% to 7.35 ± 4.76% (figure 5.3) and absolute change in 
brachial artery diameter from 0.01 ± 0.02 cm to 0.03 ± 0.02 cm (figure 5.4) between 
week 1 and week 12.  There was no significant change in percentage (figure 5.3) or 
absolute (figure 5.4) endothelial-independent dilation between week 1 and week 12.  
There was no significant change in baseline brachial artery diameter, or baseline or 
peak blood flow velocity (figure 5.5) between week 1 and week 12.   
 
Figure 5.3: Percentage change in brachial artery diameter with flow-mediated 
dilation and following glyceryl-trinitrate administration at week 1 and 
week 12, †p<0.01 vs. week 1 
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Figure 5.4: Absolute change in brachial artery diameter with flow-mediated dilation 
and following glyceryl trinitrate administration at week 1 and week 12, 
† p < 0.05 vs. week 1 
 
Figure 5.5: Peak blood flow velocity at week 1 and 12 
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Walking Performance 
Treadmill PFWT increased (p<0.05) from 174.8 ± 109.4 s to 247.8 ± 115.6 s 
and MWT increased (p<0.01) from 259.5 ± 155.7 s to 447.7 ± 300.0 s between week 
1 and week 12 (figure 5.6).  Compared with week 1, there was no significant change 
in peak VQO2, ventilation, RER or HR during the treadmill test to maximal claudication 
at week 12 (table 5.3).  Heart rate and the percentage of HRpeak at the onset of 
claudication were significantly lower at week 12 than week 1.   
 
Figure 5.6: Pain free and maximal walking time at week 1 and week 12; *p<0.05 vs. 
week 1; †p<0.01 vs. week 1 
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Table 5.3: Participant responses during the treadmill test to maximal claudication 
 Week 1 Week 12 
Treadmill grade (%) 2.91 ± 2.74 6.73 ± 5.16† 
VQO2peak (ml
.
kg
-1.
min
1
) 15.84 ± 3.4 15.08 ± 2.76 
VQO2peak (L
.
min
-1
) 1.22 ± 0.32 1.16 ± 0.24 
Ventilation (L.min-1) 29.77 ± 7.63 30.56 ± 8.30 
RER 0.85 ± 0.08 0.88 ± 0.10 
HRpeak (beats.min-1) 106.30 ± 20.85 109.60 ± 19.54 
HR at onset of claudication (beats.min-1) 102.38 ± 18.45 94.89 ± 15.80* 
HR at onset of claudication (%HRpeak) 95.10 ± 3.61 89.14 ± 6.45* 
HR at maximal claudication (beats.min-1) 105.10 ± 22.14 109.00 ± 20.02 
HR at maximal claudication (%HRpeak)  98.65 ± 3.55 99.37 ± 1.34 
Values are means ± SD; *p<0.05 vs. week 1; †p<0.01 vs. week 1 
The distance covered during the 6MWT increased significantly from 333.0 ± 
52.7 m to 364.6 ± 52.4 m between week 1 and week 12 (figure 5.7).  There was no 
significant change in HR response during the 6MWT between week 1 and week 12 
(table 5.4).   
 
Figure 5.7: Six minute walk test distance at week 1 and week 12; *p<0.05 vs. week 1 
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Table 5.4: Heart rate responses during 6MWT 
 Week 1 Week 12 
HR (beats
.
min
-1
) 89.37 ± 13.55 93.45 ± 15.64 
HR  (%HRpeak) 87.12 ± 6.35 87.10 ± 8.18 
HRpeak (beats.min-1) 97.00 ± 13.31 100.44 ± 17.59 
HR at onset of claudication (beats.min-1) 93.13 ± 12.33 93.63 ± 9.78 
HR at onset of claudication (%HRpeak) 89.09 ± 6.03 86.67 ± 7.16 
HR at onset of claudication (%6MWTpeak) 94.96 ± 4.14 96.40 ± 1.73 
Values are means ± SD 
There was no significant difference in the mean treadmill velocity and grade, 
PFWT, exercise bout time, number of exercise bouts, and total exercise time during 
training sessions at week 1 and week 12 (table 5.5). 
Table 5.5: Average training session characteristics 
 Week 1 Week 12 
Treadmill velocity (km.h-1) 3.29 ± 0.60 3.61 ± 0.78 
Treadmill grade (%) 0.10 ± 0.25 0.63 ± 0.95 
Pain free walking time (s) 261.33 ± 136.48 251.11 ± 101.69 
Exercise bout time (s) 474.82 ± 224.73 585.73 ± 217.67 
Number of exercise bouts 2.82 ± 0.46 2.82 ± 0.41 
Total exercise time (s) 1387.82 ± 485.11 1559.82 ± 278.77 
Values are means ± SD 
Activity and Sedentary Behaviour 
There was a significant decrease in total daily sedentary time, from 19.1 ± 2.6 
h to 18.4 ± 2.9 h, and a significant increase in total daily standing time from 3.7 ± 2.0 
h to 4.2 ± 2.2 h, and total daily ambulating time, from 1.2 ± 0.8 h to 1.4 ± 0.7 h, 
between week 1 and week 12 (figure 5.8).  There was no significant change in step 
count or MVPA (table 5.4).  
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Figure 5.8: Total daily time (h) spent sedentary, standing, and ambulating at week 1 
and week 12, *p<0.05 vs. week 1 
Table 5.6: Average daily step count and duration in moderate-to-vigorous physical 
activity 
 Week 1 Week 12 Week 12 excluding 
training days 
Step count 5657 ± 4303 6825 ± 4304 6103 ± 4835 
MVPA (>25 steps.epoch-1) (h) 0.25 ± 0.37 0.29 ± 0.39 0.23 ± 0.43 
MVPA (>16 steps.epoch-1) (h) 0.52 ± 0.51 0.66 ± 0.50 0.54 ± 0.58 
Values are means ± SD 
When the exercise training days were removed from the week 12 analysis, 
the significant decrease in total daily sedentary time and the significant increase in 
total daily standing time remained.  However, there was no longer a significant 
change in total daily ambulating time (figure 5.9).  There was no change in the 
number and duration of sedentary bouts.   
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Figure 5.9: Total daily time (h) spent sedentary, standing, and ambulating at week 1 
and week 12 excluding exercise training days, *p<0.05 vs. week 1 
Quality of Life 
There was a significant improvement in the PAQ summary score, due to a 
significant improvement in the symptom stability, symptom frequency/burden, QOL, 
and social function domains (figure 5.10).  There was no significant change in the 
physical function or treatment satisfaction domains. 
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Figure 5.10: The Peripheral Artery Questionnaire domain scores at week 1 and week 
12, *p<0.05 vs. week 1; †p< 0.01 vs. week 1; ‡p<0.001 vs. week 1 
Summary of Results 
Twelve weeks of community-based exercise rehabilitation was associated 
with significant improvements in endothelial-dependent dilation, walking 
performance and QOL.  There was no change in endothelial-independent dilation or 
ABI.  There was a positive alteration in daily activity and sedentary behaviour 
patterns.  Sedentary time decreased, standing time increased, and ambulating time 
increased on training days.   
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Chapter VI 
DISCUSSION 
Overview 
Peripheral arterial disease and it’s symptom intermittent claudication can 
severely impair functional capacity and consequently diminish daily physical activity 
and quality of life 140,236.  Excessive sedentary behaviour may have detrimental 
effects on cardiometabolic health 6,159, which may contribute to disease progression.  
Exercise can substantially improve symptom severity, functional capacity, daily 
physical activity levels, and quality of life in individuals with PAD 8,9.  However, the 
mechanisms through which exercise achieves these adaptations is not fully 
understood and further research is required to gain a greater understanding that can 
be used to optimize treatment strategies for PAD.   
A series of studies were undertaken to determine sedentary behaviour and 
its effects, and the effects of acute and chronic exercise on endothelial function in 
men and women with PAD. 
Study 1 
Study 1 measured the daily sedentary, standing and ambulating time and the 
number and duration of sedentary bouts in men and women with PAD using an 
inclinometer-based motion sensor.  Participants spent a mean of 18.9 ± 2.1 h, 3.9 ± 
1.8 h, and 1.2 ± 0.6 h of the total day sedentary, standing, and ambulating, 
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respectively.  Gardner et al., (2007) reported daily sedentary and ambulatory times 
of 19.6 ± 1.8 h and 4.4 ± 1.8 h, respectively in 98 men and women, mean age 66 ± 12 
yr, with PAD, measured using a step activity monitor 144.  The daily ambulatory time 
was significantly lower than 129 age- and gender-matched controls, whereas there 
was no difference in sedentary time between groups.  The step activity monitor 
defined sedentary time as 0 steps.min-1, therefore sitting and standing were both 
classified as sedentary.  The definition of sedentary behaviour is activities that do 
not increase energy expenditure substantially above the resting level 380.  Standing 
involves isometric contraction of the antigravity muscles and raises energy 
expenditure above resting levels, contributing to total daily energy expenditure 188.  
Study 1 is the first study to directly and objectively measure sedentary time and 
differentiate between sitting and standing in individuals with PAD.  Further research 
is required to compare “true” daily sedentary time between individuals with PAD 
and healthy controls.   
The fact that the total daily ambulating time of individuals with PAD is lower 
in Study 1 than reported by Gardner et al. (1.2 ± 0.6 h vs. 4.4 ± 1.82 h), but total step 
count is greater (5575 ± 3197 steps.d-1 vs. 3149 ± 1557 steps.d-1), would indicate that 
participants in Study 1 ambulated at a higher cadence.  Participants in Study 1 spent 
39 ± 16% of the total daily ambulating time at a cadence of >16 steps.epoch-1.  
Gardner et al. defined high cadence as >15 steps.epoch-1 and only 7 ± 5% of the total 
daily ambulating time was spent at this cadence.  The difference in ambulating speed 
does not appear to be due to differences in ABI or age, but may result from 
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differences in functional capacity.  Six minute walk distance was 11% longer in Study 
1 compared with the study by Gardner et al.  The step count in Study 1 was in line 
with findings by Sieminski and Gardner (1997) and Clarke et al., (2013) of 4737 ± 
2712 steps.d-1 and 6524 ± 2710 steps.d-1, respectively 140,145.  Both of these studies 
found a significant difference in step count between individuals with PAD and 
healthy age-matched controls.   
In Study 1, physical activity was associated with PAD severity.  There was a 
significant relation between MVPA defined as >25 steps.epoch-1 and resting ABI 
(rs=0.44, p<0.05).  This is in agreement with previous findings.  Sieminski and 
Gardner (1997) reported a significant association between ABI and daily energy 
expenditure, measured by accelerometer (r=0.41), and step count, measured by 
pedometer (r=0.41) 140.  For every 0.10 decrease in ABI, daily activity was 42 kcal.d-1 
or 612 steps.d-1 lower.  Gardner et al., (1999) found no relation between EEPA, 
determined using both DLW or indirect calorimetry, and ABI or calf blood flow 381.  
They did, however, find a significant relation between EEPA and markers of 
microcirculation, namely calf transcutaneous heating power at rest, with post-
occlusion reactive hyperemia, and after maximal exercise.   
Post-exercise change in ankle SBP is an indicator of the dynamic functional 
significance of an arterial stenosis.  In Study 1, the post-exercise change in ankle SBP 
was inversely related with total daily sedentary time and positively related with total 
daily standing time.  Excessive sedentary behaviour has been found to have 
detrimental effects on cardiometabolic health, which may contribute to disease 
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progression and, at least in part, account for the association between PAD severity 
and daily sedentary time.  Epidemiological studies in the general population have 
reported significant associations between self-reported and accelerometer-derived 
sedentary time and cardiometabolic risk markers 5,6,158–160,162,163,166,167.  In Study 1 CV 
risk factors were not related to total daily sedentary time, but were related to the 
pattern of sedentary time accumulation.  The pattern of sedentary time 
accumulation has been found to be of clinical relevance in addition to the 
detrimental effects of total daily sedentary time.  Prolonged sedentary bouts appear 
particularly detrimental to health and the number of breaks in sedentary time has 
been found to be inversely related to cardiometabolic risk markers, independent of 
total sedentary time 6,7,166.  Study 1 was the first study to determine the pattern of 
sedentary behaviour in individuals with PAD. The greatest duration of daily 
sedentary time was spent in bouts >60 min.  Prolonged sedentary bouts were 
associated with elevated DBP, total cholesterol, and CRP, and post-exercise change in 
ankle SBP.    
The mechanisms responsible for the adverse cardiometabolic effects 
associated with prolonged sedentary behaviour are not fully understood.  Potential 
mechanisms include the suppression of skeletal muscle LPL activity due to loss of 
local contractile activity leading to impairment in lipid metabolism 181, a reduction in 
insulin action 187, and the replacement of light-intensity activity 157.  Interrupting 
sedentary time with light or moderate-intensity exercise has been shown to lower 
glucose and insulin 362.  In Study 1, BMI, body mass, and post-exercise change in 
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ankle SBP were associated with the number or percentage of ambulatory breaks 
rather than total breaks, suggesting the role of light-intensity physical activity in the 
prevention of the adverse health effects associated with prolonged sedentary 
behaviour and potentially supporting the theory of the loss of low-intensity activity 
as the mechanism responsible for the negative molecular impact of inactivity.   
In addition to an association with disease severity, previous studies have also 
found a relation between daily physical activity and functional capacity in individuals 
with PAD.  Gardner et al., (1998) found a significant association between EEPA, 
measured using both DLW and indirect calorimetry, and MWD and 6MWD.  In Study 
1, there was no significant relation between physical activity and PFWT, MWT, or 
6MWT.  This is an unexpected and difficult to explain finding.  MVPA was derived 
from step cadence in Study 1 as accelerometer counts were unavailable and perhaps 
MVPA derived from accelerometer counts may have correlated with walking 
performance.  However, Sieminski and Gardner (1997) found a significant relation 
between MWT and step count measured using a pedometer 140.  A significant 
relation has also been found between MWD and physical activity and step count, 
step cadence, and total activity time  measured using a step activity monitor 148.  
In PAD the delivery of blood flow to the peripheral tissues depends not only 
on the severity of the stenotic occlusion but also on the regulatory mechanisms that 
control blood flow, specifically vascular tone 292.  Vascular reactivity, assessed by 
FMD, is impaired in individuals with PAD compared with healthy controls 293,294 and 
is associated with the severity of PAD, determined by ABI, in asymptomatic and 
 190
symptomatic individuals 294.  In addition, improvement in vascular reactivity is 
proposed as a mechanism through which exercise improves symptoms in individuals 
with PAD.  In Study 1, FMD was significantly related with MVPA.  Payvandi et al., 
(2009) also found a significant relation between daily physical activity, measured by 
both accelerometer and pedometer, and FMD in individuals with PAD 311. Endothelial 
dysfunction is a primary event in the pathogenesis of atherosclerosis. In PAD it can 
be exacerbated by chronic exposure to low-grade I-RI during exercise.  High levels of 
daily physical activity may have a protective effect against endothelial dysfunction. 
Peripheral arterial disease and its associated symptoms can have a 
detrimental effect on personal, social, and occupational aspects of daily living, thus 
severely diminishing QOL 234.  Quality of life is related to ABI and leg symptom 
severity 382.  Study 1 is the first to examine the relation between QOL and both daily 
physical activity and sedentary behaviours.  The PAQ scores were associated with 
overall activity and sedentary behaviours but not the pattern of accumulation of the 
sedentary behaviour.  The overall PAQ summary score was significantly related with 
total daily sedentary, standing, and ambulating time, step count, robust MVPA, and 
PAD MVPA.  The PAQ domain most affected by activity and sedentary behaviour was 
social function.  It was inversely related with daily sedentary time and positively 
related with measures of activity.  The physical function domain was related to 
measures of physical activity only and not sedentary behaviour.   
Previous research has highlighted the relation between PAD severity and low 
levels of daily physical activity.  Study 1 is the first to identify an association between 
 191
PAD severity and sedentary behaviour.  The clinical implication of these findings is 
that in addition to targeting increases in physical activity, interventions in individuals 
with PAD should aim to decrease sedentary time.  The association between PAD 
severity and sedentary time may be due to the adverse effects of prolonged 
sedentary bouts on CV risk factors and breaks in sedentary time may have a positive 
effect on these risk factors.  Therefore, interventions should not only aim to reduce 
total sedentary time but also to break up sedentary time with frequent interruptions 
of light-intensity activity.  
Further research is required to investigate the effect of reducing and 
breaking sedentary time on disease severity, CV risk factors, and QOL in individuals 
with PAD.  There is a need to identify effective methods for altering sedentary 
behaviour.  The development of a home-based monitoring system or stimulator 
device to inform patients of their sedentary behaviours or remind them to break 
sedentary behaviour may aid in altering behaviour patterns.  The mechanisms 
underpinning the association between excessive and prolonged sedentary behaviour 
and adverse cardiometabolic effects are not fully understood and need to be further 
investigated.  Research is needed to clarify if this association is due to the absence of 
NEAT or unique cellular and molecular processes. 
Study 2 
Study 2 compared the effects of an acute bout of intermittent walking to OC 
and MC on endothelial-dependent and -independent dilation in men and women 
with PAD.  There was no effect on endothelial-dependent or –independent dilation 
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following exercise under both conditions.  Previous research found a transient 
impairment in FMD following acute exercise to maximal claudication in individuals 
with PAD 12,14–16.  This is in contrast to no change or significant increases in FMD 
following acute exercise in healthy individuals 18 and individuals with CAD 19.   
The impairment in FMD in individuals with PAD is dependent upon the 
degree of ischemia produced in the diseased limb during exercise and occurs 
following exercise to maximal claudication but not exercise to the onset of 
claudication 14.  The reduction in FMD with maximal exercise appears to be due to 
reduced NO bioavailability.  Treatment with nitroaspirin, a NO-donating aspirin, but 
not aspirin, prevented the reduction in FMD following maximal exercise 17.  The 
ischemia induced by exercise to maximal claudication and the subsequent I-RI is 
likely responsible for the reduced NO bioavailability.  The oxidative stress and 
inflammatory response associated with I-RI can cause both a reduction in NO 
synthesis and an increase in NO biodegradation.  Plasma markers of oxidative stress 
14, oxidative damage 95, and markers of inflammation 17,254,255 are significantly 
increased in PAD patients compared with healthy controls following acute exercise 
to maximal claudication.  In a study by Silvestro et al., (2002) exercise to maximal 
claudication was associated with a significant decrease in FMD and a significant 
increase in plasma levels of thiobarbituric acid-reactive substances (TBARS), an index 
of oxidative stress, and sICAM-1, compared with no change with exercise to the 
onset of claudication 14.  There was no significant relation between increases in 
TBARS and changes in FMD and sICAM-1.  However, the impairment in FMD and 
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elevation of TBARs and sICAM-1 were eliminated by administration of an 
antioxidant, Vitamin C.  
The absence of an impairment in FMD following acute intermittent exercise 
to either OC or MC in Study 2 is likely due to the absence of an acute increase in 
oxidative stress and inflammation.  There was no change in plasma concentration of 
inflammatory markers INF-γ, TNF-α, IL-6, IL-1β, and WBCs with either exercise 
condition.  In fact, both exercise conditions were associated with a significant 
decrease in INF-γ 1 h after exercise.  Acute inflammation has been shown to impair 
FMD in humans 383.  These findings are in contrast to previous research that has 
shown significant increases in IL-6, IL-1β, TNF-α, leukocytes, sVCAM-1, and sICAM-1 
in PAD 
17,254,255.  
The cytokines INF-γ, TNF-α, IL-6, IL-1β were selected as inflammatory 
markers because they are among the most commonly cited and researched 
inflammatory biomarkers in the study of both atherosclerosis 91,384 and exercise 
physiology 385, which would allow for comparative analysis.  There was no 
compelling reason to select other markers.  The cytokines selected are expressed 
during the initial stages of the cytokine cascade of the fast innate inflammatory 
response and their production is upregulated rapidly in response to vigorous PA 386 
and other forms of stress, including IR-I 387.  Previous research has shown significant 
elevations in circulating levels of IL-1β, IL-6, and TNF-α following acute exercise in 
individuals with PAD 254,388. 
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Additional inflammatory markers that could have been analyzed include IL-8, 
ICAM-1, VCAM-1, and P-, E-, and L-selectin, which have also been shown to increase 
following acute exercise in individuals with PAD 17,388.  CRP is a leading biomarker of 
inflammation but is not influenced by acute exercise in individuals with PAD 389.  
Cytokines IL-1β, IL-6, and TNF-α are released early in the cytokine cascade and are 
pleiotrophic and have been implicated in the induction of an array of adhesion 
molecules, chemokines 384 and acute phase proteins 390.  Therefore they are 
upstream of these additional markers.   
The absence of an inflammatory response is most likely due to the nature of 
the exercise protocol.  Previous studies have employed acute exercise protocols 
consisting of a single short continuous bout of exercise, ranging in duration from 
approximately 2 min to 10 min.  Current ACSM physical activity guidelines for adults, 
older adults, and adults with clinically significant chronic conditions or functional 
limitations recommend a minimum of 30 min moderate-intensity aerobic physical 
activity on 5 d.wk-1 or a minimum of 20 min vigorous-intensity aerobic physical 
activity on 3 d.wk-1 378,379.  Activity can be accumulated from bouts of ≥ 10 min.  The 
functional limitation associated with intermittent claudication means that exercise 
rehabilitation programs designed for individuals with PAD often employ intermittent 
walking consisting of multiple exercise bouts to allow participants to accumulate 
minutes of exercise.  In Study 2, the acute exercise protocol involved intermittent 
exercise to either OC or MC to accumulate 30 min of exercise.   
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The mechanisms through which multiple bouts of exercise may eliminate the 
detrimental effects of single bouts of exercise on inflammation and FMD are unclear.  
Putative mechanisms include the clearance of ROS and inflammatory mediators with 
repeated hyperemic episodes or the stimulation of antioxidant defenses.  Laminar 
shear has been shown to upregulate superoxide dismutase and glutathione 
peroxidase expression in endothelial cells 391,392.  Repeated exposure to shear stress 
may also increase NO synthesis, which would increase vasodilation but may also 
inhibit ROS production through the direct inhibition of superoxide formation, 
possibly through the suppression of NADPH-oxidase upregulation 393 and/or inhibit 
leukocyte activation.    
In Study 2, the mean exercise bout duration was significantly longer during 
the exercise to MC than the exercise to OC, and therefore fewer exercise bouts were 
required to accumulate 30 min of exercise and there were fewer recovery bouts 
during exercise.  Interestingly, there was no difference in recovery duration during 
exercise bouts whether participants walked to OC or MC.  Therefore, overall 
recovery time and hence, session time was significantly shorter in the MC condition 
than the onset of claudication condition.  Given that a lack of time is a commonly 
sited barrier to cardiac rehabilitation exercise adherence 394, the validation of 
effective, time-efficient exercise protocols provide advantageous treatment 
approaches.   
Study 2 found no adverse effects on FMD or inflammation with acute 
intermittent exercise to maximal claudication.  Previous exercise training studies 
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assessing the effect of exercise on endothelial function in PAD have used 
intermittent submaximal exercise protocols and have found significant 
improvements in FMD 11–13,246,313.  To date, no studies have determined the effect of 
exercise training involving intermittent exercise to maximal claudication on FMD in 
individuals with PAD.  However, exercise training involving intermittent exercise to 
maximal claudication has been shown to have beneficial effects on pain-free and 
maximal walking performance in individuals with PAD 207,346,395.  Therefore, 
intermittent exercise to maximal claudication may represent an effective and more 
time efficient exercise prescription than exercise to the onset of claudication.  
However, according to the hedonic theory of motivation, people are likely to repeat 
an activity if they derive pleasure, a sense of energy, or enjoyment from their 
participation in the activity and are unlikely to repeat an activity if they derive 
displeasure, a sense of exhaustion, pain, or discomfort 396.  Exercise to maximal 
claudication pain may deter people from maintaining participation in an exercise 
programme and further research is required to determine the long-term adherence 
to such a protocol.   
Further research is required to identify the reasons why, unlike acute short 
continuous exercise, acute intermittent exercise does not impair FMD in individuals 
with PAD.  The effect of acute intermittent exercise on oxidative stress, antioxidant 
enzymes, and NO bioavailability needs to be further investigated. 
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Study 3 
Study 3 evaluated the effect of a 12-week community-based exercise 
rehabilitation programme on endothelial-dependent and –independent dilation in 
men and women with PAD.  There was a significant increase in FMD between week 1 
and week 12.  The increase in FMD occurred in the absence of significant changes in 
endothelial-independent dilation, baseline brachial artery diameter, and baseline 
and peak blood flow velocity.  Previous studies investigating the effect of exercise 
training on endothelial function in individuals with PAD have employed submaximal 
intermittent exercise protocols 11–13,313.  Study 3 is the first study to determine the 
effect of intermittent exercise to maximal claudication on FMD in individuals with 
PAD.  In addition, all but one of the previous studies have failed to measure 
endothelial-independent dilation, which prohibits conclusions being drawn that the 
observed improvement in vasodilation is endothelial-dependent.  In Study 3, there 
was no significant change in endothelial-independent dilation, indicating that the 
improvements in vasodilation were due to improvements in endothelial function.   
The magnitude of improvement in FMD in Study 3 (158%) appears greater 
than previous studies.  Andreozzi et al., (2007) reported a significant improvement of 
35% in FMD following 6 weeks of ITW at 60-70% of maximal walking ability 3 d.wk-1 
12.  The smaller improvement compared with Study 3 may be the result of a weaker 
exercise stimulus, a shorter exercise programme duration, or a better baseline FMD.  
Following a 12 week exercise programme involving ITW to moderately severe 
claudication in participants with similar baseline FMD to Study 3, Allen et al., (2010) 
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reported a 79% increase in FMD from 2.4% to 4.3% 11.  Mika et al., (2012) 
investigated the effects of differing exercise stimuli and compared the effects of 
pain-free and moderate pain intermittent walking training on FMD in individuals 
with PAD 313.  Flow-mediated dilation increased by 36% and 56% in the pain-free and 
moderate pain groups, respectively.  However the difference between groups was 
not statistically significant.  In Study 3, intermittent exercise to maximal claudication 
is likely to have induced a greater shear stress stimulus on the endothelium than 
previous studies involving submaximal exercise.  Chronic exposure to this stress may 
profoundly upregulate mRNA expression of eNOS resulting in greater NO production 
and a greater improvement in FMD 312.   
Another potential mechanism that may explain the greater improvement in 
FMD with exercise to maximal claudication is an increased ischemic stimulus and 
subsequent ROS production.  In low concentrations ROS are important redox 
signaling molecules involved in the regulation of cellular O2 homeostasis.  Some 
studies in animals have shown that the ROS hydrogen peroxide (H2O2) upregulates 
eNOS in response to exercise training 397.  In humans, H2O2 has been shown to 
induce coronary arteriole vasodilation 398 and antioxidant administration has been 
shown to decreased exercise-induced brachial artery vasodilation 399.   
Previous research investigating the effect of exercise rehabilitation on FMD in 
individuals with PAD has involved primarly hospital- or laboratory-based exercise 
programmes.  Study 3 is the first study to determine the effect of community-based 
exercise rehabilitation programme on FMD in individuals with PAD.  The growing 
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epidemic of CVD and its escalating economic burden requires the employment of 
economically viable secondary prevention strategies.  Home- and community-based 
exercise programmes provide an alternative to hospital-based programmes, but it is 
necessary to determine the efficacy of these alternatives if their use is to become 
more widespread in the treatment of PAD.        
Study 3 also determined the effect of a 12-week community-based exercise 
rehabilitation programme on disease severity, walking performance, daily physical 
activity, and QOL in men and women with PAD.  There was no significant change in 
ABI between week 1 and week 12.  Previous research findings on the effect of 
exercise training on ABI have been equivocal, however the majority of studies have 
found no change in ABI and a Cochrane review of 22 RCTs investigating the effect of 
exercise rehabilitation in individuals with IC concluded that exercise did not 
significantly affect ABI 9.  The absence of a change in ABI in the presence of a 
significant improvement in FMD may appear conflicting.  However, ABI is a measure 
of resting limb perfusion and FMD is measured in response to a hyperemic stimulus.   
Pain-free and maximal walking time increased significantly by 60% and 84%, 
respectively in Study 3.  A meta-analysis of 21 RCTs and non-randomized and 
uncontrolled trials reported a mean improvement of 179% and 122% in PFWD and 
MWD, respectively 8.  The apparently smaller improvements in Study 3 may be due 
to the exercise programme components.  The meta-analysis determined the 
programme components that were most effective in improving walking ability and 
concluded improvements were significantly greater when participants exercised for 
 200
≥3 sessions.wk-1 compared with <3 sessions.wk-1 and for ≥6 months compared with 
<6 months.  The exercise programme in Study 3 involved 2 sessions.wk-1 for 12 
weeks.   
Other systematic reviews did not pool data because of differences in 
demographic data, baseline characteristics, exercise protocols, and testing protocols 
across studies.  In a systematic review of 10 randomized controlled trials (RCTs) 
investigating the effect of exercise on walking performance in individuals with IC, 
Brandsma et al., (1998) found improvements in MWT ranging from 28% to 210% 192.  
A Cochrane review of 22 RCTs investigating the effect of exercise rehabilitation on 
relieving symptoms and improving walking ability in individuals with intermittent IC 
found the overall improvement in walking ability was 50% to 200% 9.  
Community-based exercise rehabilitation was associated with significant 
improvements in PFWD and MWD by 187% and 142%, respectively after 3 months 
and by 240% and 191% after 6 months in a study by Bendermacher et al., (2007) 265.  
However, adherence to the community-based programme was problematic, 40% of 
participants discontinued the exercise programme.  Reasons for drop-out included 
satisfaction with the acquired improvements, unsatisfying results, lack of motivation, 
comorbidities, and other reasons.  Kruidenier et al., (2009) had similar difficulties 
during a year-long community-based exercise programme, with 53% of participants 
discontinuing the programme 400.  For the 129 men and women who did complete 
the programme significant improvements were found in PFWD and MWD.  A recent 
study reported that only 66% of PAD patients accepted the invitation to attend a 
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community-based exercise programme 401.  Of these 35% failed to initiate 
attendance in the programme, 24% did not start the programme, 8% did not 
complete more than the initial 3 sessions, and over a 3 month period, regular 
attendance was registered for only 16%.  In Study 3, 73% of participants completed 
the programme and training adherence was 83.91%.  However, the sample size was 
small and the number of participants who were referred to the programme and did 
not attend is unknown.   
Study 3 also determined the effect of exercise rehabilitation on 6MWD.  The 
6MWT may be a better measure of walking ability in a community setting than the 
treadmill test, given that participants select the walking speed and can alter their 
speed with the development of claudication pain.  The 6MWT is also more strongly 
related to daily physical activity levels than treadmill test outcomes 402.  In Study 3, 
6MWD increased significantly by 10% between week 1 and week 12.  At baseline, 4 
participants were unable to walk continuously and rested during the test and one 
participant stopped twice.  At week 12, all participants completed the 6MWT 
without stopping.   
Previous research in individuals with PAD has found similar results.  Gardner 
et al., (2001) and McDermott et al., (2009) found a 12% and 11% improvement in 
6MWD, respectively following 24 weeks of ITW 3 d.wk-1 200,246. Tsai et al., (2002) 
reported a larger improvement of 21% in 6MWD following 12 weeks of ITW 3 d.wk-1 
than controls 209, which may be due to a lower baseline performance.  An inverse 
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relation between baseline walking performance values and the change in walking 
performance has been previously shown in individuals with PAD 13.   
There was no change in VQO2peak with exercise training in Study 3.  The 
ambulatory limitation caused by intermittent claudication may restrict individuals 
with PAD from exercising at an intensity sufficient to induce central adaptations.  
Despite the majority, if not all, previous research reporting improvements in walking 
distances in individuals with PAD with chronic exercise, the findings on VQO2peak 
have been controversial.  Using the same training protocol, Hiatt et al., 101 found a 
significant improvement in VQO2peak in 19 men, mean age 60 ± 12.5 yr, with PAD, 
whereas Gardner et al., 200 reported no improvement in 61 men and women, mean 
age of 70.5 ± 1 yr, with PAD.  The lack of improvement in the study by Gardner et al., 
may be due to the older age of the participants and a greater number of 
comorbidities, which may reduce the intensity at which they can exercise.  In Study 
3, there was a significant decrease in the HR at the onset of claudication pain with 
training, despite participants walking for longer and to a higher treadmill grade 
before the onset of claudication.  This finding suggests the exercise training intensity 
was sufficient to induce some form of CV adaptation.   
In Study 3, participation in the community-based exercise rehabilitation 
programme was associated with significant changes in daily activity and sedentary 
behaviours.  The improvements in claudication symptoms and ambulatory capacity 
associated with exercise rehabilitation may remove the limitations preventing 
individuals with PAD from leading physically active lives.  Total daily sedentary time 
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decreased by 3.7% or 42 min (p<0.05).  Standing time increased by 13.5% or 30 min 
(p<0.05) and ambulating time increased by 16.7% or 12 min (p<0.05).  The increase 
in ambulating time was attributed to attendance at the exercise programme 
sessions. There was no significant change in ambulating time on non-training days.  
In contrast, sedentary and standing times were significantly altered on non-training 
days.  Study 3 is the first study to determine the effect of exercise rehabilitation on 
daily sedentary and standing time in individuals with PAD and demonstrates that 
community-based exercise rehabilitation is effective in decreasing total daily 
sedentary time and increasing standing time.  However, there was no change in the 
number or duration of sedentary bouts, indicating the programme was not effective 
at breaking up sedentary time. 
The effect of exercise rehabilitation on daily physical activity in individuals 
with PAD has been investigated by a small number of studies and findings are 
inconsistent.  Following 6 months of ITW training to near-maximal claudication 3 
d.wk-1, Gardner et al., (2000) reported a significant improvement in daily physical 
activity, determined by both a Caltrac accelerometer worn over 2 d and the 
Minnesota LTPA questionnaire, in individuals with PAD 245.  Accelerometer-derived 
physical activity increased by 31% and the change was significantly related with a 
change in PFWD and MWD.  Self-reported physical activity increased by 62% but the 
change was not associated with the improvements in walking performance.  In a 
subsequent RCT using the same exercise protocol, Gardner et al., (2001) found a 
significant increase in accelerometer-derived physical activity, but no change in self-
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reported physical activity in individuals with PAD compared with controls 200.  These 
findings suggest the increase in physical activity was primarily unstructured activity, 
such as walking around the home.  
In a study including both symptomatic and asymptomatic PAD patients, 
McDermott et al., (2009) found no significant improvement in daily physical activity, 
determined using accelerometers worn over 7 d, following either ITW or lower 
extremity resistance training for 6 months 246.  It is possible that the lack of 
impairment in functional capacity experienced by asymptomatic participants at 
baseline may explain the findings.  In Study 3, despite the significant increase in total 
daily ambulating time there was no significant change in step count.  This may be 
attributable to the large inter-individual variation at baseline and week 12.  Similarly, 
2 studies using pedometers worn over 7 d found no change in step count following 
exercise rehabilitation 198,218.   
There was a significant improvement in the PAQ summary score between 
week 1 and week 12 in Study 3.  This was accounted for by significant improvements 
in the symptom stability, symptom frequency/burden, QOL, and social function 
domains.  There was no significant change in the physical function or treatment 
satisfaction domains.  A recent systematic review of 23 exercise trials measuring the 
impact on QOL in patients with PAD found that all studies using the Medical 
Outcomes Study Short Form (SF-36) reported improvements in the physical 
functioning domain, with some also reporting improvements in the bodily pain, role 
functioning, vitality, general health and health transition domains 241.  In studies 
 205
using a disease-specific questionnaire, improvements have been found across a 
range of QOL domains.  Using the PAQ, Murphy et al., (2012) reported significant 
improvements across all domains except symptom stability and treatment 
satisfaction following 26 weeks of supervised exercise rehabilitation compared with 
optimal medical care 218. 
The reason for the lack of improvement in self-reported physical function in 
Study 3, despite significant improvement in objectively measured physical function, 
is unclear.  Murphy et al., (2012) found no relation between the PAQ physical 
function score and the change in MWT following exercise rehabilitation, although 
the score was strongly related with the change in PFWT 218.  Spertus et al., (2004) 
found no relation between the PAQ physical limitation score and total exercise time 
at baseline but a significant relation at follow-up after revascularization, suggesting 
the PAQ domain is responsive to clinical change 370.  Using the Walking Impairment 
Questionnaire, Hiatt et al., 101 found significant improvements, whereas Gardner et 
al., 200 found no improvement following the same exercise protocol.  Both studies 
reported improvements in treadmill walking performance.  However VQO2peak 
improved in the study by Hiatt et al., only, which may suggest a link between 
improvements in aerobic fitness and QOL.  Participants in the study by Gardner et 
al., were also older and had a greater number of comorbidities, which may indicate 
the influence of additional factors on an individual’s perception of physical function.  
Lastly, the improvements in walking performance in Study 3 were at the low end of 
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the range of improvement following exercise described by the Cochrane review 9, 
which may call into question the clinical relevance of these improvements.    
The findings of Study 3 give rise to a number of clinical implications and 
indications for further research.  Firstly, intermittent exercise to maximal 
claudication may be a more effective training protocol to improve endothelial 
function in individuals with PAD.  However, this needs to be investigated in a 
randomized controlled trial.  If these findings are confirmed the mechanisms, 
responsible for the greater adaptation with maximal exercise will require further 
investigation.  Future studies should measure NO bioavailability and markers of 
oxidative stress.  The findings of Study 3 may also lend support to the theory that 
improvement in endothelial function is a mechanism through which exercise training 
improves symptoms in PAD.  However, there was no relation between changes in 
endothelial function and changes in walking performance, indicating that other 
mechanisms are involved.  
Study 3 adds to the very limited pool of research on the effect of community-
based exercise rehabilitation in individuals with PAD.  Community-based exercise 
may circumvent the limitations of hospital-based programmes such as treatment 
cost and transportation difficulty.  It provides a patient and economically friendly 
alternative secondary prevention strategy and Study 3 provides evidence of its 
efficiency in improving functional capacity, daily physical activity and sedentary 
behaviours, and QOL in individuals with PAD.  The limited research on community-
based exercise programmes for PAD necessitates further study to determine the 
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optimal structure and protocol, participant adherence, and the duration of effects 
after such programs.  Future research should also assess the effects of community-
based exercise in direct comparison to hospital- or clinic-based exercise. 
Future Research  
The findings of this series of studies provoke a number of interesting topics 
for future research.   Firstly, the sedentary behaviour patterns of individuals with 
PAD need to be compared with that of non-PAD age-matched controls, to clarify if 
the observed behaviour is a consequence of PAD or typical of an elderly population.  
Research is required to identify effective methods for reducing sedentary behaviour 
and to investigate the effect of reducing sedentary behaviour.  A greater 
understanding of the mechanisms underpinning the association between sedentary 
behaviour and cardiometabolic health not just in a PAD population but in the general 
population should be a major concern of future research.  This would provide insight 
into whether and why altering sedentary behaviour can have beneficial effects on 
health and may highlight a promising treatment modality, as it is likely easier to 
motivate an individual to ‘stop sitting rather than start walking’. 
Study 2 found no adverse effects on FMD or inflammation with acute 
intermittent exercise to maximal claudication.  Further research is required to 
identify the reasons why this form of exercise protocol had no adverse effects unlike 
previous protocols of short continuous maximal exercise in individuals with PAD.  
Intermittent exercise to maximal claudication represented a more time efficient 
exercise prescription compared with intermittent exercise to the onset of 
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claudication.  A RCT should be performed to compare the training adaptations of 
these 2 intermittent protocols.  Exercising to maximal claudication pain may cause 
displeasure and deter individuals with PAD from maintaining participation in an 
exercise programme.  Further research is required to determine the long-term 
adherence to such a protocol.   
Finally, Study 3 supported the effectiveness of community-based exercise 
rehabilitation in the treatment of PAD.  Further study is required to determine the 
optimal structure and protocol, participant adherence, and the duration of effects 
after such programs.  Future research should also assess the effects of community-
based exercise in direct comparison to hospital- or clinic-based exercise.   
Study Limitations 
The primary limitation in this series of studies is the absence of a control 
group in Study 1 and Study 3.  In Study 1, it is not possible to determine whether the 
activity and sedentary behaviour patterns observed in individuals with PAD differ 
from the non-PAD population.  In Study 3, it is possible, although unlikely, that the 
improvements in endothelial function, walking performance, daily physical activity 
and sedentary behaviours, and QOL were due to regression to the mean.  Secondly, 
the sample size in each study was relatively small, which reflects the difficulty in 
recruiting a unique clinical population.  Access to individuals with PAD was solely to 
those referred for exercise rehabilitation from local hospitals.  We first had to 
establish the exercise rehabilitation programme and wait for hospital referrals.  The 
initial referrals were recruited for pilot testing.  The testing procedures for each 
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study were demanding and developing a rapport with the referrals was important 
for participation recruitment.  Consequently, participant recruitment was slow and 
every effort was made to recruit the maximum number of participants within the 
given time-frame.  Characterizing the behaviour patterns of a PAD population would 
benefit from a larger sample size.  In addition, the number of participants falls short 
of previous studies investigating the effects of acute and chronic exercise on FMD.   
Thirdly, a technical issue occurred during the analysis of the ActivPAL 
accelerometer counts and step cadence had to be used to identify MVPA.  The use of 
step cadence, particularly at low speeds, may lead to reduced accuracy when 
assessing energy expenditure 363.  Finally, despite its widespread use and relation 
with invasive measures of endothelial function, there are a number of technical and 
interpretive limitations of the FMD technique 366.  These include the variability of 
FMD, the lack of a consensus on a normal FMD, and the lack of a standardized 
protocol with regard to cuff placement, occlusion time, timing post-occlusion, gating, 
and normalization for shear stress.   
Medication use presents a challenge to the use and interpretation of FMD 
because many pharmacological stimuli may potentially influence vascular tone and 
endothelial function 403.  In line with current guidelines for FMD assessment 366, all 
vasoactive medications were withheld for at least 4 half-lives, where possible.  
Vasoactive medications were defined as drugs that directly cause vasodilation or 
vasoconstriction, e.g. NTG, sildenafil citrate.  Recent evidence suggests that the 
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continuation of non-nitrate vasoactive drugs has no significant effect on brachial 
reactivity 404.  
Conventional CV drugs have pleiotrophic actions that may include 
improvement of endothelial function.  The pleiotrophic effects of drugs interfering 
with the renin–angiotensin–aldosterone system may prevent endothelial 
dysfunction and eNOS uncoupling.  Both angiotensin-converting-enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs) have been found to exert 
beneficial effects on endothelial function independent of their anti-hypertensive 
effects 405.  ACE inhibitors and ARBs have indirect antioxidant effects by preventing 
the activation of NADPH oxidase and increasing the activity of extracellular SOD 406.  
ARBs may also increase BH4 levels 407 and reduce endothelin-1 activity 408.      
Statin therapy is associated with significant improvements in both peripheral 
endothelial function, assessed by FMD and venous occlusion plethysmography, and 
coronary endothelial function, assessed by angiography as the vasomotor response 
to intracoronary infusion of ACh 409.  In addition to their cholesterol lowering 
properties, statins can upregulate eNOS via several different mechanisms, including 
1) increased eNOS mRNA stability through inhibition of Rho isoprenylation, 2) 
increased eNOS phosphorylation through PI3K-dependent signaling, 3) restoration of 
eNOS activity through reduction of caveolin-1 abundance 410.   
Beta-blockers are a heterogeneous group of antihypertensive agents with 
different selectivity for adrenergic receptors and/or additional effects in heart and 
peripheral circulation.  Third generation β-blockers, including carvedilol and 
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nebivolol, display vasodilator properties.  The non-selective agent carvedilol 
mediates vasodilation by blocking α1-adrenergic receptors located in SMC, which 
when stimulated trigger vasoconstriction 411.  Nebivolol is highly selective for β1-
adrenergic receptors and increases NO bioavailability by enhancing NOS activity and 
antioxidant effects via β3-adrenergic receptor stimulation 412.   
Finally, calcium channel blockers (CCB) bind to voltage sensitive Ca channels 
and reversibly inhibit Ca entry into cardiac and vascular SMCs, thus decreasing 
intracellular Ca concentrations and causing SMC relaxation 413.  Additionally certain 
types of CCBs can enhance endothelial function by increasing eNOS activity and 
perhaps increasing antioxidant capacity. 
Conclusion 
Peripheral arterial disease is a cause of increased risk of mortality and 
morbidity in the elderly population.  With an ageing population and the growing 
epidemic of CVD, the need for an understanding of the factors that influence the 
progression and regression of PAD is ever more pertinent.  This will allow the 
development of optimal primary and secondary prevention strategies.  This series of 
studies is the first to identify the adverse effect of excessive daily sedentary time on 
PAD severity and QOL, whereas simply standing may have a protective effect.  This 
adverse effect may at least in part be due to the detrimental association between 
prolonged sedentary bouts and CV risk factors, which may contribute to disease 
progression.  Breaking up daily sedentary time may have positive implications on CV 
risk factors and PAD severity and interventions targeted at this population should 
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seek to alter their sedentary behaviour patterns in addition to increasing daily 
physical activity.   
Exercise is a powerful treatment tool for PAD and is recommended as the 
first-line of therapy for the majority of PAD patients.  In spite of this, the 
mechanisms that underpin the improvements incurred with exercise in individuals 
with PAD are not fully understood, which restricts the identification of the optimal 
exercise protocol.  In this series of studies, intermittent exercise emerged as an ideal 
exercise prescription because in addition to allowing PAD patients accumulate 
minutes of exercise despite the limitations imposed by intermittent claudication, the 
multiple bouts may have a protective effect against the ischemia-reperfusion injury 
associated with exercise to maximal claudication.  Adopting this intermittent 
strategy will allow individuals with PAD to exercise to maximal claudication and 
potentially stimulate greater improvements, without inducing an inflammatory 
response.   
In this series of studies, community-based exercise rehabilitation also 
emerged as a potential effective treatment modality for PAD.  Exercise rehabilitation 
in this format offers an economically viable alternative to hospital-based 
programmes.  It may also remove barriers, e.g. transportation, and provide 
motivators, e.g. peer support, to exercise in older adults 414, which in combination 
with it’s supervised and structured nature has the potential to lead to the long-term 
maintenance of exercise in individuals with PAD.   
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Appendix A 
 Dublin City University 
RESEARCH ETHICS COMMITTEE 
APPLICATION FOR APPROVAL OF A PROJECT INVOLVING HUMAN PARTICIPANTS 
Application No. (office use only)  DCUREC/2009/   
Period of Approval (office use only) ....../....../...... to..../..../.... 
This application form is to be used by researchers seeking ethics approval for individual projects and studies. 
The signed original and an electronic copy of your completed application must be submitted to the DCU 
Research Ethics Committee.   
NB - The hard copy must be signed by the PI.  The electronic copy should consist of one file only, which 
incorporates all supplementary documentation.  The completed application must be proofread and 
spellchecked before submission to the REC.  All sections of the application form should be completed.  
Applications which do not adhere to these requirements will not be accepted for review and will be 
returned directly to the applicant. 
Applications must be completed on the form; answers in the form of attachments will not be accepted, 
except where indicated.  No handwritten applications will be accepted.  Research must not commence until 
written approval has been received from the Research Ethics Committee. 
PROJECT TITLE Effect of a 12 Week Community-based Exercise Rehabilitation Programme on 
Vascular Health in Patients with Peripheral Arterial Disease 
 
PRINCIPAL 
INVESTIGATOR 
Prof. Niall M. Moyna 
 
Please confirm that all supplementary information is included 
in your application (in both signed original and electronic 
copy). If questionnaire or interview questions are submitted in 
draft form, a copy of the final documentation must be 
submitted for final approval when available. 
INCLUDED NOT 
APPLICABLE 
Bibliography    
Recruitment advertisement    
Plain language statement/Information Statement    
Informed Consent form    
Evidence of external approvals related to the research    
Questionnaire  draft final  
Interview Schedule  draft final  
Debriefing material    
Other    
 
Please note: 
1. Any amendments to the original approved proposal must receive prior REC approval. 
2. As a condition of approval investigators are required to document and report immediately to the 
Secretary of the Research Ethics Committee any adverse events, any issues which might negatively 
impact on the conduct of the research and/or any complaint from a participant relating to their 
participation in the study 
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1. ADMINISTRATIVE DETAILS 
THIS PROJECT IS:  Research Project  Funded Consultancy 
(tick as many as apply)  Practical Class  Clinical Trial 
  Student Research Project  
Final Year Research Project 
 Other - Please Describe:  
  Research 
Masters 
 Taught Masters 
  PhD  Undergraduate 
Project Start Date: Start: 01/06/10  Project End date:      End: 31/05/11 
 
1.1 INVESTIGATOR CONTACT DETAILS 
PRINCIPAL INVESTIGATOR(S):  
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Prof Moyna Niall 01 7008802 01 7008888 niall.moyna@dcu.ie 
OTHER INVESTIGATORS: 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Dr. 
Dr. 
Dr. 
Ms. 
Ms. 
Ms. 
Mc Caffrey 
Woods 
Murphy 
Furlong  
Hughes 
Gray 
Noel 
Catherine 
Ronan 
Brona  
Sarah 
Cleona 
087 2797597 
01 7008008 
01 7008824 
086 3687961 
086 8673608 
01 8034478 
01 7008888 
01 7008888 
01 7008888 
01 7008888 
01 7008888 
01 8034252 
noel.mccaffrey@dcu.ie 
Catherine.woods@dcu.ie 
ronan.murphy@dcu.ie 
brona.furlong2@mail.dcu.ie  
sarah.hughes3@mail.dcu.ie 
cgray@mater.ie  
 
FACULTY/DEPARTMENT/SCHOOL/CENTRE: School of Health and Human Performance 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT DUBLIN CITY UNIVERSITY? 
 YES  NO  
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER ETHICS COMMITTEE, OR HAS IT BEEN 
PREVIOUSLY SUBMITTED TO AN ETHICS COMMITTEE? 
 YES  NO 
 
DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, accurate.  I have read the 
University’s current research ethics guidelines, and accept responsibility for the conduct of the procedures 
set out in the attached application in accordance with the guidelines, the University’s policy on Conflict of 
Interest and any other condition laid down by the Dublin City University Research Ethics Committee or its 
Sub-Committees.  I have attempted to identify all risks related to the research that may arise in conducting 
this research and acknowledge my obligations and the rights of the participants. 
If there any affiliation or financial interest for researcher(s) in this research or its outcomes or any other 
circumstances which might represent a perceived, potential or actual conflict of interest this should be 
declared in accordance with Dublin City University policy on Conflicts of Interest.  
I and my co-investigators or supporting staff have the appropriate qualifications, experience and facilities to 
conduct the research set out in the attached application and to deal with any emergencies and contingencies 
related to the research that may arise. 
Signature(s): 
Principal investigation:    
Print name(s) in block letters: Niall M. Moyna 
Date: 11 May 2010  
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2. PROJECT OUTLINE  
2.1 LAY DESCRIPTION  
Peripheral arterial disease is a form of cardiovascular disease that mainly affects the legs.  One of 
the symptoms of PAD is muscle pain that develops in the legs during exercise.  This is known as 
intermittent claudication.  As a result, PAD patients tend to do relatively little exercise.  It is possible 
that exercise training can improve walking ability and exercise ability in patients with PAD.  The 
purpose of this study is to assess the effect of a 12 week community-based exercise rehabilitation 
programme (SmartSteps) on walking ability, aerobic fitness and the health of blood vessels in 
patients with peripheral arterial disease (PAD). 
AIMS OF AND JUSTIFICATION FOR THE RESEARCH  
PAD is a prevalent disease among people older than 55, and is a strong predictor of myocardial 
infarction, stroke and death from vascular causes.  Patients with PAD are 6 times more likely to die 
from cardiovascular disease than individuals without PAD.  PAD is a major cause of morbidity and 
mortality in older populations.  People with PAD often experience a poor quality of life.  One of the 
symptoms of PAD is muscle pain that develops in the lower extremities during exercise.   This is 
known as intermittent claudication.  Consequently, PAD patients tend to undertake relatively little 
exercise.  Exercise may improve ambulatory function and exercise capacity and overall morbidity 
and mortality in patients with PAD.  Damage to the endothelium layer of blood vessels is an early 
indicator of CVD.  Endothelial dysfunction manifests as an inability of the blood vessel to dilate in 
response to a flow stimulus.  Patients with PAD have impaired brachial artery reactivity and 
exercise training may help to improve endothelial function.  The aim of this study is to assess the 
effect of a 12 week community-based exercise rehabilitation programme (SmartSteps) on 
ambulatory function, exercise capacity and vascular health in patients with PAD 
2.3 PROPOSED METHOD 
Overview 
The study will take place in Dublin City University.  Subjects will visit the Vascular Research Unit in 
the School of Health and Human Performance on 3 separate occasions.   
Visit 1: Subjects will have the blood pressure in the arms and ankles measured at rest and 
immediately following a treadmill walking test.   
Visit 2: Subjects will have a blood sample taken and endothelial dependent and independent 
dilation assessed.  They will repeat the treadmill walking test.   
SmartSteps:  Subjects will then exercise 2d/wk for 12 week as part of a community based exercise 
rehabilitation programme called SmartSteps.  The programme will take place in DCU. 
Visit 3: After the 12 weeks subjects will return to the Vascular Research Unit.  Subjects will have a 
blood sample taken, blood pressure in their arms and ankles measured and endothelial dependent 
and independent dilation assessed.  They will repeat the treadmill walking test.   
Endothelial dependent and independent dilation:  Endothelial dependent dilation will be 
determined in response to reactive hyperemia following 5 min of lower arm occlusion.  A blood 
pressure cuff will be placed on the left arm for blood pressure monitoring and another on the right 
lower arm for occlusion.  ECG leads will be attached to monitor heart rate.  Subjects will rest for 10 
min in a supine position.  Blood pressure will be determined during the final 2 minutes of the rest 
period.  Baseline blood flow and brachial artery diameter (SonoSite, MicroMaxx) will be recorded.  
The right arm blood pressure cuff will then be inflated to approximately 220-230 mmHg and 
maintained at that pressure for 5 minutes.  The cuff will then be rapidly deflated after 5 min of 
occlusion.  Doppler blood flow measurement will be obtained during the first minute following cuff 
deflation.  Brachial artery diameter will be assessed at one and three minutes post occlusion.  
Subjects will then rest for 15 minutes to eliminate endothelium dependent effects on brachial 
artery diameter.  After this period, endothelial independent dilation will be assessed.  Baseline 
blood flow and brachial artery diameter will be recorded and used as a baseline prior to sublingual 
nitroglycerine administration.  Nitroglycerin (0.4mg) will be placed under the subjects tongue.  
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Doppler blood flow measurement will be obtained three minutes following the sublingual 
nitroglycerin administration and brachial artery diameter measurements will be assessed 3 and 5 
minutes post nitroglycerin administration.  If the subject is taking Viagra they will notify Brona 
Furlong.  They will not be permitted to take Viagra for at least 24 hours before the administration of 
nitroglycerin. 
Treadmill test:  The treadmill test will involve an incremental walking protocol to volitional fatigue.  
Subjects will wear a mouthpiece or facemask during the test to measure oxygen uptake.  A 12 lead 
ECG will be used to continuously monitor the electrical activity of the heart.  Rating of perceived 
exertion will be measured every 5 min.   
SmartSteps: SmartSteps is a community-based exercise rehabilitation programme aimed at 
individuals with PAD.  DCU, Beaumont Hospital and the Mater Misericordiae Hospital are in the 
process of developing SmartSteps.  The programme will be located at DCU Sports Complex.  
SmartSteps will be a sister programme of HeartSmart, the Phase IV community based cardiac 
rehabilitation programme in DCU.  Phase IV cardiac rehabilitation aims to assist patients with the 
long-term maintenance of lifestyle changes.  HeartSmart was established in 2006 by DCU, 
Beaumont Hospital, the Mater Misericordiae Hospital and Connolly Memorial Hospital.  The 
programme is specifically designed for patients who have successfully completed hospital based 
phase III cardiac rehabilitation programme.  Patients, who meet the inclusion criteria, are referred 
to the programme by the cardiac rehabilitation teams at the three partner hospitals.  Participants 
undertaking the SmartSteps will be individuals with diagnosed PAD, who have been referred by 
vascular surgeons in the participating hospitals.  Participants will attend supervised exercise 
sessions twice per week.  The exercise sessions involve 5 minutes of warm-up exercises, 30 minutes 
of intermittent walking and 5 minutes of cool down exercises.   
2.4 PARTICIPANT PROFILE  
Men and women aged 40-65 yr with diagnosed PAD, who have been referred to the SmartSteps 
programme by the vascular surgeons in Beaumont Hospital and the Mater Misericordiae Hospital 
will be recruited.   
Inclusion Criteria: 
• Referred by the vascular departments in Beaumont Hospital and The Mater Hospital  
• Stable angina 
• Ratio of arm blood pressure to ankle blood pressure  <0.95 at rest or <0.85 after exercise 
• Fontaine Stage II PAD (intermittent claudication upon ambulation) for > 3 months 
• Clinically stable and in good health for a minimum of two weeks prior to beginning the study 
Exclusion Criteria:   
• Fontaine Stage I PAD (ambulation not limited by claudication) 
• Fontaine Stage III PAD (pain at rest) 
• Ulceration or gangrene 
• Vascular surgery or angioplasty in past 6 months 
• Co-morbidities contradictive to exercise 
• Factors other than intermittent claudication limiting exercise tolerance  
• Diabetes mellitus 
• Unable to walk on a treadmill 
• Current smoker 
• Unstable angina 
• Systolic  blood pressure >180 mmHg and/or diastolic blood pressure > 100 mmHg 
• Resting tachycardia   
• Unstable or acute heart failure 
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2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED 
Men and women referred to the SmartSteps programme by the vascular surgeons in Beaumont 
Hospital and the Mater Misericordiae Hospital will be informed of the research study.  Participants 
must complete an induction day before commencing the SmartSteps programme.  Participants will 
be informed of the research study at the induction day.  A brief summary of the study will be 
provided to explain the study to the individuals and provide contact details.  Following an 
expression of interest, potential subjects will be asked to visit the Vascular Research Unit in the 
School of Health and Human Performance.  They will be told by agreeing to attend the first session 
they are not obligated to participate in the study.  During the first visit blood pressure in the arms 
and ankles will be assessed in identify subjects with a ratio of arm to ankle pressure of <0.95 at rest 
and <0.85 after exercise.  An explanation will be given to each potential subject to explain the 
nature, benefits, risks and discomforts of the study.  They will be provided with a plain language 
statement, and the informed consent will be explained.  They will be encouraged to ask questions, 
and any individual with doubts about participating in the study will have an opportunity to ask 
questions.  Individuals who wish to participate in the study will have to provide written informed 
consent.   Contact details will be provided to ensure all queries or concerns of the participant can 
be dealt with immediately. 
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM RESULTS WILL BE DISSEMINATED, 
INCLUDING WHETHER PARTICIPANTS WILL BE PROVIDED WITH ANY INFORMATION AS TO THE 
FINDINGS OR OUTCOMES OF THE PROJECT? 
The results will form the basis for a postgraduate thesis and will be presented at scientific meetings 
and published in scientific journals.  The identity of individual participants will not be divulged.  
Group information will only be presented.  Participants will be provided with a copy of their results, 
summarising information such as body mass index, blood pressure and cholesterol levels. 
2.7 OTHER APPROVALS REQUIRED Has permission to gain access to another location, organisation etc. 
been obtained?  Copies of letters of approval to be provided when available. 
 YES  NO  NOT APPLICABLE 
 (If YES, please specify from whom and attach a copy.  If NO, please explain when this will be 
obtained.) 
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED BY THE REC? 
 
3. RISK AND RISK MANAGEMENT 
3.1 ARE THE RISKS TO SUBJECTS AND/OR RESEARCHERS ASSOCIATED WITH YOUR PROJECT GREATER 
THAN THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 YES  NO If YES, this proposal will be subject to full REC review 
If NO, this proposal may be processed by expedited administrative review 
 
  
 YES  NO 
REC/2009/172 - Effect of Exercise Duration on Vascular Health in 
Patients with Cardiovascular Disease 
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3.2 DOES THE RESEARCH INVOLVE? 
 YES NO 
• use of a questionnaire? (attach copy)?   
• interviews (attach interview questions)?   
• observation of participants without their knowledge?   
• participant observation (provide details in section 2)?   
• audio- or video-taping interviewees or events?   
• access to personal and/or confidential data (including student, patient or 
client data) without the participant’s specific consent? 
 
 
• administration of any stimuli, tasks, investigations or procedures which 
may be experienced by participants as physically or mentally painful, 
stressful or unpleasant during or after the research process? 
  
• performance of any acts which might diminish the self-esteem of 
participants or cause them to experience embarrassment, regret or 
depression? 
  
• investigation of participants involved in illegal activities?   
• procedures that involve deception of participants?   
• administration of any substance or agent?   
• use of non-treatment of placebo control conditions?   
• collection of body tissues or fluid samples?   
• collection and/or testing of DNA samples?   
• participation in a clinical trial?   
• administration of ionising radiation to participants?   
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES  
1. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, heart attack, 
or death in less than one in 30,000 patients.  Subjects will continuously monitored using a 12 
lead ECG. 
2. Drawing blood may cause a slight pain where the needle is inserted and can leave a bruise.  A 
person trained to take blood will be used to decrease these risks.   The amount of blood drawn 
is not harmful 
3. Assessment of endothelial dependent and independent dilation will require restriction of 
blood flow for 5 minutes.  This may cause slight discomfort in the arm, which will go away 
after the blood pressure cuff in deflated.  The nitroglycerin used may induce a headache that 
may last 5 - 10 minutes. 
Alternatives to the risks:  It is not possible to assess endothelial dependent and independent 
dilation without the use of brachial artery reactivity and the administration of nitroglycerin.  
Analysis of cardiovascular biomarkers cannot be undertaken without a sample of blood.  The 
investigators are certified and experienced in phlebotomy and ultrasonography.   
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR INDIRECT) TO PARTICIPANTS FROM THIS 
RESEARCH? 
 YES  NO Participants will be provided with a copy of their results, 
summarising information such as blood pressure and fitness levels 
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3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. risk of infection or where research is 
undertaken at an off-campus location) 
 YES  NO Working with blood and needles carries risks, however the exposure 
to blood and needles is minimal and the School of Health and Human 
Performance has standard operating procedures for the handling of 
biological products. 
3.6 ADVERSE/UNEXPECTED OUTCOMES 
The School of Health and Human Performance has the facilities to implement all aspects of this 
study and has an emergency plan for adverse events.  In the unlikely event of a major adverse 
outcome, an ambulance will be called and the participant will immediately be sent to Beaumont 
Hospital. In the unlikely event of a minor adverse outcome, the situation will be dealt with by the 
attending study physician with subsequent attention at the on-campus VHI SwiftCare clinic if 
required.   
3.7 MONITORING 
The principal investigator will be involved in all aspects of the research, including participant 
recruitment and data collection.  The research team will have weekly meetings to update on all 
aspects of the study. The School of Health and Human Performance has a detailed list of Standard 
Operating Procedures for each of the protocols in this study.  All researchers, including students, 
must be familiar with the procedures and the Safety Statement before beginning data collection. 
3.8 SUPPORT FOR PARTICIPANTS 
This project does not require additional support for participants 
3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES TO PARTICIPANTS? 
 YES  NO (If YES, please provide further details.)      
4. INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS (Approx. 200 words – see Guidelines) 
Prof. Moyna is an exercise physiologist and has extensive experience in cardiovascular research. 
Dr. Noel McCaffrey is a physician with extensive experience in exercise related research 
Ms. Brona Furlong is a graduate student in the School of Health and Human Performance, DCU.  
She has extensive experience in studies involving human experimentation, and has undertaken 
extensive training in ultrasonography under the guidance of Cleona Gray, Chief Vascular 
Technologist in the Department of Vascular Surgery in the Mater Hospital, Dublin. 
Dr Ronan Murphy has 12 years of post PhD experience and training in cell and molecular biology, 
vascular biology, and thrombosis & haemostasis. He received his undergraduate degree and Ph.D. 
with NUI Galway. Following this he worked for two years as a Clinical Research Scientist in the field 
of Pharmacogenomics. He was awarded a Fellowship from the HRB to work on bleeding disorders.  
Thereafter, he went to work for Prof. S.J. Shattil, at The Scripps Research Institute, San Diego (2000-
2003). He has also been a visiting scientist to the Blood Research Institute, Milwaukee, USA. 
 
5. CONFIDENTIALITY/ANONYMITY 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE PROTECTED? 
 YES  NO  
IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE FOLLOWING QUESTIONS: 
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5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED? 
Confidentiality is an important issue during data collection.  Participant’s identity and other 
personal information will not be revealed, published or used in further studies.  Subjects will be 
assigned an ID number under which all personal information will be stored in a secure locked 
cabinet and saved in a password-protected file in a computer at DCU.  The principal investigator, 
and collaborators listed on this ethics application will have access to the data. 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: (Have you included appropriate information in 
the plain language statement and consent form?  See Guidelines) 
 YES  NO (If NO, please advise how participants will be advised) 
6 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL (see Guidelines) 
6.1 HOW WILL THE DATA/SAMPLES BE STORED? (The REC recommends that all data be stored on 
campus) 
Stored at DCU      
Stored at another site     (Please explain where and for what 
purpose) 
6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
Access by named researchers only   
Access by people other than named researcher(s)  (Please explain who and for what purpose) 
Other  :     (Please explain) 
  
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE EXPLAIN HOW, WHEN AND BY WHOM THIS 
WILL BE DONE? 
The principal investigator will be responsible for security of the data.  The data will be kept in 
locked cabinet in the Vascular Research Unit in the School of Health and Human Performance in 
DCU. Access to the data will only be attainable by the named researchers.  Data will be kept for a 
minimum of five years from the date of publication of the research.  Aside from the named 
researchers, no others will have access to the raw data.  Data will be shredded by Prof. Moyna after 
5 years. 
.7. FUNDING 
7.1 HOW IS THIS WORK BEING FUNDED? 
Irish Research Council for Science, Engineering and Technology  
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
NA 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE CONSIDERATION FOR FUNDING BY A GRANTING 
BODY?  
 YES  NO  Not Applicable 
7.4  HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE OF THE FUNDING? 
 YES  NO  Not Applicable 
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8. PLAIN LANGUAGE STATEMENT 
Plain Language Statement 
Dublin City University 
Project Title:  Effect of a 12 Week Community-based Exercise Rehabilitation 
Programme on Vascular Health in Patients with Peripheral Arterial 
Disease 
The Research Study will take place in the School of Health and Human Performance, DCU. 
The principle investigator is: Prof. Niall M. Moyna, (Tel:  7008802 Fax 7008888) EMAIL 
niall.moyna@dcu.ie 
I. Peripheral arterial disease (PAD) is a disease of blood vessels primarily in the legs.  PAD is a 
common disease among people older than 55 years.  It is a major cause of reduced quality of 
life and death in older populations.  PAD increases the thickness of blood vessels, and also 
reduces the ability of blood vessel to dilate (get bigger).  This can lead to blood flow restriction 
to the legs.  We can use a simple ultrasound procedure to measure degree of blood flow 
restriction.  Tiny pieces of the damaged blood vessel wall break off into the blood and these 
can be measured by taking a blood sample.  Exercise can help to improve the walking ability of 
individuals with PAD.  The purpose of this study is to evaluate the effect of a 12 week exercise 
programme on your walking ability, exercise capacity and the health of your blood vessels.  
You will be allowed to take part in the study if you meet the entry criteria and sign the 
informed consent.  
If you agree to take part in the study you will be asked to make 3 visits to the Vascular 
Research Unit in the School of Health and Human Performance in DCU.  You will fast for at 
least 12 hours and will not be allowed to exercise for at least 24 hours before these visits.   
II. Visit 1: You will walk on a treadmill.  You will have electrodes placed on your chest to allow 
the researchers observe the electrical activity of your heart while you are walking.  You will 
wear a mouthpiece to allow the researchers measure the amount of oxygen you use during 
the exercise. You will have the blood pressure in your arms and ankles measured before and 
after the exercise.  This visit will last approximately 1 hour. 
Visit 2: You will have a blood sample taken.  About 2 tablespoons of blood will be taken.  The 
health of a blood vessel in your arm will also be measured at the same times that blood 
samples are taken.  This will be done by using an ultrasound to take an image of your blood 
vessel.  This involves blocking the blood flow to your arm for 5 minutes using a blood pressure 
cuff and taking a nitroglycerin tablet under your tongue.  You will repeat the treadmill walking 
test from the first visit.  This visit will last approximately 2 hours.   
SmartSteps: You will take part in SmartSteps exercise rehabilitation programme in the DCU 
Sports Complex.  You will attend a SmartSteps exercise session twice per week for 12 weeks.  
After the 12 weeks of SmartSteps you will return to the Vascular Research Unit for Visit 3. 
Visit 3: is the same Visit 2.  You will have a blood sample taken, the blood pressure in your 
arms and ankles measured and the health of a blood vessel in your arm measured.  You will 
repeat the treadmill walking test.  This visit will last approximately 2 hours.   
III. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, heart attack, or 
death in less than 1 in 30,000 patients.  Your heart rate will be continuously monitored using a 
12 lead ECG.     
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Drawing blood may cause a slight pain where the needle is inserted and may leave a bruise.  A 
person trained to take blood will be used to decrease these risks.   
Taking an ultrasound image of your arm requires blocking the blood flow to your arm for 5 
minutes using a blood pressure cuff.  This may cause slight discomfort in your arm, which will go 
away after the blood pressure cuff in deflated.  The nitroglycerin used in this study may cause a 
headache that could last 5 to 10 min. 
IV. Your confidentiality will be guarded.  All information we gather will be stored in a secure filing 
cabinet.  The results of the study will be used for a postgraduate project and may be published 
in academic journals. You will not be identified, as your information will be presented as part of 
a group.  You will be assigned an ID number under which all personal information will be stored 
in the secure locked filing cabinet and saved in a password protected file in a computer at DCU.  
You need to be aware that confidentiality of information provided can only be protected within 
the limitations of the law.  It is possible for data to be subject to subpoena, freedom of 
information claim or mandated reporting by some professions.  
V. Involvement in this study is completely voluntary.  You may withdraw from the Research Study 
at any point. 
VI. If you have concerns about this study and wish to contact an independent person, please 
contact: The Secretary, Dublin City University Research Ethics Committee, c/o Office of the Vice-
President for Research, Dublin City University, Dublin 9.  Tel 01-7008000 
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9. INFORMED CONSENT FORM 
Informed Consent 
Dublin City University 
Project Title Effect of a 12 Week Community-based Exercise Rehabilitation Programme on Vascular 
Health in Patients with Peripheral Arterial Disease 
Principle Investigator Prof. Niall M. Moyna 
Introduction to this study 
Peripheral arterial disease (PAD) is disease of blood vessels primarily in the legs.  PAD is a prevalent disease 
among people older than 55 and is a major cause of reduced quality of life and death in older populations.  
PAD can be identified by measuring and comparing the blood pressure in your arms and ankles.  PAD 
damages blood vessels and reduces the ability of blood vessel to dilate (get bigger).  We can also use a 
simple ultrasound procedure to measure how much the blood vessels can dilate.  Damaged blood vessels 
release cells into the blood which can be measured by taking a blood sample.  Regular physical activity 
improves the health of blood vessels, and also has a beneficial effect on walking ability in individuals with 
PAD.  This study will evaluate the effect of a 12 week exercise programme on your walking ability, exercise 
capacity and the health of your blood vessels.   
Participants Requirements 
1. I will visit the Vascular Research Unit in the School of Health and Human Performance DCU on 3 
separate days.  Each visit will last approximately 2 hours.  During my first visit I will walk on a treadmill.  
I will have electrodes placed on my chest to allow the researchers observe the electrical activity of my 
heart during exercise.  I will wear a mouthpiece to measure the amount of oxygen I use during the 
exercise.  I will have the blood pressure in my arms and ankles measured before and after the treadmill 
exercise.  
2. During my second visit I will have a blood sample taken.  The total amount of blood drawn will be 2 
tablespoons (30 cc).  I will have the health of the arteries in my arm measured.  I will repeat the 
treadmill walking test.   
3. To test the health of the arteries in my arms I will lie on my back, and an ultrasound will be placed on 
my upper arm to create an image of my artery.  After the first image is recorded, a blood pressure cuff 
will be inflated on my forearm to block blood flow for five minutes.  This may be uncomfortable.  The 
cuff will be released and the images of my arteries repeated.  I will rest for 15 minutes and then have a 
nitroglycerin pill placed under my tongue.  The nitroglycerin will cause my arm arteries to enlarge and 
how much they enlarge will again be documented by taking a third set of pictures. 
4. I will take part in SmartSteps in DCU’s Sports Complex.  I will attend exercise sessions twice a week for 
12 weeks.  The sessions will involve walking until discomfort in my legs develops, resting until the 
discomfort disappears and then walking again.  I will do this for approximately 30 minutes.   
5. After the 12 week programme I will return to the Vascular Research Unit.  A blood sample will be 
taken, the blood pressure in my arms and ankles will be measured and the health of the arteries in my 
arm will be measured.  I will repeat the treadmill walking test.    
6. I will fast for at least 12 hours and will not exercise for at least 24 hours before each visit.  If I am taking 
Viagra I will notify Brona Furlong.  I will not take Viagra for at least 24 hours before these two visits.   
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Potential risks to participants from involvement in the Research Study  
1. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, heart attack, or death 
in less than one in 30,000 patients.  My heart rate will be continuously monitored using a 12 lead ECG.     
2. Drawing blood may cause a slight pain where the needle is inserted and can leave a bruise.  A person 
trained to take blood will be used to decrease these risks. 
3. The pictures of my arm arteries require blocking the blood flow to my arm for 5 minutes.  This may 
cause slight discomfort in the arm, which will go away after the blood pressure cuff in deflated.  The 
nitroglycerin used in this study may induce a headache that could last 5 to 10 min.   
Benefits (direct or indirect) to participants from involvement in the Research Study 
After completing the study I will be provided with a copy of my results, summarising information such as my 
body mass index, blood pressure and cholesterol levels.  There are no other direct benefits to me. 
Participant – please complete the following (circle Yes or No for each question) 
Have you read or had read to you the Plain Language Statement?  Yes  No  
Do you understand the information provided?    Yes  No  
Have you had an opportunity to ask questions and discuss this study?  Yes  No  
Have you received satisfactory answers to all your questions?   Yes  No  
Advice as to arrangements to be made to protect confidentiality of data, including that confidentiality of 
information provided is subject to legal limitations. 
Your identity and other personal information will not be revealed, published or used in further studies.  You 
will be assigned an ID number under which all personal information will be stored in a secure locked cabinet 
and saved in a password protected file in a computer at DCU.  The named investigators will have access to 
the data.  Data will be shredded after 5 years by Prof. Moyna. 
Confidentiality is insured, but you must be aware that confidentiality of information provided can only be 
protected within the limitations of the law.  It is possible for data to be subject to subpoena, freedom of 
information claim or mandated reporting by some professions. 
If you are in a dependent relationship with any of the researchers their involvement in the project will not 
affect ongoing assessment/grades/management or treatment of health at DCU. 
Signature: 
I have read and understood the information in this form.  The researchers have answered my questions and 
concerns, and I have a copy of this consent form.  Therefore, I (print name) ______________________ 
consent to take part in this research project entitled Effect of a 12 Week Community-based Exercise 
Rehabilitation Programme on Vascular Health in Patients with Peripheral Arterial Disease.  
Participants Signature:  ____________________________________ 
Name in Block Capitals       
Witness:          
Date:          
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Appendix B 
 
General Health Questionnaire 
Name: ………………………………………………  Occupation: …………………………… 
 
Address: …………………………………………………………………………………………………………………. 
 
Telephone: (Home) …………………………..  (Work): …………………………………. 
_________________________________________________________________ 
Do you have, or have you ever suffered from: Diabetes? Yes / No 
 Asthma? Yes / No 
 Epilepsy? Yes / No 
Have you ever had pains in your chest or heart? Yes / No 
Do you ever feel faint or have spells of dizziness?  Yes / No 
Do you have or have you ever had high blood pressure? Yes / No 
Do you have a muscle, back or joint problem that could be aggravated by 
physical activity or made worse with exercise? 
Yes / No 
Do you have any current injuries? Yes / No 
In the past week, have you suffered from any illness which required you to be 
in bed or off work for one day or more? 
Yes / No 
Do you smoke? Yes / No If yes, how many per day? 
Do you drink? Yes / No If yes, how many units per week? 
Is there a good physical reason not mentioned here why you should not carry 
out laboratory testing? 
Yes / No 
Please provide any further information concerning any condition/complaints that you 
suffer from and any medication that you may be taking by prescription or otherwise: 
…………………………………………………………………………………………………………………………………… 
Date:   Signature: 
 
Authorizing Signature: 
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Appendix C 
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Appendix D 
The Peripheral Artery Questionnaire 
The following questions refer to blockages in the arteries of your body, particularly your 
legs, and how that might affect your life.  Please read and complete the following 
questions.  There are no right or wrong answers.  Please mark the answer that best 
applies to you. 
1. Blockages in the arteries, often referred to as peripheral vascular disease, 
affect different people in different ways.  Some feel cramping or aching while 
others feel fatigue.  Which leg (or buttock) causes you the most severe 
discomfort, fatigue, pain, aching or cramps? 
The Right leg (buttock) The Left leg (buttock) Both are the same Neither 
☐ ☐ ☐ ☐ 
2. Please review the list below and indicate how much limitation you have due to your 
peripheral vascular disease (discomfort, fatigue, pain, aching or cramps in your calves (or 
buttock)) over the past 4 weeks. 
 
Place an X in one box on each line 
Activity 
Extremely 
Limited 
Quite a bit 
Limited 
Moderately 
Limited 
Slightly 
Limited 
Not at all 
Limited 
Limited for 
other reasons 
or did not do 
the activity 
Walking around 
your home 
☐ ☐ ☐ ☐ ☐ ☐ 
Walking 100-
200 yards on 
level ground 
☐ ☐ ☐ ☐ ☐ ☐ 
Walking 100-
200 yards up a 
hill 
☐ ☐ ☐ ☐ ☐ ☐ 
Walking 300-
400 yards on 
level ground  
☐ ☐ ☐ ☐ ☐ ☐ 
Hurrying or 
jogging (as if to 
catch a bus) 
☐ ☐ ☐ ☐ ☐ ☐ 
Vigorous work 
or exercise 
☐ ☐ ☐ ☐ ☐ ☐ 
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☐ ☐ ☐ ☐ ☐ ☐ ☐ 
5. Over the past 4 weeks, how much has discomfort, fatigue, pain, aching, or cramps 
in your calves (or buttocks) bothered you? 
It has been… 
Extremely 
bothersome 
Moderately 
bothersome 
Somewhat 
bothersome 
Slightly 
bothersome 
Not at all 
bothersome 
I’ve had no leg 
discomfort 
☐ ☐ ☐ ☐ ☐ ☐ 
6. Over the past 4 weeks, how often have you been awakened with pain, aching or 
cramps in your legs or feet? 
Every night 3 or more 
times per week 
but not every 
night 
1-2 times per 
week 
Less than once 
a week 
Never over the 
past 4 weeks 
☐ ☐ ☐ ☐ ☐ 
7. How satisfied are you that everything possible is being done to treat your 
peripheral vascular disease? 
Not satisfied at 
all 
Mostly 
dissatisfied 
Somewhat 
satisfied 
Mostly satisfied Completely 
satisfied 
☐ ☐ ☐ ☐ ☐ 
 
  
3. Compared with 4 weeks ago, have your symptoms of peripheral vascular 
disease (discomfort, fatigue, pain, aching, or cramps in your calves (or 
buttocks) changed? 
My symptoms have become… 
Much 
worse 
Slightly 
worse 
Not 
changed 
Slightly 
better 
Much 
better 
I have had no 
symptoms over 
the past 4 weeks 
☐ ☐ ☐ ☐ ☐ ☐ 
4. Over the past 4 weeks, how many times did you have discomfort, fatigue, 
pain, aching, or cramps in your calves (or buttocks)? 
All of the 
time 
Several 
times per 
day 
At least 
once a day 
3 or more 
times per 
week but 
not every 
day 
1-2 times 
per week 
Less than once a 
week 
Never 
over the 
past 4 
weeks 
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8. How satisfied are you with the explanations your doctor has given you about your 
peripheral vascular disease? 
Not satisfied at 
all 
Mostly 
dissatisfied 
Somewhat 
satisfied 
Mostly satisfied Completely 
satisfied 
☐ ☐ ☐ ☐ ☐ 
9. Overall, how satisfied are you with the current treatment of your peripheral vascular 
disease? 
Not satisfied at 
all 
Mostly 
dissatisfied 
Somewhat 
satisfied 
Mostly satisfied Completely 
satisfied 
☐ ☐ ☐ ☐ ☐ 
10. Over the past 4 weeks, how much has your peripheral vascular disease limited your 
enjoyment of life? 
It has 
extremely 
limited my 
enjoyment of 
life 
It has limited 
my enjoyment 
of life quite a 
bit 
It has 
moderately 
limited my 
enjoyment of 
life 
It has slightly 
limited my 
enjoyment of 
life 
It has not 
limited my 
enjoyment of 
life at all 
☐ ☐ ☐ ☐ ☐ 
11. If you had to spend the rest of your life with your peripheral vascular disease the way 
it is right now, how would you feel about this? 
Not satisfied at 
all 
Mostly 
dissatisfied 
Somewhat 
satisfied 
Mostly satisfied Completely 
satisfied 
☐ ☐ ☐ ☐ ☐ 
12. Over the past 4 weeks, how often have you felt discouraged or down in the dumps 
because of your peripheral vascular disease? 
I felt that way 
all of the time 
I felt that way 
most of time 
I occasionally 
felt that way 
I rarely felt that 
way 
I never felt that 
way 
☐ ☐ ☐ ☐ ☐ 
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13. How much does your peripheral vascular disease affect your lifestyle? Please indicate 
how your discomfort, fatigue, pain, aching or cramps in your calves (or buttocks) 
may have limited your participation in the following activities over the past 4 weeks. 
Please place an X in one box on each line 
Activity 
Severely 
limited 
Limited 
quite a bit  
Moderately 
limited 
Slightly 
limited 
Did not 
limit at all 
Does not apply 
or did not do 
for other 
reasons 
Hobbies, 
recreational 
activities 
☐ ☐ ☐ ☐ ☐ ☐ 
Visiting family 
or friends out of 
your home 
☐ ☐ ☐ ☐ ☐ ☐ 
Working or 
doing household 
chores 
☐ ☐ ☐ ☐ ☐ ☐ 
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Appendix E 
 
Dublin City University 
RESEARCH ETHICS COMMITTEE 
APPLICATION FOR APPROVAL OF A PROJECT 
INVOLVING HUMAN PARTICIPANTS 
Application No. (office use only)  DCUREC/2010/  
Period of Approval (office use only) ..../..../.... to ..../..../.... 
This application form is to be used by researchers seeking ethics approval for individual projects and studies. 
The signed original and an electronic copy of your completed application must be submitted to the DCU 
Research Ethics Committee.   
NB - The hard copy must be signed by the PI.  The electronic copy should consist of one file only, 
which incorporates all supplementary documentation.  The completed application must be proofread 
and spellchecked before submission to the REC.  All sections of the application form should be 
completed.  Applications which do not adhere to these requirements will not be accepted for review 
and will be returned directly to the applicant. 
Applications must be completed on the form; answers in the form of attachments will not be accepted, except 
where indicated.  No handwritten applications will be accepted.  Research must not commence until written 
approval has been received from the Research Ethics Committee. 
PROJECT TITLE Effect of Acute Exercise on Vascular Health in Patients with 
Peripheral Arterial Disease 
PRINCIPAL 
INVESTIGATOR(S) 
Prof. Niall M. Moyna 
Please confirm that all supplementary information is included in your application (in both signed original and 
electronic copy). If questionnaire or interview questions are submitted in draft form, a copy of the final 
documentation must be submitted for final approval when available. 
 
INCLUDED NOT APPLICABLE 
Bibliography    
Recruitment advertisement    
Plain language statement/Information Statement    
Informed Consent form    
Evidence of external approvals related to the research    
Questionnaire  draft  final  
Interview Schedule  draft  final  
Debriefing material     
Other    
 
Please note: 
3. Any amendments to the original approved proposal must receive prior REC approval. 
4. As a condition of approval investigators are required to document and report immediately to the Secretary 
of the Research Ethics Committee any adverse events, any issues which might negatively impact on the 
conduct of the research and/or any complaint from a participant relating to their participation in the study 
Please submit the signed original, plus the electronic copy of your completed application to:  
Ms. Fiona Brennan, Research Officer, Office of the Vice-President for Research  
(fiona.brennan@dcu.ie, Ph. 01-7007816) 
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1. ADMINISTRATIVE DETAILS 
 
 
THIS PROJECT IS: 
 Research Project  Funded Consultancy 
(tick as many as apply) 
 Practical Class  Clinical Trial 
 
 Student Research Project  
(please give details) 
 
Other  - Please Describe:  
 
Research
Masters 
Taught Masters 
 
PhD Undergraduate 
 
Project Start Date: 24/01/2011 Project End date: 31/07/2011 
 
 
1.1 INVESTIGATOR CONTACT DETAILS (see Guidelines) 
 
PRINCIPAL INVESTIGATOR(S):  
 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Prof. Moyna Niall 01 7008802 01 7008888 niall.moyna@dcu.ie  
 
OTHER INVESTIGATORS: 
 
TITLE SURNAME FIRST NAME PHONE FAX EMAIL 
Dr McCaffrey Noel 087 2797597 01 7008888 noel.mccaffrey@dcu.ie 
Dr Woods Catherine 01 7008008 01 7008888 Catherine.woods@dcu.ie 
Dr Murphy Ronan 01 7008824 01 7008888 ronan.murphy@dcu.ie 
Ms Furlong Brona 01 7008472 01 7008888 brona.furlong2@mail.dcu.ie 
Ms Hughes Sarah 01 7008470 01 7008888 sarah.hughes3@mail.dcu.ie 
Ms Gray Cleona 01 8034478 01 8034252 cgray@mater.ie 
 
FACULTY/DEPARTMENT/SCHOOL/ CENTRE: 
(NB – if Nursing, please note all students including PhD’s 
must attach the letter from the Nursing Ethics Advisory 
Committee to this application) 
 
School of Health and Human Performance 
 
 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT DUBLIN CITY UNIVERSITY? 
 
 YES  NO (If NO, give details of off-campus location.) 
 
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER ETHICS COMMITTEE, OR HAS IT BEEN 
PREVIOUSLY SUBMITTED TO AN ETHICS COMMITTEE?) 
 
 YES  NO (If YES, please provide details and copies of approval(s) received etc.)   
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DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, accurate.  I have read the 
University’s current research ethics guidelines, and accept responsibility for the conduct of the procedures 
set out in the attached application in accordance with the guidelines, the University’s policy on Conflict of 
Interest and any other condition laid down by the Dublin City University Research Ethics Committee or its 
Sub-Committees.  I have attempted to identify all risks related to the research that may arise in conducting 
this research and acknowledge my obligations and the rights of the participants. 
If there any affiliation or financial interest for researcher(s) in this research or its outcomes or any other 
circumstances which might represent a perceived, potential or actual conflict of interest this should be 
declared in accordance with Dublin City University policy on Conflicts of Interest.  
I and my co-investigators or supporting staff have the appropriate qualifications, experience and facilities to 
conduct the research set out in the attached application and to deal with any emergencies and contingencies 
related to the research that may arise. 
Signature(s): 
Principal investigation:    
Print name(s) in block letters: Niall M. Moyna 
Date: 11 Dec 2010  
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2. PROJECT OUTLINE  
 
2.1 LAY DESCRIPTION (see Guidelines) 
Peripheral arterial disease (PAD) is a form of cardiovascular disease that manifests 
primarily in the lower limbs.  PAD is prevalent in 3-12% of the general population ≥ 
40 years of age and continues to increase with advancing age.  Approximately 40-60% 
of PAD patients have concomitant coronary artery or cerebrovascular disease and are 
at a 2-3 fold increased risk of fatal or non-fatal heart attack, stroke and all-cause 
mortality.  One of the primary symptoms of PAD is intermittent claudication, a form of 
muscle pain that develops in the lower limbs during exercise.  Symptoms can be 
become so severe that they limit activities of daily living and thus diminish quality of 
life.  Exercise improves symptoms and functional capacity in patients with PAD.  DCU 
Sport has recently established SmartSteps, a community-based exercise rehabilitation 
programme aimed at individuals with PAD.  Current ACSM physical activity 
recommendations advocate an accumulation of 200 kcal of energy expenditure through 
exercise five days a week in order to attain health benefits.  The best possible way for 
patients with PAD to achieve this target has not been identified.  High intensity exercise 
induces claudication symptoms more rapidly compared with low intensity exercise.  
This forces the patient to rest until the symptoms subside before resuming exercise.  
Low intensity exercise allows the patient to exercise for longer before the onset of 
claudication symptoms.  This study will assess whether energy expenditure of 200 
kcal is achieved more rapidly in patients with PAD by undertaking high intensity 
exercise with a greater number of rest periods or low intensity exercise with fewer 
rest periods.   
The mechanisms through which exercise may improve claudication symptoms and 
functional capacity in patients with PAD are in part related to changes in vascular 
health and muscle metabolism.  This study will compare the effects of exercise 
intensity on vascular health and muscle metabolism. 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH (see Guidelines) 
High intensity exercise induces claudication symptoms more rapidly compared with 
low intensity exercise.  This forces the patient to rest until the symptoms subside 
before resuming exercise.  Low intensity exercise allows the patient to exercise for 
longer before the onset of claudication symptoms.  Current ACSM physical activity 
recommendations advocate an accumulation of 200 kcal of energy expenditure through 
exercise five days a week in order to attain health benefits.  The primary aim of this 
study is to determine whether energy expenditure of 200 kcal is achieved more 
rapidly by high intensity exercise with a greater number of rest periods or low 
intensity exercise with fewer rest periods.   
The beneficial effects of exercise in PAD patients are related to improvements in 
vascular health and muscle metabolism.  Endothelial function refers to the ability of 
the blood vessels to dilate and is an indicator of vascular health.  Vascular health can 
also be assessed by measuring the number of microparticles circulating in the blood.  
These micoparticles are released by the damaged endothelium, and currently little is 
known about the effect of exercise on their number and function in patients with PAD.  
PAD is associated with increased plasma acylcarnitine content.  Exercise can reduce 
plasma acylcarnitine levels.  This study will compare the effects of different exercise 
intensities on endothelial function and blood content of microparticles and aclycarntine.   
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2.3  PROPOSED METHOD (see Guidelines) 
Overview 
The study will take place in Dublin City University.  Subjects will visit the Vascular 
Research Unit in the School of Health and Human Performance on 3 separate 
occasions.   
Visit 1: Subjects will have their arm and ankle blood pressure measured at rest and 
immediately following a treadmill walking test.   
Visit 2: Subjects will perform either low or high-intensity intermittent treadmill 
walking to expend 200 kcal.  Before and after the exercise subjects will have a blood 
sample taken, endothelial dependent and independent dilation assessed and arm and 
ankle blood pressures measured  
Visit 3: Same as Visit 2 except for the exercise intensity. 
 
Endothelial dependent and independent dilation:  Endothelial dependent dilation 
will be determined in response to reactive hyperemia following 5 min of lower arm 
occlusion.  The increase in blood flow following 5 minutes of occlusion activates 
mechano-receptors on the surface of the vascular endothelium resulting in the 
conversion of L-arginine to nitric oxide.  Nitric oxide is a potent vasodilator and its 
production is dependent on a healthy vascular endothelium.  The degree of dilation in 
the brachial artery correlates with the degree of dilation in the coronary artery 
following infusion of acetylcholine allowing brachial artery reactivity to be used as a 
surrogate marker for coronary artery function.  A blood pressure cuff will be placed on 
the left arm for blood pressure monitoring and another on the right lower arm for 
occlusion.  ECG leads will be attached to monitor heart rate.  Subjects will rest for 10 
min in a supine position.  Blood pressure will be determined during the final 2 minutes 
of the rest period.  Baseline blood flow and brachial artery diameter (SonoSite, 
MicroMaxx) will be recorded.  The right arm blood pressure cuff will then be inflated 
to approximately 220-230 mmHg and maintained at that pressure for 5 minutes.  The 
cuff will then be rapidly deflated after 5 min of occlusion.  Doppler blood flow 
measurement will be obtained during the first minute following cuff deflation.  
Brachial artery diameter will be assessed at one and three minutes post occlusion.  
Subjects will then rest for 15 minutes to eliminate endothelium dependent effects on 
brachial artery diameter.  After this period, endothelial independent dilation will be 
assessed.  Baseline blood flow and brachial artery diameter will be recorded and used 
as a baseline prior to sublingual glyceryl trinitrate administration.  Glyceryl trinitrate 
(0.4mg) will be placed under the subjects tongue.  Doppler blood flow measurement 
will be obtained three minutes following the sublingual glyceryl trinitrate 
administration and brachial artery diameter measurements will be assessed 3 and 5 
minutes post glyceryl trinitrate administration.  If the subject is taking Viagra they will 
notify Brona Furlong.  They will not be permitted to take Viagra for at least 24 hours 
before the administration of glyceryl trinitrate. 
Treadmill test:  The treadmill test will involve an incremental walking protocol to 
volitional fatigue.  The treadmill velocity will remain constant at 2.0 mph.  The 
gradient will be 0%, and will be increased by 2% every 2 minutes.  A physician will be 
present during the test.  Subjects will wear a mouthpiece or facemask during the test 
to measure oxygen uptake.  A 12 lead ECG will be used to continuously monitor the 
electrical activity of the heart.  Rating of perceived exertion will be measured every 5 
min.   
Intermittent treadmill walking: Subjects will walk on a treadmill at 2 mph and at a 
grade equal to 40% or 80% of the maximum grade achieved during the treadmill test 
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in Visit 1.  The treadmill exercise will be undertaken by having the subjects exercise 
until claudication symptoms develop, then rest until symptoms subside.  The exercise-
rest cycle will be repeated until the subjects expend 200 kcal.  A physician will be 
present during the test.  Subjects will wear a mouthpiece or facemask during the test 
to measure oxygen uptake.  A 12 lead ECG will be used to continuously monitor the 
electrical activity of the heart.  Rating of perceived exertion will be measured every 5 
min.   
2.4 PARTICIPANT PROFILE (see Guidelines) 
Men and women ≥ 40 yrs of age with diagnosed PAD, who have been referred to the 
SmartSteps programme by the vascular surgeons in Beaumont Hospital and the Mater 
Misericordiae Hospital will be recruited.   
Inclusion Criteria: 
• Referred to the SmartSteps programme by the vascular surgeons in Beaumont 
Hospital and The Mater Hospital  
• Ratio of arm blood pressure to ankle blood pressure  <0.95 at rest or <0.85 after 
exercise 
• Fontaine Stage II PAD (intermittent claudication upon ambulation) for > 3 
months 
• Clinically stable and in good health for a minimum of two weeks prior to 
beginning the study 
Exclusion Criteria:   
• Fontaine Stage I PAD (ambulation not limited by claudication) 
• Fontaine Stage III PAD (pain at rest) 
• Ulceration or gangrene 
• Vascular surgery or angioplasty in past 6 months 
• Co-morbidities contradictive to exercise 
• Factors other than intermittent claudication limiting exercise tolerance  
• Diabetes mellitus 
• Unable to walk on a treadmill 
• Current smoker 
• Unstable angina 
• Systolic blood pressure >180mmHg and/or diastolic blood pressure >100mmHg 
• Resting tachycardia   
• Unstable or acute heart failure 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED (see Guidelines) 
20 men and women enrolled in the DCU SmartSteps programme will be recruited.  
Subjects referred to the SmartSteps programme by the vascular surgeons in 
Beaumont Hospital and the Mater Misericordiae Hospital will be informed of the 
research study.  A brief summary of the study will be provided to explain the study to 
the individuals and provide contact details.  Following an expression of interest, 
potential subjects will visit the Vascular Research Unit in the School of Health and 
Human Performance.  They will be told that by agreeing to attend the first session 
they are not obligated to participate in the study.  During the first visit blood pressure 
in the arms and ankles will be assessed to identify subjects with a ratio of arm to ankle 
pressure of <0.95 at rest and <0.85 after exercise.  An explanation will be given to 
each potential subject to explain the nature, benefits, risks and discomforts of the 
study.  They will be provided with a plain language statement, and the informed 
consent will be explained.  They will be encouraged to ask questions, and any 
individual with doubts about participating in the study will have an opportunity to ask 
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questions.  Individuals who wish to participate in the study will have to provide 
written informed consent.   Contact details will be provided to ensure all queries or 
concerns of the participant can be dealt with immediately. 
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM RESULTS WILL BE DISSEMINATED, 
INCLUDING WHETHER PARTICIPANTS WILL BE PROVIDED WITH ANY INFORMATION AS TO 
THE FINDINGS OR OUTCOMES OF THE PROJECT? 
The results will form the basis for a postgraduate thesis and will be presented at 
scientific meetings and published in scientific journals.  The identity of individual 
participants will not be divulged.  Group information will only be presented.  
Participants will be provided with a copy of their results, summarising information 
such as body mass index, blood pressure and cholesterol levels. 
2.7 OTHER APPROVALS REQUIRED Has permission to gain access to another location, organisation 
etc. been obtained?  Copies of letters of approval to be provided when available. 
 YES  NO  NOT APPLICABLE 
(If YES, please specify from whom and attach a copy.  If NO, please explain when this will be 
obtained.) 
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED BY THE REC? 
 YES  NO 
(If YES, please state both the REC Application Number and Project Title) 
REC/2010/048 - Effect of a 12 Week Community-based Exercise Rehabilitation 
Programme on Vascular Health in Patients with Peripheral Arterial Disease 
 
3. RISK AND RISK MANAGEMENT 
3.1 ARE THE RISKS TO SUBJECTS AND/OR RESEARCHERS ASSOCIATED WITH YOUR PROJECT 
GREATER THAN THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 YES  NO If YES, this proposal will be subject to full REC review 
If NO, this proposal may be processed by expedited administrative review 
3.2 DOES THE RESEARCH INVOLVE: 
 YES NO 
• use of a questionnaire? (attach copy)?   
• interviews (attach interview questions)?   
• observation of participants without their knowledge?   
• participant observation (provide details in section 2)?   
• audio- or video-taping interviewees or events?   
• access to personal and/or confidential data (including student, patient  
or client data) without the participant’s specific consent? 
  
• administration of any stimuli, tasks, investigations or procedures which 
may be experienced by participants as physically or mentally painful, 
stressful or unpleasant during or after the research process? 
 
 
• performance of any acts which might diminish the self-esteem of 
participants or cause them to experience embarrassment, regret or 
depression? 
  
• investigation of participants involved in illegal activities?   
• procedures that involve deception of participants?   
• administration of any substance or agent?   
• use of non-treatment of placebo control conditions?   
• collection of body tissues or fluid samples?   
• collection and/or testing of DNA samples?   
• participation in a clinical trial?   
• administration of ionising radiation to participants?   
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3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK MANAGEMENT PROCEDURES (see 
Guidelines) 
1. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, 
heart attack, or death in less than one in 30,000 patients.  Subjects will 
continuously monitored using a 12 lead ECG. 
2. Drawing blood may cause a slight pain where the needle is inserted and can leave 
a bruise.  A person trained to take blood will be used to decrease these risks.   The 
amount of blood drawn is not harmful. 
3. Assessment of endothelial dependent and independent dilation will require 
restriction of blood flow for 5 minutes.  This may cause slight discomfort in the 
arm, which will go away after the blood pressure cuff in deflated.  The glyceryl 
trinitrate used may induce a headache that may last 5 - 10 minutes. 
Alternatives to the risks:  It is not possible to assess endothelial dependent and 
independent dilation without the use of brachial artery reactivity and the 
administration of glyceryl trinitrate.  Analysis of cardiovascular biomarkers cannot be 
undertaken without a sample of blood.  The investigators are certified and 
experienced in phlebotomy and ultrasonography.   
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR INDIRECT) TO PARTICIPANTS FROM 
THIS RESEARCH? 
 YES  NO (If YES, provide details.) Participants will be provided with a 
copy of their results, summarising information such as 
blood pressure and fitness levels 
3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. risk of infection or where research 
is undertaken at an off-campus location) 
 YES  NO (If YES, please describe.) Working with blood and needles 
carries risks, however the exposure to blood and needles is 
minimal and the School of Health and Human Performance 
has standard operating procedures for the handling of 
biological products. 
3.6 ADVERSE/UNEXPECTED OUTCOMES (see Guidelines) 
The School of Health and Human Performance has the facilities to implement all 
aspects of this study and has an emergency plan for adverse events.  In the unlikely 
event of a major adverse outcome, an ambulance will be called and the participant will 
immediately be sent to Beaumont Hospital. In the unlikely event of a minor adverse 
outcome, the situation will be dealt with by the attending study physician with 
subsequent attention at the on-campus VHI SwiftCare clinic if required.   
3.7 MONITORING (see Guidelines) 
The principal investigator will be involved in all aspects of the research, including 
participant recruitment and data collection.  The research team will have weekly 
meetings to update on all aspects of the study. The School of Health and Human 
Performance has a detailed list of Standard Operating Procedures for each of the 
protocols in this study.  All researchers, including students, must be familiar with the 
procedures and the Safety Statement before beginning data collection. 
3.8 SUPPORT FOR PARTICIPANTS (see Guidelines) 
This project does not require additional support for participants. 
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3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES TO PARTICIPANTS? 
 YES  NO (If YES, please provide further details.)      
4. INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND SKILLS (Approx. 
200 words – see Guidelines) 
Prof. Moyna is an exercise physiologist and has extensive experience in cardiovascular 
research. 
Dr. Noel McCaffrey is a physician with extensive experience in exercise related research 
Ms. Brona Furlong is a graduate student in the School of Health and Human Performance, 
DCU.  She has extensive experience in studies involving human experimentation, and has 
undertaken extensive training in ultrasonography under the guidance of Cleona Gray, Chief 
Vascular Technologist in the Department of Vascular Surgery in the Mater Hospital, Dublin. 
Dr Ronan Murphy has 12 years of post PhD experience and training in cell and molecular 
biology, vascular biology, and thrombosis & haemostasis. He received his undergraduate 
degree and Ph.D. with NUI Galway. Following this he worked for two years as a Clinical 
Research Scientist in the field of Pharmacogenomics. He was awarded a Fellowship from the 
HRB to work on bleeding disorders.  Thereafter, he went to work for Prof. S.J. Shattil, at The 
Scripps Research Institute, San Diego (2000-2003). He has also been a visiting scientist to the 
Blood Research Institute, Milwaukee, USA. 
Ms. Cleona Gray is the chief vascular sonographer in the Mater Hospital.  Her role in the 
study is to train Brona Furlong in ultrasonography techniques. 
5. CONFIDENTIALITY/ANONYMITY 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE PROTECTED? 
 YES  NO (If NO, please explain) 
 
 IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE FOLLOWING QUESTIONS: 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE RESPECTED? (see Guidelines) 
Confidentiality is an important issue during data collection.  Participant’s identity and 
other personal information will not be revealed, published or used in further studies.  
Subjects will be assigned an ID number under which all personal information will be 
stored in a secure locked cabinet and saved in a password-protected file in a 
computer at DCU.  The principal investigator, and collaborators listed on this ethics 
application will have access to the data. 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: (Have you included appropriate information in 
the plain language statement and consent form?  See Guidelines) 
 YES  NO (If NO, please advise how participants will be advised.) 
 
6 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL (see Guidelines) 
6.1 HOW WILL THE DATA/SAMPLES BE STORED? (The REC recommends that all data be stored on 
campus) 
Stored at DCU     
Stored at another site    (Please explain where and for what purpose) 
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6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
Access by named researchers only         
Access by people other than named researcher(s)  (Please explain who and for what purpose) 
Other  :     (Please explain) 
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE EXPLAIN HOW, WHEN AND BY 
WHOM THIS WILL BE DONE? 
The principal investigator will be responsible for security of the data.  The data will be 
kept in locked cabinet in the Vascular Research Unit in the School of Health and 
Human Performance in DCU. Access to the data will only be attainable by the named 
researchers.  Data will be kept for a minimum of five years from the date of 
publication of the research.  Aside from the named researchers, no others will have 
access to the raw data.  Data will be shredded by Prof. Moyna after 5 years. 
7. FUNDING 
7.1 HOW IS THIS WORK BEING FUNDED? 
Irish Research Council for Science, Engineering and Technology 
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE CONSIDERATION FOR FUNDING BY A 
GRANTING BODY?  
 YES  NO  
I.4   HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE OF THE FUNDING? 
Plain Language Statement  
7.5 DO ANY OF THE RESEARCHERS, SUPERVISORS OR FUNDERS OF THIS PROJECT HAVE A 
PERSONAL, FINANCIAL OR COMMERCIAL INTEREST IN ITS OUTCOME THAT MIGHT 
COMPROMISE THE INDEPENDENCE AND INTEGRITY OF THE RESEARCH, OR BIAS THE 
CONDUCT OR RESULTS OF THE RESEARCH, OR UNDULY DELAY OR OTHERWISE AFFECT 
THEIR PUBLICATION? 
 YES  NO (If Yes, please specify how this conflict of interest will be addressed.) 
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8. PLAIN LANGUAGE STATEMENT (Approx. 400 words – see Guidelines) 
Project Title:  Effect of Acute Exercise on Vascular Health in Patients with Peripheral 
Arterial Disease 
The Research Study will take place in the School of Health and Human 
Performance, DCU. 
The principal investigator is Prof. Niall M. Moyna (Tel: 7008802 Fax: 7008888) 
Email: niall.moyna@dcu.ie 
I. Peripheral arterial disease (PAD) is a disease of the blood vessels that primarily 
affects the legs.  PAD is a common disease among people older than 55 years.  A 
common symptom of PAD is leg pain during exercise that disappears with rest.  
This is known as intermittent claudication and it can severely diminish quality of 
life.  Exercise can help to improve symptoms and walking ability in individuals 
with PAD.  Current guidelines recommend you expend 200 kcal through exercise 
five days a week in order to achieve health benefits.  On account of intermittent 
claudication, the best way for individuals with PAD to achieve the 200 kcal target 
is unknown.  High intensity exercise brings on claudication pain more rapidly 
compared with low intensity exercise.  This forces the individual to rest until the 
pain disappears before starting to exercise again.  Low intensity exercise allows 
the individual to exercise for longer before the onset of claudication.  This study 
will assess whether 200 kcal is expended more rapidly in patients with PAD by 
undertaking high intensity exercise with a greater number of rest periods or low 
intensity exercise with fewer rest periods.   
PAD reduces the ability of blood vessels to dilate (get bigger).  This can lead to 
blood flow restriction to the legs.  We can use a simple ultrasound procedure to 
measure the degree to which the blood vessels can dilate.  Tiny pieces of the 
damaged blood vessel wall break off into the blood and these can be measured by 
taking a blood sample.  From the blood sample we can also measure the extent to 
which your muscles use the oxygen that the blood supplies to the legs. 
You will be allowed to take part in the study if you meet the entry criteria and 
sign the informed consent. If you agree to take part in the study you will be asked 
to make 3 visits to the Vascular Research Unit in the School of Health and Human 
Performance in DCU.  You will fast for at least 12 hours and will not be allowed to 
exercise for at least 24 hours before these visits.   
II. Visit 1: You will walk on a treadmill.  The electrical activity of your heart will be 
assessed by a 12 lead electrocardiogram.  This is a special machine that takes 12 
different views of your heart (like photographs) while you are exercising.  You 
will have electrodes placed on your chest to measure the electrical activity of your 
heart.  You will wear a mouthpiece to allow the researchers measure the amount 
of oxygen you use during the exercise. You will have the blood pressure in your 
arms and ankles measured before and after the exercise.  This visit will last 
approximately 1 hour. 
Visit 2:  You will walk on a treadmill at either a low or high-exercise intensity.  
Before and after the exercise, you will have a blood sample taken.  About 2 
tablespoons of blood will be taken.  The health of a blood vessel in your arm will 
also be measured after the blood samples are taken.  This will be done by using an 
ultrasound to take an image of your blood vessel.  This involves blocking the 
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blood flow to your arm for 5 minutes using a blood pressure cuff and taking one 
spray of glyceryl trinitrate under your tongue.  You will have the blood pressure 
in your arms and ankles measured before and after exercise.  This visit will last 
approximately 2 hours.   
Visit 3: is the same as Visit 2 except you will exercise at the other intensity.  You 
will have a blood sample taken, the blood pressure in your arms and ankles 
measured and the health of a blood vessel in your arm measured.  This visit will 
last approximately 2 hours.   
III. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, 
heart attack, or death in less than 1 in 30,000 patients.  Your heart rate will be 
continuously monitored using a 12 lead ECG.     
Drawing blood may cause a slight pain where the needle is inserted and may 
leave a bruise.  A person trained to take blood will be used to decrease these 
risks.   
Taking an ultrasound image of your arm requires blocking the blood flow to your 
arm for 5 minutes using a blood pressure cuff.  This may cause slight discomfort 
in your arm, which will go away after the blood pressure cuff in deflated.  The 
glyceryl trinitrate  used in this study may cause a headache that could last 5 to 10 
min. 
IV. Your confidentiality will be guarded.  All information we gather will be stored in a 
secure filing cabinet.  The results of the study will be used for a postgraduate 
project and may be published in academic journals. You will not be identified, as 
your information will be presented as part of a group.  You will be assigned an ID 
number under which all personal information will be stored in the secure locked 
filing cabinet and saved in a password protected file in a computer at DCU.  You 
need to be aware that confidentiality of information provided can only be 
protected within the limitations of the law.  It is possible for data to be subject to 
subpoena, freedom of information claim or mandated reporting by some 
professions.  
V. Involvement in this study is completely voluntary.  You may withdraw from the 
Research Study at any point.  Withdrawal from the study will not affect your 
participation in the SmartSteps Programme or the medical management of your 
condition. 
VI. This study is funded by the Irish Research Council for Science, Engineering and 
Technology (IRCSET). 
VII. If you have concerns about this study and wish to contact an independent 
person, please contact: The Secretary, Dublin City University Research 
Ethics Committee, c/o Office of the Vice-President for Research, Dublin City 
University, Dublin 9.  Tel 01-7008000 
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9. INFORMED CONSENT FORM (Approx. 300 words – see Guidelines) 
Informed Consent 
Dublin City University 
Project Title:  Effect of Acute Exercise on Vascular Health in Patients with Peripheral Arterial 
Disease 
Principal Investigator: Prof. Niall M. Moyna 
Introduction to this study 
Peripheral arterial disease (PAD) is a disease of the blood vessels that primarily affects the 
legs.  PAD is a common disease among people older than 55 years.  A common symptom of 
PAD is leg pain during exercise that disappears with rest.  This is known as intermittent 
claudication and it can severely diminish quality of life.  Exercise can help to improve 
symptoms and walking ability in individuals with PAD.  Current guidelines recommend 
that adults burn 200 kcal through exercise five days a week in order to achieve health 
benefits.  On account of intermittent claudication, the best way for individuals with PAD to 
achieve the 200 kcal target is unkown.  High intensity exercise brings on claudication pain 
more rapidly compared with low intensity exercise.  This forces the individual to rest until 
the pain disappears before starting to exercise again.  Low intensity exercise allows the 
individual to exercise for longer before the onset of claudication.  This study will assess 
whether 200 kcal is burned more rapidly in patients with PAD by undertaking high 
intensity exercise with a greater number of rest periods or low intensity exercise with 
fewer rest periods.   
PAD reduces the ability of blood vessels to dilate (get bigger).  This can lead to blood flow 
restriction to the legs.  We can use a simple ultrasound procedure to measure the degree to 
which the blood vessels can dilate.  Tiny pieces of the damaged blood vessel wall break off 
into the blood and these can be measured by taking a blood sample.  From the blood 
sample we can also measure the extent to which your muscles use the oxygen that the 
blood supplies to the legs. 
Participants Requirements 
1. I will visit the Vascular Research Unit in the School of Health and Human Performance 
DCU on 3 separate days.  Each visit will last approximately 2 hours.  During my first 
visit I will walk on a treadmill.  The electrical activity of my heart will be assessed by a 
12 lead electrocardiogram.  This is a special machine that takes 12 different views of 
my heart (like photographs) while I am exercising.  I will have electrodes placed on 
my chest to measure the electrical activity of my heart.  I will wear a mouthpiece to 
measure the amount of oxygen I use during the exercise.  I will have the blood 
pressure in my arms and ankles measured before and after the treadmill exercise.  
2. During my second visit I will walk on a treadmill at low or high intensity.  The 
electrical activity of my heart will be assessed by a 12 lead electrocardiogram.  I will 
wear a mouthpiece to measure the amount of oxygen I use during the exercise.  Before 
and after the exercise I will have a blood sample taken.  The total amount of blood 
drawn will be 2 tablespoons (30 cc).  I will have the health of the arteries in my arm 
assessed and the blood pressure in my arms and ankles measured.   
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3. To test the health of the arteries in my arms I will lie on my back, and an ultrasound 
will be placed on my upper arm to create an image of my artery.  After the first image 
is recorded, a blood pressure cuff will be inflated on my forearm to block blood flow 
for five minutes.  This may be uncomfortable.  The cuff will be released and the images 
of my arteries repeated.  I will rest for 15 minutes and then have one spray of glyceryl 
trinitrte sprayed under my tongue.  The glyceryl trinitrate will cause my arm arteries 
to enlarge and how much they enlarge will again be documented by taking a third set 
of pictures. 
4. My third visit will be same as the second visit with the exception of the intensity at 
which I walk.   
5. I will fast for at least 12 hours and will not exercise for at least 24 hours before each 
visit.  If I am taking Viagra I will notify Brona Furlong.  I will not take Viagra for at least 
24 hours before these two visits.   
Potential risks to participants from involvement in the Research Study  
1. Exercise carries with it a very small risk of discomfort, abnormal heart rhythms, heart 
attack, or death in less than one in 30,000 patients.  My heart rate will be continuously 
monitored using a 12 lead ECG.     
2. Drawing blood may cause a slight pain where the needle is inserted and can leave a 
bruise.  A person trained to take blood will be used to decrease these risks 
3. The pictures of my arm arteries require blocking the blood flow to my arm for 5 
minutes.  This may cause slight discomfort in the arm, which will go away after the 
blood pressure cuff in deflated.  The glyceryl trinitrate used in this study may induce a 
headache that could last 5 to 10 min.   
Benefits (direct or indirect) to participants from involvement in the Research Study 
After completing the study I will be provided with a copy of my results, summarising 
information such as my body mass index, blood pressure and cholesterol levels.  There are 
no other direct benefits to me. 
 
Participant – please complete the following (Circle Yes or No for each question) 
 
 Have you read or had read to you the Plain Language Statement   Yes/No 
Do you understand the information provided?     Yes/No 
Have you had an opportunity to ask questions and discuss this study?   Yes/No 
Have you received satisfactory answers to all your questions?    Yes/No 
Are you aware that your interview will be audiotaped?    Yes/No 
Advice as to arrangements to be made to protect confidentiality of data, including that 
confidentiality of information provided is subject to legal limitations. 
Your identity and other personal information will not be revealed, published or used in 
further studies.  You will be assigned an ID number under which all personal information 
will be stored in a secure locked cabinet and saved in a password protected file in a 
computer at DCU.  The named investigators will have access to the data.  Data will be 
shredded after 5 years by Prof. Moyna. 
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Confidentiality is insured, but you must be aware that confidentiality of information 
provided can only be protected within the limitations of the law.  It is possible for data to 
be subject to subpoena, freedom of information claim or mandated reporting by some 
professions. 
If you are in a dependent relationship with any of the researchers their involvement in the 
project will not affect ongoing assessment/grades/management or treatment of health at 
DCU.  Involvement in this study is completely voluntary.  You may withdraw from the 
Research Study at any point.  Withdrawal from the study will not affect your participation 
in the SmartSteps Programme or the medical management of your condition. 
Signature: 
I have read and understood the information in this form.  The researchers have answered 
my questions and concerns, and I have a copy of this consent form.  Therefore, I (print 
name) ______________________ consent to take part in this research project entitled Effect of a 
12 Week Community-based Exercise Rehabilitation Programme on Vascular Health in 
Patients with Peripheral Arterial Disease.  
Participants Signature:  ___________________________________________ 
Name in Block Capitals       
Witness:          
Date:           
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Appendix F 
 
  
Perceived Claudication Pain Scale 
 
0  No Symptoms 
0.5 Tiredness, Heaviness or 
Tightness 
1  Onset of Pain 
2  Mild Pain 
3  Moderate Pain 
4  Maximal Pain 
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Appendix G 
Table: Daily activity and sedentary behaviour 
Total sedentary time (h) 18.92 ± 2.11 
Total standing time (h) 3.87 ± 1.75 
Total ambulating time (h) 1.17 ± 0.57 
Total non-sedentary time (h) 4.98 ± 2.13 
Total no. of steps 5575.02 ± 3197.28 
MVPA defined as >25 steps/epoch (h) 0.24 ± 0.30 
MVPA defined as >16 steps/epoch (h) 0.50 ± 0.38 
Percentage of total day spent sedentary (%) 78.99 ± 8.98 
Percentage of total day spent standing (%) 16.13 ± 7.29 
Percentage of total day spent ambulating (%) 4.89 ± 2.37 
Percentage of total day spent non-sedentary (%) 21.02 ± 8.98  
Percentage of waking day spent sedentary (%) 67.56 ± 13.34 
Percentage of waking day spent standing (%) 24.89 ± 10.99 
Percentage of waking day spent ambulating (%) 7.57 ± 3.45 
Percentage of waking day spent non-sedentary (%) 32.46 ± 13.35 
Values are means ± SD 
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Table: Number and duration of sedentary bouts 
Total no. of sedentary bouts  39.61 ± 11.99 
Total no. of sedentary bouts of <5 min 18.88 ± 9.24 
Total duration spent in sedentary bouts of <5 min (h) 0.55 ± 0.29 
Total no. of sedentary bouts of 5-10 min 6.08 ± 2.96 
Total duration spent in sedentary bouts of 5-10 min (h) 0.71 ± 0.33 
Total no. of sedentary bouts of 11-20 min 5.98 ± 1.92 
Total duration spent in sedentary bouts of 11-20 min (h) 1.42 ± 0.48 
Total no. of sedentary bouts of 21-30 min 3.17 ± 1.04 
Total duration spent in sedentary bouts of 21-30 min (h) 1.30 ± 0.44 
Total no. of sedentary bouts of 31-40 min 1.66 ± 0.68 
Total duration spent in sedentary bouts of 31-40 min (h) 0.94 ± 0.40 
Total no. of sedentary bouts of 41-60 min 1.60 ± 0.74 
Total duration spent in sedentary bouts of 41-60 min (h) 1.30 ± 0.61 
Total no. of sedentary bouts of >60 min 2.24 ± 1.14 
Total duration spent in sedentary bouts of >60 min (h) 3.98 ± 2.33 
Total no. of sedentary bouts of >90 min 1.15 ± 0.79 
Total duration spent in sedentary bouts of >90 min (h) 2.63 ± 1.95 
Total no. of sedentary bouts of >2 h 0.63 ± 0.62 
Total duration spent in sedentary bouts of >2 h (h) 1.70 ± 1.73 
Total no. of sedentary bouts of >3 h 0.16 ± 0.23 
Total duration spent in sedentary bouts of >3 h (h) 0.60 ± 0.88 
Total no. of sedentary bouts of >4 h 0.04 ± 0.09 
Total duration spent in sedentary bouts of >4 h (h) 0.19 ± 0.41 
Values are means ± SD 
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Table 3.4: Patterns of sedentary behaviour  
Total day spent in sedentary bouts of <5 min (%) 2.30 ± 1.2 
Waking day spent in sedentary bouts of <5 min (%) 3.54 ± 1.74 
Total sedentary time spent in sedentary bouts of <5 min (%) 3.10 ± 2.95 
Waking sedentary time spent in sedentary bouts of <5 min (%) 6.05 ± 4.60 
Total day spent in sedentary bouts of 5-10 min (%) 2.94 ± 1.40 
Waking day spent in sedentary bouts of 5-10 min (%) 4.55 ± 2.07 
Total sedentary time spent in sedentary bouts of 5-10 min (%) 3.95 ± 2.32 
Waking sedentary time spent in sedentary bouts of 5-10 min (%) 7.73 ± 5.34 
Total day spent in sedentary bouts of 11-20 min (%) 5.93 ± 2.01 
Waking day spent in sedentary bouts of 11-20  min (%) 9.19 ± 3.03 
Total sedentary time spent in sedentary bouts of 11-20 min (%) 7.70 ± 2.83 
Waking sedentary time spent in sedentary bouts of 11-20 min (%) 14.55 ± 5.69 
Total day spent in sedentary bouts of 21-30 min (%) 5.43 ± 1.84 
Waking day spent in sedentary bouts of 21-30 min (%) 8.58 ± 3.08 
Total sedentary time spent in sedentary bouts of 21-30 min (%) 6.89 ± 2.22 
Waking sedentary time spent in sedentary bouts of 21-30 min (%) 13.03 ± 4.35 
Total day spent in sedentary bouts of 31-40 min (%) 3.92 ± 1.65 
Waking day spent in sedentary bouts of 31-40 min (%) 6.09 ± 2.50 
Total sedentary time spent in sedentary bouts of 31-40 min (%) 5.03 ± 2.14 
Waking sedentary time spent in sedentary bouts of 31-40 min (%) 9.35 ± 3.86 
Total day spent in sedentary bouts of 41-60 min (%) 5.43 ± 2.55 
Waking day spent in sedentary bouts of 41-60 min (%) 8.56 ± 4.17 
Total sedentary time spent in sedentary bouts of 41-60 min (%) 6.79 ± 2.99 
Waking sedentary time spent in sedentary bouts of 41-60 min (%) 12.63 ± 5.44 
Total day spent in sedentary bouts of >60 min (%) 16.59 ± 9.71 
Waking day spent in sedentary bouts of >60 min (%) 25.87 ± 14.64 
Total sedentary time spent in sedentary bouts of >60 min (%) 20.02 ± 10.93 
Waking sedentary time spent in sedentary bouts of >60 min (%) 35.59 ± 17.82 
Total day spent in sedentary bouts of >90 min (%) 10.96 ± 8.14 
Waking day spent in sedentary bouts of >90 min (%) 17.12 ± 12.28 
Total sedentary time spent in sedentary bouts of >90 min (%) 13.13 ± 9.30 
Waking sedentary time spent in sedentary bouts of >90 min (%) 23.31 ± 15.29 
Total day spent in sedentary bouts of >2 h (%) 7.08 ± 7.19 
Waking day spent in sedentary bouts of >2 h (%) 11.19 ± 11.30 
Total sedentary time spent in sedentary bouts of >2 h (%) 8.34 ± 8.18 
Waking sedentary time spent in sedentary bouts of >2 h (%) 14.83 ± 14.35 
Total day spent in sedentary bouts of >3 h (%) 2.50 ± 3.65 
Waking day spent in sedentary bouts of >3 h (%) 4.06 ± 5.93 
Total sedentary time spent in sedentary bouts of >3 h (%) 2.91 ± 4.21 
Waking sedentary time spent in sedentary bouts of >3 h (%) 5.40 ± 7.92 
Total day spent in sedentary bouts of >4 h (%) 0.79 ± 1.71 
Waking day spent in sedentary bouts of >4 h (%) 1.35 ± 2.94 
Total sedentary time spent in sedentary bouts of >4 h (%) 0.95 ± 2.07 
Waking sedentary time spent in sedentary bouts of >4 h (%) 1.95 ± 4.30 
Values are means ± S 
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Appendix H 
Table: The Peripheral Arterial Questionnaire scores at week 1 and following 12 
weeks of community-based exercise rehabilitation  
Domain Week 1 Week 12 
Physical function 33.71 ± 15.97 42.42 ± 22.5 
Symptom stability 52.5 ± 14.19 77.5 ± 14.19† 
Symptom frequency/burden 53.05 ± 9.21 61.94 ± 13.23* 
Treatment satisfaction 71.67 ± 24.28 75.0 ± 22.91 
Quality of life 32.5 ± 13.86 52.50 ± 20.05† 
Social function 52.08 ± 24.70 72.92 ± 25.88* 
Summary Score 39.47 ± 14.35 55.01 ± 18.69† 
Values are means ± SD; *p < 0.05 vs. week 1; †p < 0.01 vs. week 1 
